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Preface
GAP Toolkit Module 1 was prepared with the support of the United Nations
International Drug Control Programme under the Global Assessment Programme on
Drug Abuse (GAP). The main objective of GAP is to assist countries in collecting reliable
and internationally comparable drug abuse data, in building capacity at the local level to
collect data that can guide demand reduction activities, and in improving cross-national,
regional and global reporting on drug trends. To support that process, the GAP Toolkit
Module 1 has been produced to assist States Members of the United Nations in devel-
oping culturally appropriate systems, relevant to the countries concerned, for collecting
drug information, to support existing drug information systems by promoting their con-
formity with internationally recognized standards of good practice, and to focus on har-
monization of drug abuse indicators.
Module 1 of the GAP toolkit forms one component of a compendium of methodological
guides that have been developed to support data collection activities. Other modules
currently under development provide support in the following areas: school surveys;
indirect prevalence estimation techniques; data interpretation and management for pol-
icy formation; and basic data manipulation using a statistical software package for the
social sciences (SPSS).
Other GAP activities include the provision of technical and financial assistance in the
establishment of drug information systems and support for and coordination of global
data collection activities. For further information on GAP toolkit modules, contact
gap@undcp.org or visit the GAP web site at www.undcp.org.
The purpose of the toolkit is to provide a practical and accessible guide to implement-
ing data collection in core areas. The toolkit modules are designed to provide a starting
point for the development of specific activities, referring the reader to more detailed
information sources on specific issues, rather than being an end resource itself. GAP
toolkits are based on principles of data collection that have been agreed upon by an
international panel of experts and endorsed by States Members of the United Nations.
Although the models presented are based on existing working models that have been
found effective, a key principle is that approaches have to be adapted to meet local needs
and conditions. Module 1 of the toolkit therefore provides specific examples to guide the
reader through the process of adapting general principles and models to specific con-
texts, and is not intended to reflect the complete range or diversity of current drug infor-
mation systems or data collection methods.
For further information, visit the GAP web site at www.undcp.org, email gap@undcp.org,
or contact the Demand Reduction Section, UNDCP, P.O. Box 500, A-1400 Vienna, Austria.
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Introduction
Background
Although there are countries that can claim successes in controlling the
demand for illicit drugs, abuse throughout the world continues to grow. In
particular, illicit drug abuse in some developing countries has increased
dramatically. However, knowledge of the scale of illicit drug use is still inad-
equate, and understanding of the patterns and trends limited.
To provide effective policies to reduce drug abuse, Governments need data
about when, where and why people use illicit drugs. Patterns of drug use
transcend national borders as users in all regions of the world get access to
a greater variety of drugs, and as social trends, in particular among young
people, spread more rapidly than before through better communications.
The globalization of drug abuse means that demand reduction policies also
have to be global, as must the information system on which they rely. 
In 1998, the General Assembly, at its twentieth special session, devoted to
countering the world drug problem together, adopted a Political
Declaration (resolution S-20/2, annex) calling for the elimination or signif-
icant reduction of the supply of and demand for illicit drugs by the year
2008. That was the first time that the international community had agreed
on such specific drug control objectives. However, the systematic data
needed to monitor and evaluate progress towards those goals are not yet
available. For that reason, the General Assembly requested the United
Nations International Drug Control Programme (UNDCP) to provide
Member States with the assistance needed to compile comparable data.
UNDCP was asked to collect and analyse the data and report thereon to the
Commission on Narcotic Drugs. In response to those requests, UNDCP
launched the Global Assessment Programme on Drug Abuse (GAP). GAP
has been designed to:
(a) Support Member States in building the systems needed to collect
reliable data to inform policy and action;
(b) Encourage regional partnerships to share experiences and technical
developments;
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(c) Facilitate a better understanding of global patterns and trends in drug abuse by
encouraging the adoption of sound methods of collecting comparable data.
Those aims reflect the challenge posed in the Declaration on the Guiding Principles of
Drug Demand Reduction adopted by the General Assembly at its twentieth special session
(resolution S-20/3, annex), which states the following: 
“Demand reduction programmes should be based on a regular assessment of the
nature and magnitude of drug use and drug-related problems in the population …
Assessments should be undertaken by States in a comprehensive, systematic and
periodic manner, drawing on results of relevant studies, allowing for geographical
considerations and using similar definitions, indicators and procedures to assess the
drug situation.”
The main objective of GAP is to assist Member States in building the capacity to collect
internationally comparable drug abuse data and to assess the magnitude and patterns of
drug abuse at country, regional and global levels. The development of national and regio-
nal information systems should not only contribute to the building of capacity at the local
level to collect data that can guide demand reduction activities, but also improve cross-
national, regional and global reporting on drug trends. To support that process, the GAP
Toolkit Module 1 has been produced to assist Member States in developing culturally
appropriate systems, relevant to each country, for collecting drug information, to support
existing drug information systems by promoting their conformity with internationally rec-
ognized standards of good practice, and to focus on harmonization of drug abuse indica-
tors. Standardization of indicators and the wider adoption of sound methods for data col-
lection will result in an enhanced analysis of trends in drug abuse in both developed and
developing countries. For more information on GAP, visit the GAP web site at
www.undcp.org, email gap@undcp.org, or contact the Demand Reduction Section,
UNDCP, P.O. Box 500, A-1400 Vienna, Austria.
Principles and core indicators of data collection: 
the Lisbon consensus
Integral to efforts to improve international data on drug consumption is harmonization of
data collection methods and activities. An important first step in achieving harmonization
was taken in January 2000 with a joint meeting of representatives from international bod-
ies and regional drug information networks and other relevant technical experts. The pur-
pose of the international expert forum was to discuss the principles, structures and indi-
cators necessary for effective drug information systems. The meeting was hosted in Lisbon
by the European Monitoring Centre on Drugs and Drug Addiction (EMCDDA) and sup-
ported by UNDCP through GAP. Particular consideration was given by the international
expert forum to the development of a set of core epidemiological demand indicators
against which Member States could report on their respective situations. The indicators
were chosen to the extent that they addressed areas in which routine data collection was
considered possible at least for some countries. They are not intended to provide a com-
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prehensive information base for all policy questions, as areas that require dedicated
research exercises are not suitable for inclusion in an ongoing information system. The
identified core indicators and a discussion of their application are set forth below:
Drug consumption among the general population
Drug consumption among the general population pertains to estimates of the prevalence
and incidence of drug consumption among the general population (those aged between 15
and 64). Understanding the level of drug consumption in any population is often the start-
ing point for policy discussions. Generating estimates of general population prevalence
and incidence is therefore a key task of most drug information systems. Attention is often
focused on estimating prevalence. However, levels of incidence (new cases) are likely to be
equally important for policy formation. With respect to the estimation of both prevalence
and incidence, it should be noted that this area does not lend itself to any single method-
ological solution. While surveys provide one method for achieving estimates in this area,
other estimation methods also exist, such as data from sentinel surveillance systems and
indirect statistical estimation techniques. In many countries, conducting national preva-
lence surveys may be currently not possible for reasons of cost, or because of method-
ological or practical difficulties.
Drug consumption among the youth population
Drug consumption among the youth population refers to estimates of the prevalence and
incidence of drug consumption among youth (those aged between 15 and 24). Because
drug consumption among young people is often a particular concern of policy makers, and
because age cohorts of young people make a convenient sampling unit, estimates of drug
consumption among the youth population form an important part of many drug informa-
tion systems. School surveys have been used extensively to generate estimates in this area.
However, because school attendance patterns vary between countries, and because surveys
may exclude important sections of the youth population, other approaches may also be
necessary.
High-risk drug abuse
High-risk drug abuse pertains to estimates of the number of drug injectors and of the pro-
portion engaging in high-risk behaviours and to estimates of the number of daily users and
of regular or dependent abusers. Some drug-taking behaviours are particularly associated
with severe problems and as such merit attention. The most common data collected in this
area are the number of drug injectors and of the dependent or very frequent users of drugs.
Specific methods are needed to gain information on behaviours such as injection, as their
hidden nature and low prevalence usually mean that they are poorly covered by general
population estimates. With respect to drug injection and the transmission of infectious
agents, it is also necessary to collect information on rates of high risk injecting behaviours
(equipment-sharing).
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Service utilization for drug problems
Service utilization refers to the number of individuals seeking help for a drug problem.
Drug treatment registers are often used as a proxy indicator of treatment demand. This
information is useful for analysis of service utilization and can be used as an indicator of
trends in prevalence and patterns of high-risk drug consumption. The drug treatment reg-
istries may not be appropriate where general health and social services are the main
providers of help. It should be remembered that the scale, structure and nature of servi-
ces for those with drug problems vary greatly across countries. Therefore, definitional clar-
ity is particularly important reporting in service utilization, as is an understanding of the
methodological and analytical issues pertinent to drawing conclusions from service popu-
lations and applying them to drug problems among the general population.
Drug-related morbidity
Drug-related morbidity pertains to cases of disease directly or proportionally attributable to
drug consumption, and in this context refers principally to infection rates of the human
immunodeficiency virus (HIV), hepatitis B virus and hepatitis C virus among drug injectors.
Health costs are of obvious importance in informing policy development with regard to illi-
cit drug consumption. Common measures include drug-related infections such as HIV, hep-
atitis B, hepatitis C and behavioural risk factors among drug injectors. Conceptual problems
do exist in this area and further development work is required. In particular, problems exist
in estimating the contribution that drug consumption has made to cases of disease in which
there are other attributed causes, and in calculating the proportion of cases in which drug
use is the sole attributed cause when a number of possible causes exist. 
Drug-related mortality
Drug-related mortality refers to the data on the deaths directly attributable to drug con-
sumption. While potentially useful and clearly important, reliable data on this area are
usually not widely available. Diagnostic criteria do exist to distinguish between psychiatric
morbidity attributed to drug consumption and other psychiatric morbidity. However, this
level of detail is often unavailable. There is also considerable debate about the potential of
some illicit substances to cause psychiatric problems, as well as the role of pre-existing
psychiatric conditions in the development of drug problems. Regardless of the nature of
the relationship between drug consumption and mental health problems, co-morbidity
remains a major concern as elevated levels of drug consumption are often found among
those with mental health problems. This area is currently poorly understood and requires
further research.
Principles for data collection
In addition to gaining consensus on the core indicators of drug consumption, there was
agreement on the principles that should underpin data collection activities. The collection of
meaningful data on drug consumption should be guided by the following broad principles:
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(a) Data should be timely and relevant to the needs of policy makers and service
providers;
(b) While not sufficient in themselves for a comprehensive understanding of patterns of
drug consumption, efforts to improve the comparability and quality of data at inter-
national level should focus on a limited number of indicators and a manageable pri-
ority core data set; 
(c) Simple indicators of drug consumption must be subject to appropriate analysis
before strategic conclusions can be drawn. Analysis and interpretation of basic sta-
tistical data is greatly enhanced when combined with research, both qualitative and
quantitative, and with broader information on context;
(d) Multi-method and multi-source approaches are of particular benefit in the collection
and analysis of data on drug consumption and its consequences;
(e) Data should be collected in accordance with sound scientific methodological princi-
ples to ensure reliability and validity;
(f) Methods need to be adaptable and sensitive to the different cultures and contexts
in which they are to be employed;
(g) Data collection, analysis and reporting should be as consistent and comparable as
possible in order to facilitate meaningful discussions of changes, similarities and dif-
ferences in the drug phenomenon;
(h) Methods and sources of information should be clearly stated and open to review; 
(i) Data collection and reporting should be in accordance with recognized standards of
research ethics;
(j) Data collection should be feasible and cost-effective in the terms of the national con-
text in which it occurs.
Human networks and organizational structures
It is recognized that the identification of good methods alone is not sufficient for improv-
ing data collection capacity. It is also necessary to develop appropriate networks and orga-
nizational structures to provide the infrastructure necessary to support data collection. To
this end, there is a need for improved capacity to analyse and interpret information on
drug consumption, and this depends on the application of good methods, human
resources and the availability of appropriate resources. That will require training and tech-
nical support, ongoing political support and investment to ensure sustainability and suc-
cess of data collection systems. Throughout the present guide, reference is made to some
of the regional and national systems that have been developed in this area. Those systems
and networks allow for a dialogue between scientists and policy makers that can ensure
that data collection meets the needs of policy formation. While expenditure on data col-
lection has to be cost-effective, given the resources available within a country, it also needs
to be accepted that investment in data collection activities is both necessary and resource-
efficient, in that it improves the development, targeting and evaluation of other demand
reduction investments. In many countries, there is now a recognition by policy makers of
the value of sound information as well as an appreciation of the infrastructure needed to
provide this information. It is part of the purpose of the present toolkit to summarize the
lessons that have been learned in this development process to assist countries that wish
to adopt a strategic approach to developing their information resources.
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The discussion paper arising from the 'Lisbon Consensus’ meeting (E/CN.7/2000/CRP.3)
was endorsed by States Members at the forty-third session of the Commission on 
Narcotic Drugs, held in March 2000, and can be found on the GAP web site
(http://www.undcp.org/pdf/drug_demand_gap_lisbon_consensus.pdf).
Global mechanisms for data collection
Drawing a comprehensive picture of the global patterns and trends in illicit drug consump-
tion is not an easy task. At a global level, one mechanism exists that is designed to assem-
ble an overview of the world drug abuse situation–the annual reports questionnaire. The
annual reports questionnaire is the mechanism used by Member States to meet the obliga-
tions of the international drug control treaties to report on various aspects of the illicit drug
problem to the Commission on Narcotic Drugs. Further information can be found at
www.undcp.org. Most pertinent to monitoring global patterns and trends in drug consump-
tion is part II of the annual reports questionnaire, which can be found in the supporting
material of the present toolkit module. Part II of the questionnaire has been adopted in a
revised form from January 2002 to reflect the agreed core indicators of drug consumption
(see above overview of indicators under section “Principles of data collection” or go to
http://www.undcp.org/pdf/drug_demand_gap_lisbon_consensus.pdf) and be sufficiently
versatile to allow countries at different levels of data collection capacity to report.
Specifically, the revised questionnaire provides for global data collection on an agreed set of
core drug consumption indicators using three levels of reporting: summary expert opinion;
unstandardized or partial quantitative data; and standardized quantitative data. While the
questionnaire is only intended as a summary data set, it does provide a useful vehicle for
encouraging the adoption of multisource data collection methods and harmonized core indi-
cators. The annual reports questionnaire is not intended to be sufficient for all the needs of
policy makers, but can provide a basic structure for data collection efforts. Countries that
adopt the core measures found in the form also ensure that data collection exercises result
in information that is compatible with international standards. 
Currently, a picture of the global drug situation is built upon data from the annual reports
questionnaire in conjunction with other published material on drug consumption, and
relies heavily on data provided by national and regional drug information systems. A copy
of the most recent report on the world drug abuse situation can be found at
http://undcp.org/cnd_session_45.html.
Summary
Reliable, accurate and up-to-date data on drug consumption are needed to guide the imple-
mentation of demand reduction activities; however, such data are lacking in many coun-
tries. Available data often vary in quality and methods of collection and are difficult to
compare across countries and regions. Therefore, there is a pressing need in many coun-
tries to foster ongoing political commitment for the collection of data on drug consump-
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7WHY COLLECT DRUG ABUSE INFORMATION?
Data on drug use and abuse answer key questions that enable an appropriate pub-
lic health response from policy makers. It has been pointed out on numerous occa-
sions that for conscientious policy makers dealing with drug problems accurate
data ought to be a fundamental element of sensible decision-making.
Policy-making decisions are all too often determined without consideration of epi-
demiological data. Such data are not only useful to show that a nation or a region
experiences a drug problem, but the value of data related to drug use and abuse
consists in the assistance that the data provide at all levels at which relevant
health decisions have to be made.
At various levels, records from clients may justify the plea for financial aid to
establish or improve a service. For example, records of the type of drugs used, the
type and frequency of sexual risk behaviour and the number of self-discharges in
comparison to the previous year can provide in-depth information about the func-
tioning of treatment services and systems. In addition they can pinpoint areas for
improvement of the service.
At the community level, data may help to identify trends within communities and
enable policy makers to identify shortcomings at an early stage and be able to take
appropriate counter measures. The early detection of crack cocaine consumption or
of new methods of use in a community where only marijuana use was known is
highly relevant. Such information provides a background for local strategies for
prevention, treatment and control.
At the national level, strategies are increasingly focused on demand reduction,
which must be based on reliable and valid epidemiological data. Furthermore,
countries where national data are regularly collected are able to participate better
in international discussions on drug issues. The regular assessment of the status of
drug use and abuse can also serve as an early warning system that will alert other
countries, as new trends in drug abuse have the tendency to cross national borders
and spread to neighbouring countries.
tion and its consequences; to support the development of technical expertise for the
sound collection and analysis of data; and to establish and support human networks for
the collection, analysis and dissemination of data on drug consumption. The present
toolkit is a forerunner to the development of sound data collection activities, by support-
ing the development of human networks around which specific data collection activities
can grow, while maximizing the utilization of existing information, local knowledge and
available infrastructure. The toolkit is based on the principles for data collection that were
identified in the Lisbon consensus. The areas identified for inclusion in an ongoing rou-
tine data collection system reflect the core indicators of the annual reports questionnaire.
8Finally, at the global level, drug use data help to develop new global drug control
policies. A global information system can facilitate the building of political resolve
and a spirit of cooperation between developed and developing countries in com-
bating the spread of illicit drug use and in strengthening the common and shared
responsibility to implement and evaluate global demand reduction strategies.
For further discussion of issues around drug epidemiology and policy, refer to the
Bulletin on Narcotics, vol. LIV, No. 1 (2002), while further guidance on the inter-
pretation of data for policy is provided under the GAP toolkit
(http://www.undcp.org/drug_demand_gap_m-toolkit.html).
Drug abuse information is collected in order to inform current policies regarding
interdiction, prevention and treatment by:
• Identifying existing drug use patterns-types of drugs available and types of
drugs used by whom and in what ways
• Detecting new drugs being used or new methods of using existing drugs
• Monitoring changing trends in drug using patterns over time, over geographic
area and across population groups
PART ONE
Development of an Integrated
Drug Information System

Description of an integrated
drug information system
Background
Drug abuse has become a global problem requiring more comprehensive
international cooperation to reduce the availability of and demand for
drugs. Although drug abuse is becoming an increasing problem for many
countries, it is largely the more affluent developed countries that have
acquired the most experience in addressing the problem. Probably the
most important lesson learned by those countries is that to understand
their drug abuse problems and to be more efficient in addressing those
problems, a multisource integrated drug information system is essential.
Such a system, if well designed, not only will provide information on the
types of drugs being used and the characteristics of those using them,
but also will generate questions for other more focused studies to 
provide information that would serve to plan effective prevention and
treatment programmes.
In many parts of the world, those responsible for responding to drug prob-
lems, at both at the city and the national level, do not have access to cen-
tralized data systems that provide information regarding drug-using pat-
terns. The present toolkit has been designed to assist researchers and
administrators who wish to develop such data systems so that key questions
about drug use in their countries can be addressed and appropriate deci-
sions about programming interventions can be made. The challenge to those
who wish to undertake the creation of a centralized data system to assess
drug abuse or misuse is that in most countries the use of drugs is highly stig-
matized. There may be laws against the possession and use of drugs making
those who use them lawbreakers, and the general public may hold negative
social attitudes towards those who use drugs. In such contexts, drug users
often wish to hide their behaviours. In addition, the very nature of drug use,
that is, the variability in the types and qualities of drugs available, is dyna-
mic and amorphous, requiring timely assessments on a regular basis. Such
conditions have made the assessment of drug use highly complex and mul-
tiple methods to collect information on drug use have been developed. To
make information available that captures the drug use situation at any par-
ticular time as accurately as possible requires a number of data-gathering
Chapter I
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activities. These may range from key informant interviews or conducting focus groups with
drug users and professionals such as law enforcement officers or drug use treatment
providers to large household surveys. Those researchers who conduct such studies describe
their activities as the tiles within the true mosaic portrait of the drug-using population.
Each activity or tile provides a bit of information that describes drug use. 
The approach that is recommended in the toolkit is the development of an integrated
drug information system. Such a system includes an accumulation of a database made
up of information from a variety of both “passive” sources such as existing reports or
other databases and “active” sources such as population surveys. The data are reviewed
by a group of drug abuse experts who are familiar with and interested in the local drug
problem. The experts discuss the data that have been collected to interpret what the data
suggest and what questions can be answered using the data. The experts also specify
gaps in the database, set priorities as to which gaps need to be closed and develop
specifics about how to address those gaps. A summary of the data and the outcome of
the discussions are prepared in a report that is disseminated to policy makers, pro-
gramme planners and practitioners and other researchers. The focus of the present tool-
kit is on local systems, that is, information systems that consist of data for a city or coun-
try. When several cities within a country, or several countries within a region want to
form a larger system, such a system or network would consist of one representative from
each of the local systems or networks. Each representative would present the findings
from his or her network. 
The toolkit is written to help those interested in developing an integrated drug informa-
tion system at a local level. It is organized as a guide to a process of self-assessment and
planning. It begins with a description of an ideal integrated drug information system. This
description is followed by a self-assessment process, called an “information, needs and
resources analysis”, that can be completed by an individual or, preferably, a group of indi-
viduals with an interest in drug use. The assessment is designed to determine what
resources are available within the defined geopolitical area that can be incorporated into
a data system and what missing resources are needed in order to put a complete system
in place, and undertakes a strategic analysis of this information to formulate a strategic
development plan. The next process outlined in the toolkit assists in setting priorities
among the gaps identified. Finally, the toolkit offers step-by-step procedures to help
address those gaps identified as being important. The toolkit can be used by individuals
or groups to conduct their own assessments or can be used in a formal training pro-
gramme. It is recognized that developing a comprehensive information system on patterns
NOTE:
Drug use is a difficult and complex topic to monitor. All information sources have
limitations and reflect only one aspect of the behaviour. Therefore, for a compre-
hensive understanding, it is necessary to develop a multisource or multi-indicator
system that can provide insight into the different aspects of the problem.
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and trends in drug abuse will be a long-term endeavour. This module of the toolkit is
designed to assist in the formulation of a development strategy, based on an analysis 
of existing resources, which is informed by local priorities and identifies realistic and
short-, medium- and long-term goals.
Further guidelines on carrying out drug abuse epidemiology can be found on the GAP web
site, http://undcp.org/drug_demand_gap.html, and in the World Health Organization
Guide to Drug Abuse Epidemiology (Geneva, 2000) (http://www.who.int/substance_
abuse/pubs_psychoactive_drugs.htm).
Drug abuse epidemiology and information systems
Key to knowing what data sources could be included in an information system is an
understanding of the epidemiology of drug abuse. In general, epidemiology is an approach
to organizing information regarding a health condition to identify what is the cause of the
condition and how to reduce or eliminate its impact on the morbidity (involving those get-
BUILDING A LOCAL SYSTEM REQUIRES:
• A coordinator, someone with a strong interest in developing the system who is
ideally knowledgeable about existing data sources and knows other drug abuse
professionals (for example, drug abuse treatment providers, researchers and
prevention specialists) and drug-abuse-related professionals (for example,
mental health specialists, university researchers, law enforcement officers or
data persons and medical examiners or coroners);
• An interactive network of drug abuse and drug-abuse-related professionals
with access to existing data and who are committed to meeting at least once
a year for a full day to discuss their data. This network is extremely important,
in particular, when it is not sure what information is available or where to look
for data;
• Clarification of the objectives of the network as follows:
(a) Identifying existing drug abuse patterns within the defined geograph-
ic areas and periods of times covered by the data to be decided upon by the
group;
(b) Identifying changes in drug abuse patterns over defined periods of
time, including types of drugs, modes of administration and characteristics
of drug users;
(c) Monitoring the changes to determine if they represent emergent drug
problems;
(d) Disseminating information to community agencies and interested pro-
fessional groups.
• Development of a standardized way of reporting information at the meeting;
• Stimulation of discussion of findings to address the objectives of the network;
• Development of a final report format;
• Development of a dissemination plan that includes a mailing list.
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ting ill) and mortality (involving those dying) of both those affected by the condition and
those vulnerable to becoming affected.
Epidemiologists will accept that a certain percentage of the population will experience
some health conditions, for instance some children will not be inoculated for measles
and therefore will contract measles, or some children will be genetically predisposed to
diabetes. However, when the percentages increase, or if affected groups evidence differ-
ing characteristics, epidemiologists become concerned. They then conduct analyses of
existing data to generate hypotheses to explain the increases or changing characteris-
tics. Those hypotheses form the core of epidemiological research. The findings from the
studies addressing the hypotheses then become the basis for prevention interventions
and research. Therefore, epidemiological studies include those that are referred to as
descriptive, from which hypotheses are generated, and those that are analytic, which
address specific hypotheses. The present toolkit focuses on the first type of study,
descriptive epidemiology.
Descriptive epidemiology serves to answer the “what” and “who” questions such as:
(a) What is the nature of the drug use problem in the population (what drugs are being
used; how are they used; how frequently are they used)?
(b) To what extent is the general population using the drugs (what is the rate of new
use within the past year; how many persons have been using drugs for more than
one year)?
(c) Who are the persons using the drugs (what are their characteristics; are both males
and females using drugs; are youth using drugs)?
(d) What are the social, psychological and health problems associated with the use of
the drugs and are they acute or short-term problems or are they chronic or long-
term (do people who use drugs have more family problems, do they have difficulties
keeping jobs, do they drop out of school)?
Because the field of epidemiology evolved from studies of persons with infectious dis-
eases, epidemiologists are interested in percentages of people who have the condition
within defined populations within specific periods of time. Any changes in those per-
centages over time would suggest a renewed epidemic. Therefore, it is important to be spe-
cific about the population base and the time period covered by the data being studied.
Are the data from one locale or are they from the whole country? Are the data available
for only one year or are they collected every year? Answers to those questions begin to
specify the drug-using problem. Systematic collection and review of data provides better
evidence to support prevention and treatment efforts. This is the basis for an integrated
drug information system. 
Networks are usually geographically based, that is, by city, county, province, state, nation
or region. Often this geographic base is hierarchical, with city-based systems being com-
bined to form a state or national system, and combined at a country level to form a region-
al system, and so forth.
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Monitoring of drug trends within a network is often conducted by the sentinel method. That
is, selected areas of a geographic region (for example, a city) and categories of the drug-using
population (for example, injectors and treatment attendees) are monitored through the sys-
tematic collection of data on key issues that warrant surveillance. For instance, in the United
States of America, the community epidemiology work group consists of cities from across
the country including the north-east, south-east, central, north-west, south-west and west-
ern regions and Hawaii. Although certain drug patterns are consistent across cities, there
are preferences that are unique also. Methamphetamine use is more prevalent in San Diego,
California, and the west, while crack cocaine is more prevalent in the north-east. Yet with
changing drug trafficking patterns, the use of methamphetamine is increasing in the central
and north-east areas and crack cocaine is becoming a problem in the west in certain popu-
lations. Sentinel systems for a region allow monitoring of such changing trends. While a sen-
tinel system does not provide data representative of the entire population of drug users, it
allows one to keep a watchful eye on trends in problematic drug use, or other pertinent drug
use issues, in a cost-effective and convenient way.
Selected examples of drug information systems at the regional and national level are pro-
vided below, while descriptions of different drug information systems and related issues
can be found in the proceedings of the Global Workshop on Drug Information Systems:
Methods, Activities and Future Opportunities, held in Vienna from 3 to 5 December 2001
(see http://undcp.org/drug_demand_gap.html).
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EXAMPLES OF DRUG INFORMATION SYSTEMS
Regional systems/networks
The Pompidou Group of the Council of Europe
(http://www.coe.int/pompidou)
European Monitoring Centre for Drugs and Drug Addiction
(http://www.emcdda.org)
Inter-American Drug Abuse Control Commission and the 
Inter-American Uniform Drug Use Data System
(http://www.cicad.oas.org/en/Observatory/Main.htm)
Caribbean Drug Information Network
(http://www.carec.org/projects/caridin_daess/caridin_daess.htm)
Southern African Development Community Epidemiology Network on Drug Use
(http://www.sadc.int/index.htm)
National systems
Community Epidemiological Work Group 
(http://165.112.78.61/CEWG/CEWGHome.html)
Illicit drug reporting system
(http://ndarc.med.unsw.edu.au/ndarc.nsf/website/IDRS)
South African Community Epidemiology Network on Drug Use
(http://www.sahealthinfo.org/admodule/sacendu.htm)
Canadian Community Epidemiology Network on Drug Use
(http://www.ccsa.ca/ccendu/index.htm)
Drug information report system in Mexico
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Composition of an integrated drug information system 
Any integrated drug information system should consist of three components: input, inter-
pretation and output. 
An integrated drug information system consists of: data or input relative to measures of
drug use within a population within a specified period of time; a review and interpretation
of the data by local experts who know some aspect of the drug use problem; and a mech-
anism for reporting the findings of the reviews and interpretations to other researchers,
prevention and treatment providers and policy makers. The present section will describe
the structure and operation of an ideal system drawing on the experience of successful sys-
tems. Figure I provides selected examples of drug information systems and their internet
contact details. For a review of these and other systems, refer to the proceedings of the
Global Workshop on Drug Information Systems: Activities Methods and Future
Opportunities (see http://www.undcp.org/drug_demand_gap_datacollection.html#core).
Figure I.   Structure of an integrated drug information system
Input: data sources
An integrated information system can have the ability to address a number of important
questions regarding drug-using patterns and the characteristics of users that would assist
prevention and treatment programming. The extent to which those questions are ade-
quately addressed depends on the types of data sources that are available. 
The stigma associated with the use of drugs makes the development of an information sys-
tem challenging. Although such a stigma is not usually attached to other health condi-
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tions, collecting health information from the public is still quite difficult, for in most cases
a diagnosis is required. Therefore, typical data sources in the area of health are medical
files or population surveys. Persons who have health problems are likely to show up at a
hospital, emergency department or the offices of a medical practitioner. Their complaints
are reviewed, tests are run so that a diagnosis can be made, and treatment is initiated.
Sometimes the diagnoses and the characteristics of the patients are reported to some cen-
tral file such as a registry or insurance billing offices; sometimes, if a serious infection is
noted, reports are made to the local health department. 
In population surveys, symptom lists are used to determine who in the survey may have
certain health conditions. Information then is gathered as to whether the person sought
medical care and received a diagnosis and was treated.
In many ways, similar approaches are used to compile information regarding drug use. An
understanding of problems associated with drug use assists in determining where and
what kinds of information are available. In the present section, the four major sources of
data for drug use will be discussed: existing data, population surveys, key informant inter-
views and other ethnographic approaches. 
Data from existing databases and surveys are considered quantitative. As existing data gen-
erally are not direct measures of a problem, many people label them as being more qualita-
tive. However, qualitative or ethnographic data more accurately reflect the context in which
a behaviour takes place. Although a tension exists between the quantitative and qualitative
researchers, the nature of drug abuse epidemiology is such that both approaches are extremely
important. Recognition of the significant contributions of qualitative research is underscored
by the recent publication by the EMCDDA Scientific Monograph No. 4, Understanding and
Responding to Drug Use: the Role of Qualitative Research (Lisbon, July 2000). 
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SUMMARY OF METHODS OF DATA COMPILATION
METHOD ADVANTAGES LIMITATIONS
General surveys Broad coverage Validity and representativeness
Trend data, if repeated Expensive and training needed
Precision May miss users of some drugs
Scientific standardized methods May miss some hidden groups
Special Targeted coverage Validity and representativeness
population 
surveys
Information on users of Expensive and training needed
specific drugs
Information on hidden Sampling difficult
populations
Existing data Readily available Validity and representativeness
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Existing data
To determine where to look for data on drug users, the natural history of drug use must
be considered. Each drug is known to have a physiological effect on the user. Sometimes
this effect is severe, sometimes it is mild. Many existing sources of data are based on
records relating to the negative consequences of drug abuse (for example, hospital admis-
sions). It must be remembered that many more people experiment with drugs than go on
to use them on a regular basis, and that this former group of experimental drug users is
less likely to appear in these type of data sets. It is also the case that different drug types
and consumption patterns are differently associated with the likelihood of the individual
experiencing problems. Most drugs are not used in their pure form and may be mixed with
substances that are harmful. In addition, the way the drug is used can have health effects.
For instance, injecting drugs particularly with unclean needles can cause emboli or clots,
sepsis and other infections, such as transmission of HIV. Sometimes, the user will over-
dose on the drug and die. It is also known that as users become more dependent on cer-
tain drugs, they develop a tolerance for the drug and require higher and greater dosages to
achieve the desired effects and to ward off withdrawal symptoms. Some of these individu-
als will seek treatment either by their own volition or through their families, employers or
the judicial system. Finally, drug users may violate local drug laws or get involved in ille-
gal activities to support themselves and their drug use.
The review of the natural history of drug use suggests six potential sources for information
on drug users: hospital admissions and emergency department logs; public health reports
on infectious diseases, including HIV and hepatitis B and C; poison control reports; med-
ical examiners’, coroners’ or other death records; drug use treatment admissions; and
arrest reports.
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SUMMARY OF METHODS OF DATA COMPILATION (continued)
Inexpensive Subject to collection bias 
Can look at changes over time Known users only 
Rapid Rapid, inexpensive and multi- Validity and representativeness
assessment method
methodology 
Relevance to interventions Training needed
Key informant Inexpensive Validity and representativeness
interviews, 
focus groups
Hidden populations Training needed and access can 
be difficult
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Other existing data sources
Other types of data that networks have utilized from law enforcement include drug seizure
information such as the amount and type of drugs seized over a specific period of time. In
addition, information on the street price of drugs and the quality or purity of street drugs
has been collected. There are obvious limitations as to how to use or interpret this infor-
mation, but, surprisingly, the price and quality of street drugs can take on significance over
time, particularly when used with other information gathered from more reliable sources.
Limitations
Existing data sources are good sources of information but each also has certain limita-
tions. Probably the greatest limitations to these sources are as follows: 
(a) They can include persons who may have used drugs only once; 
(b) They are not population-based, that is, prevalence and incidence rates of drug use
for the general population cannot be directly calculated from these numbers;
(c) As a drug user could appear in one or all of the records, each record cannot be con-
sidered independently of the others; 
(d) The records are sensitive to administrative and policy changes. For example, if a city
official, in response to public opinion, orders a crackdown on drug users, the num-
bers of arrests will increase; or the type of treatment available to drug users will
influence the number that find it attractive;
(e) The records usually have not been prepared with the needs of a drug epidemiologist
in mind, and therefore may not contain the necessary information or be coded in a
way that allows tracking of patterns of drug consumption.
Surveys
Two types of survey data are considered: general population surveys and surveys of special
populations. What distinguishes surveys from existing data is that the former is an active
data collection effort while the latter is more passive, including data that are collected for
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TYPES OF EXISTING DATA
• Hospital admissions and emergency department logs
• Public health reports on infectious diseases, including HIV and hepatitis B 
and C
• Poison control reports
• Medical examiners', coroners’ or other death records
• Drug use treatment admissions
• Arrest reports
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other purposes such as documenting arrests, people coming into the emergency depart-
ment for care, or deaths.
Population surveys
General population surveys, if done well, can provide a great deal of information regarding
the rate of existing drug use (prevalence rates) and the rate of new drug use (incidence
rates) for commonly used drug types. That said, the high cost and technical resources
required for a national household survey (for example, large sample-size requirements, the
need for an appropriate sampling framework, and ensuring data confidentiality and the
quality of self-report data on illicit activities) make implementation cumbersome in
resource poor settings. 
The procedures used to select potential respondents to the survey will also determine how
representative the responses are to the survey and the denominator for the rates that will
be calculated from the data that are collected. 
When conducted in a standard way over time, population surveys are able to provide not
only prevalence and incidence rates, but also patterns of use, trends in patterns of use and
characteristics of users, and correlates and consequences of drug use. Population surveys
therefore can be valuable epidemiological tools. 
Population surveys can be administered to a general population of residents within an area
or of school students. Two examples of the application of general population surveys 
can be found at http://www.emcdda.org/situation/themes/drug_use_general_popula-
tion.shtml and http://www.samhsa.gov/oas/oas.html, while school surveys are discussed
in the following section. 
There are three major methods for conducting surveys, as follows: 
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SURVEY POPULATIONS
• General population surveys use standard survey and sampling techniques to
assess drug use in the population as a whole.
• School surveys access drug abuse within a particular age band or school
grade. 
• Special surveys:
(a) Focused surveys to assess drug use within a particular sub-population
with a high risk of drug use, such as the homeless, sex workers, street chil-
dren, or children excluded from school. 
(b) Surveys of drug users within the community who are usually not in
touch with treatment or other services, which are used to explore the behav-
iour of current drug users.
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(a) Face-to-face with an interviewer reading the questions and completing the answer sheet
or being present when the respondent completes the answer sheet (self-administration); 
(b) Over the telephone, with either a live person asking the questions and completing the
answer sheet or having a computer asking the questions and having the respondent
indicate the response using the telephone pad numbers and letters; 
(c) Through the mail, with the respondent completing the surveys and returning them
through the post.
The third method has not been widely used, since the rates of returned survey forms are
generally very low. Studies have found that telephone interviews produce lower reported
rates of drug use, but the costs associated with telephone interviews are lower than the face-
to-face approaches. Most surveys of drug use are administered face-to-face within a house-
hold or within a school. In schools, the surveys are generally self-administered to whole
classes within the classroom under the supervision of a trained research staff member. 
It should be noted that, while general population surveys at the national level can provide
valuable information on the prevalence and incidence of commonly used drugs, they per-
form poorly in respect to the more problematic and stigmatized patterns of drug abuse,
such drug injecting. Problematic drug use patterns tend to be missed by general population
surveys because problematic drug users tend to concentrate in geographic clusters or
regions, are less likely to reside in conventional living settings (a proportion may be home-
less, in hospitals etc.), or may underreport their illicit activities. Moreover, the low number
of problematic drug users detected through household surveys and the lack of any detail
obtained on their behaviour means that targeted surveys of problematic drug users are nec-
essary to understand problematic drug-using behaviour. With regard to estimating the size
of problematic drug-using populations, indirect methods of estimation are often preferred,
the implementation of these methods being covered in module II of the GAP toolkit
(http://www.undcp.org/drug_demand_gap_m-toolkit.html) and discussed in the
European Monitoring Centre for Drugs and Drug Addiction Scientific Monograph Series
No. 1, Estimating the Prevalence of Problem Drug Use in Europe (Lisbon, December 1997).
Household versus school surveys for adolescents
In countries where both household or general population and school surveys are conduc-
ted, it has been shown that youngsters aged 12 to 17 tend to report lower rates of drug use
when interviewed within the household than they do when surveyed in school. It is sug-
gested that the difference is the greater anonymity that the classroom presents compared
to the home, where parents or guardians have a presence even if not proximal. However,
the problem associated with school surveys is that young drug users are more often 
truant than their non-drug using peers and may be absent at the time the survey is con-
ducted. There are always trade-offs when conducting this type of research. 
Further information on school surveys can be obtained from the Monitoring the Future
project (http://monitoringthefuture.org) and from Hibell and others, 1999 European
School Survey Project on Alcohol and Other Drugs Report (Stockholm, Swedish Council for
Information on Alcohol and Other Drugs, 2000).
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Other population surveys
Other groups that may be surveyed are the homeless and street youth. Sampling tech-
niques have been developed to ascertain an approximation of the total number of home-
less and street youth (the denominator) so that both prevalence and incidence rates can
be estimated. In addition, it is possible to conduct surveys in those institutions from
which existing data are also available. For instance, staff could interview incoming
arrestees or emergency department patients. Again, sampling procedures can be applied
to ensure representation of the universe of arrestees or patients.
Surveys of drug users themselves are a subset of population surveys, but they provide dif-
ferent information and rouse different methodological challenges due to the difficulty
defining the parameters of the illicit drug-using population. Surveys of drug users can pro-
vide in-depth information about low prevalence behaviours that are likely to be underrep-
resented in household or school surveys. While these surveys cannot in themselves be
used to estimate prevalence, they can provide some of the information necessary for the
estimation of prevalence using indirect methods. They are also often used in conjunction
with a combination of other methods in rapid assessment methodology. As with house-
hold surveys, special population surveys can use face-to-face, telephone or mailed inter-
views. However, the often itinerant or chaotic nature of some drug-using populations gen-
erally precludes the use of the latter two techniques, as they tend to result in very low
response rates. Due to the hidden nature of illicit drug-using populations, special consid-
eration also has to be given to the sampling methods used. The challenges presented by
sampling a hidden population are often outweighed by the information provided by these
surveys, as even small-scale surveys of drug users can produce valuable results that would
be difficult to generate by other means. For example, if heroin were being used by one per
cent of the population, even a very large sample of the general population, for example
10,000 people, would only generate a small sample of heroin users (that is, 100, assuming
that heroin users were adequately captured by the survey and prepared to take part),
which may not be sufficient for a meaningful analysis to be conducted. Therefore, it is usu-
ally more cost-effective and practical to try to directly sample populations of problematic
drug users through specialized surveys of community drug users.
For further information on specialized surveys of drug-using populations and their appli-
cation to drug information systems, refer to http://www.undcp.org/drug_demand_gap_m-
toolkit.html, Medina-Mora and others, WHO Guide to Drug Abuse Epidemiology (Geneva,
2000); the EMCCDA Scientific Monograph Series No. 1, Estimating the Prevalence of
Problem Drug Use, Group of Epidemiology Experts in Drug Problems of the Pompidou
Group, Handbook on Snowball Sampling (Strasbourg, Council of Europe, 1997); Hando and
others, “The development of an early warning system to detect trends in illicit drug use in
Australia: the Illicit Drug Reporting System”, Addiction Research, vol. 6 (1998), pp. 97-113;
and United Nations Office on Drugs and Crime, Guidelines on Drug Abuse Rapid Situation
Assessments and Responses (Vienna, 1999) . 
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Key informant and other ethnographic methods
When to use qualitative data
Given the multiple roles of qualitative approaches, the following three situations in the
development of an information system would benefit greatly from key informant inter-
views or other ethnographic studies:
(a) When there are no existing data or very limited data available; 
(b) When there is a need to augment data that are available; 
(c) When there is a need to interpret collected information.
For more detailed information on qualitative data collection, refer to the EMCDDA
Scientific Monograph, No. 4, Understanding and Responding to Drug Use ... . 
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ROLES OF QUALITATIVE DATA COLLECTION
The use of key informant information and ethnographic studies are essential to
understanding drug abuse patterns in any area and in any population. Rhodes ("The
multiple roles of qualitative research in understanding and responding to illicit
drug use", in Understanding and Responding to Drug Use: the Role of Qualitative
Research, EMCDDA Monograph No. 4 (Lisbon, EMCDDA, 2000)) points out that
there are several important roles that ethnographic studies can play:
(a) Reaching and researching hidden populations by using qualitative sam-
pling methods such as snowball sampling that employ field workers and
informants from the target population or others who have easy access;
(b) Understanding the experience and meaning of drug use by exploring the
social meanings that drug users attach to their use of drugs and the social
processes by which these meanings are created and reinforced. For example,
sharing injecting equipment is not just a behaviour associated with the trans-
mission of HIV or other viruses, but it is also a social behaviour that makes
human connections and symbolizes trust and reciprocity;
(c) Understanding the social contexts of drug use by specifying the interac-
tion and interdependence of physical and social environment and drug-using
behaviours. For example, the rules of a shooting gallery regarding the sale and
rental of injecting equipment affect behaviours that place injectors at risk of
infection;
(d) Informing quantitative research by elaborating or “putting flesh” on
quantitative information, in order, for example, to understand the many
processes or steps in sharing injecting equipment, such as the difference
between 'front-loading’ and 'back-loading';
(e) Complementing and questioning quantitative research. Like the above,
qualitative approaches remind the researcher that it is the experiences of the
drug users that he or she is attempting to understand in order to reach them,
without being blinded by his or her own perspectives; 
(f) Developing effective intervention and policy responses by identifying
processes and relevant contexts for reaching and engaging drug users in
interventions that strive to address the needs and experiences of drug users.
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Key informants 
Key informants can serve to provide information when data are sparse, to better charac-
terize existing data and to interpret the results of data analyses. Interviews with key
informants and “gatekeepers” to the data and the populations of interest should be a part
of the integrated drug information system. These interviews describe the nature of the
drug abuse problem within an area, responding to the following: 
(a) What types of drugs are available; 
(b) How they are used;
(c) What populations are using them;
(d) What are the significant consequences of their use. 
They can also provide the context in which the existing data are collected, describing bia-
ses in the data as well as whether upward trends represent increased use or administrative
changes in the data collection itself. In addition, asking for the key informants’ interpreta-
tion of the data collected provides further understanding of the meaning of the findings.
As it was recommended to seek a variety of existing databases to reflect the natural his-
tory of drug abuse within a community, it is also important to select key informants rep-
resenting those perspectives, and also to include drug users themselves. Interviews can be
conducted individually or in a group, as is done with focus groups. 
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ROLES OF QUALITATIVE DATA COLLECTION (continued)
Caution must be taken when using the above-mentioned approaches. Too often the
interviewing of key informants, the use of focus groups, or going into a group and
making observations seems far easier than collecting existing data or conducting a
survey. However, qualitative research is science-based and also requires training to
make the information gathered meaningful and valid. All those approaches are
active, requiring data collection that is standardized but open-ended. 
SUGGESTED KEY INFORMANT
• Treatment providers and/or treatment counsellors
• Outreach workers and/or other people who work with substance abusers on
the streets and who make poison control reports
• General health workers, youth workers or community workers
• Law enforcement officers, customs officials
• Emergency/ambulance teams, hospital staff, emergency department staff
• Infectious disease officers
• Active drug users representing diverse subpopulations defined by age, gender,
socioeconomic status, ethnic groups or preferred drugs
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Focus groups
Focus groups are another group approach to collecting information. These are composed
of small group of individuals who have been recruited because of their knowledge about
some aspect of the drug scene. Focus groups are sometime conducted with current drug
users, recovering addicts, young people, or professional groups, like those working in drug
treatment. Groups can be heterogeneous or homogeneous and must feel comfortable to
freely discuss the topic of interest. The advantage of this technique is that a considerable
insight into the topic in question can be gained quickly and cheaply. However, the quality
of the information is critically dependent on having a good facilitator who will ask an open-
ended question or make a statement to open the discussion. The facilitator does not lead
but guides the discussion, making sure that all group members participate. Such facilita-
tion requires a great deal of skill and training. The information from focus groups also has
to be interpreted with caution, as it cannot be necessarily assumed to be generalizable
beyond the membership of the group.
Other ethnographic approaches
Other ethnographic approaches can be used to collect information as well. These include
contextual mapping used to characterize an area describing ethnic neighbourhoods,
placement of churches, dealing areas, the site of social or health agencies, locations of
bars, pubs or taverns. The information is organized in various ways, such as free listing,
pile sorts, network analyses, narration or sequencing of events or projective assessment
techniques. All of these approaches provide the context of drug abuse patterns in an area.
Further information on data collection methods
Additional details regarding the data collection methods are included in the following 
section.
When to use the methods, the advantages and disadvantages associated with each and
ways of overcoming the disadvantages are also presented.
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NOTE:
Each approach is useful when an emergent drug abuse pattern is noted in an area.
The question is whether this emergent pattern is real or is an artifact of the data
collection agency or methodology. Digging into how the pattern emerged, what
consequences should be expected, and whether it will grow and expand can be
successfully explored with key informants and focus groups. 
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Interpretation: networks and communication
Integrated drug information systems require as their core, a network of community-based
agency representatives with an interest in public health and drug abuse, which form a
communication network. The network members share a common goal, the elimination or
reduction of drug abuse and its health and social consequences, and recognize that effec-
tive strategies need to be built on a sound evidence base. The role of the network is to pro-
vide this information and engage in a dialogue with policy makers on its implications for
programming. In most cases, network members are those who have access to information
or know where such information is available. The network members meet periodically,
usually once or twice a year, and bring their data or information to the meeting to be
reviewed, compared and discussed by the other members of the network. Members con-
sidered for the network include researchers as well as representatives of agencies that
work with drug abusers, such as public health and other medical agencies and institu-
tions, law enforcement agencies, drug abuse treatment programmes, and sometimes local
schools. Such networks have many advantages, including the following:
(a) They are practical;
(b) They are not costly;
(c) They make good use of existing data and other information;
(d) They have been used around the world quite effectively;
(e) They provide immediate feedback;
(f) They take advantage of many levels of expertise;
(g) They provide comprehensive information that addresses the missions of 
multiple agencies;
(h) They bring together professionals who would normally not interact;
(i) They build an infrastructure to support further research.
Organization of a network and its communication
Sponsorship of the network
The sponsorship of a network by an agency is advantageous as it puts that agency at the
forefront of the issue and provides up-to-date information on the problem, particularly any
emergent drug problem. Such sponsorship also has public relations opportunities to keep
26
NOTE:
When starting an information system in a country where existing data sources are
not developed, key informants can still provide unstructured reports from their own
experience. For example, in some African countries, the initial network meeting
received reports from treatment specialists, doctors and community workers on the
nature of the drug problem in their particular area. This provided a valuable start-
ing point for discussing more structured data collection exercises. 
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the public abreast of the problem and what actions the agency is taking to respond.
Furthermore, once an emerging drug problem is identified, the sponsoring agency can take
the lead in a community response to the problem.
National focal points
Most regional drug epidemiological networks, such those in Southern Africa, the European
Union, the Americas and the Caribbean operate through a focal point system. One agency
performs the role of a focal point for data collection for the country as a whole and is usu-
ally responsible for preparing a national report and presenting this in the regional forum.
For national systems, nominating a focal point is highly recommended. It is also important
to check that a focal point does not already exist for this kind of activity.
Who should form part of the network?
Initially at least, networks are best when they are small and the meetings are well planned.
Size is important, since everyone in the network should have sufficient time to present
their data and to take full part in the discussion. As indicated above, network members
should be recruited from several different types of agencies so that multiple perspectives—
legal, medical and social—are represented. If multiple geographic areas are represented,
then time needs to be spent on making cross-area comparisons.
Involving heads of agency
Although networks do not usually include agency directors or department heads, the suc-
cessful networks begin by getting the support of those officials. A meeting with agency
officials or their representatives to talk about the network group would provide similar
information and gain their cooperation. In this meeting, the purposes and advantages of
the network and network membership, including knowledge, skills and agency commit-
ment in terms of manpower and accessing information, could be discussed.
Hold an initial planning meeting
One of the outcomes of a meeting with heads of agency would be the structuring of a plan-
ning meeting. The planning meeting would bring together the agency representatives who
may or may not become members of the network. The planning meeting would establish
a common understanding of what the network purposes are, what agencies have data and
therefore should have places in the network and what other groups should be included in
the network, and a plan would be made for sending out invitations to the next network
meeting. The time and place for the first meeting and a meeting agenda also should be
developed, and plans for at least one subsequent meeting would be useful. 
The first network meeting
The first meeting of the network is very important as it establishes whether there will be
further such meetings. Clarifying the purpose of the network and each person’s role
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should be emphasized during the course of the meeting. The first meeting should identify
known or potential sources of data and information. It would be useful if the network had
reports from other similar networks, even from other countries, for additional ideas. For
those network members who brought information, time should be made for their presen-
tation with a follow-up discussion. Plans for follow-up activities such as accessing other
data or making contacts with others and even inviting others to join the network must be
well documented and assignments made to network members. The network coordinators
will contact network members with assignments to determine progress or whether they
need to give assistance. At the first meeting, it will be important to decide how the infor-
mation presented at the network meeting will be recorded, reported and disseminated.
Finally, dates, times and places for subsequent meetings must be decided. Early on in the
life of the network, it will be important for the group to decide on a standardized format
for presentations and reporting.
Output: reporting
Successful information systems and networks are those that reach out to decision makers
and programme planners within their regions. What to report and in what format the
report is made are significant to the life of an information system. Network reports should
reflect issues that are of importance to network members. In general there are three
reports that should be considered: 
(a) Reports made during the network meeting;
(b) Reports on drug patterns;
(c) Reports on drug patterns by geographic area. 
Standardized network reporting
The importance of standardized reporting formats for the network members was men-
tioned above. Time given to each member presenting their information should be sufficient,
but not so long that any one person will dominate the meeting. Usually reports will men-
tion how many individuals are represented by the data and what their characteristics are,
including, at a minimum, age group, sex, ethnicity, if relevant, and what drugs are used. 
With standardization, comparisons can be made across data sets (for example, comparing
characteristics of arrestees to new admissions to drug abuse treatment) and across time.
The latter is important for determining if there are changes or trends in the drug-using
population. For example, in the early 1990s, reports from drug abuse treatment pro-
grammes in some cities in the United States mentioned increased numbers of new admis-
sions who were using heroin by snorting or inhaling. This observation presaged an upsurge
in the use of heroin that reached into school-aged populations. 
In addition, networks that include representatives from a number of different communi-
ties will find that having standardized reporting makes comparisons across geographic
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areas easier to do. Finally, standardized reporting and reports can be easily used by policy
makers and others who have little time to review information. Standardization can be facil-
itated by the use of report data forms. 
Reports on drug patterns
Disseminating the data to policy makers, programme planners, practitioners, researchers
and the public is very important. One approach is to summarize by drug category, for
instance, along the following lines: 
“Indicators of methylenedioxymethamphetamine (MDMA or Ecstasy) are increasing in
the smalltown area. Use of the drug is spreading from raves and dance parties to high
schools, colleges, and other social settings frequented by youth and young adults.”
“Cocaine indicators have trended downward or stabilized in the past few years, as
the negative consequences of crack use generated an awareness of its risks among
potential users. Recent data show that indicators were stable or mixed in 12 areas,
decreased in 6, and increased in 3”.
More detailed information by drug category regarding the source of the information and the
characteristics of the users can also be added. For examples, see reports such as:
Community Epidemiology Work Group, Epidemiologic Trends in Drug Abuse, vol. 1 (Baltimore,
Maryland; National Institutes of Health, June 2000) 
EMCDDA, “Extended annual report on the state of the drugs problem in the European Union”
(Lisbon, 1999)
National Drug and Alcohol Research Centre Monograph No. 47, Australian Drug Trends 2000.
Findings from the Illicit Drug Reporting System (Sydney, University of New South Wales)
Monitoring of Alcohol and Drug Abuse Trends in South Africa, proceedings of the South
African Community Epidemiology Network on Drug Use (March 2000) 
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TYPES OF REPORTS AND TARGET AUDIENCES
Type of report Content Audience
Meeting reports Details of presentations Network members and 
sponsors
Policy reports Executive summary and Legislative members,
recommendations programme planners, 
fiscal managers
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Reports on drug use patterns by geographic area
If data are available by geographic areas, for instance within a city or between cities, a
report with sections focused simply on those geographic areas would be useful.
Comparisons across geographic areas are appropriate, particularly if similar data are col-
lected and when sufficient data are available over time. Caution should be used, however,
in interpreting these comparisons, since the reasons for any differences or similarities
found would require further investigation.
There are many ways to present data for geographic areas. The most useful organization
for such presentation would be first to summarize the types of drugs used and by whom
they are used, including source of data (for example, cocaine use among women arrestees
has risen over the last two years). 
Both programme planners and policy makers need a brief summary of the findings in the
report, the interpretation of what the findings mean and a translation of how the findings
make an impact on interdiction and prevention and treatment practices. Therefore, no mat-
ter which reporting format is used, having an executive summary is extremely important.
Summary
Chapter I of the GAP toolkit module, part one, has provided an overview of the importance
of having an integrated drug information system and a description of the components of
such a system. The following chapter II provides guidelines on how to develop a drug infor-
mation system. Before embarking on development of a drug information system, an audit
of existing information and resources should be undertaken. This process is designed to
help the user of the toolkit to assess the availability of data for his or her region and, and
on the basis of that assessment, begin to plan the development of an integrated drug infor-
mation system. This process will ensure maximum utilization of existing resources and
information, and therefore a more effective and efficient drug information system. A guide
to undertaking such an initial assessment is contained in the GAP toolkit module 1, part
two, “Information, Needs and Resources Analysis”. On the basis of the findings of that
analysis, chapter II below provides guidelines on how to: establish a local network and
communication system; develop data sources and a database; develop reporting formats
and distribution systems.
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TYPES OF REPORTS AND TARGET AUDIENCES (continued)
Mass media Key findings General public and 
community, in addition to 
public health and safety 
practitioners
Publications Research findings Professionals in 
administration and research
Development of an integrated
drug information system
The present chapter of the toolkit presents guidelines on how to establish
a network, identify data sources and establish databases, and write reports.
In addition, when databases are discussed, the advantages and disadvan-
tages of each data element and approach are presented. Establishment of a
drug information system should be guided by an initial assessment of what
information is available, what human resources and infrastructure can be
used to support the system, and some planning as to the purpose, nature,
scope and structure of the initial network. A guide to undertaking such an
initial assessment is presented in the GAP toolkit module 1, part two,
“Information, Needs and Resources Analysis”. The findings of the analysis
will guide the reader in determining the baseline information and resources
available for his or her information system. 
Establishing a network
There are a number of steps that can be taken to establish a network, which
should have the following key features:
(a) It should be comprehensive: including diversity with the representa-
tion of a number of perspectives, such as treatment, law enforce-
ment, health, policy and research;
(b) It should be small enough to allow presentation of information and
discussion of findings;
(c) It should be flexible enough to allow the inclusion of additional
expertise;
(d) It should be led by a coordinator who will organize meetings, agen-
das and reporting. Leadership could be rotated among the network
membership;
(e) It should be committed to meeting on a regular basis at least once a
year, preferably twice a year depending on the dynamic nature of the
drug abuse problem.
To prepare an inventory of resources, an ad hoc group of drug abuse
experts would be established to assist in reviewing the availability of rele-
vant data to be included in the new integrated drug information system. In
Chapter II
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the course of the review, the group would probably identify additional members to include
in the network. At some point in the process, it will be important for the network to exam-
ine what each current network member brings to the network in terms of skills and data,
and to determine what components are missing. Both skills and data should be taken into
account in the deliberations. In the skills area, the focus might be on research capabilities,
public relations or communications expertise and political connections. When thinking
about data, it is important to think not only about what may exist but also about data that
will be needed in the future.
The first meeting is an extremely important one. It is at this meeting that decisions will
be set as to how the network will function. The following material is taken from pages 7
and 8 of the United States National Institute on Drug Abuse publication Assessing Drug
Abuse Within and Across Communities (see references).
The first meeting is critical because it sets the stage for what the surveillance network will
be, how it will function, and how it will be perceived by participants and others.
Two interrelated objectives should always be kept in mind:
• Obtaining knowledge about drug abuse; 
• Developing and strengthening the work group.
Care should be taken to avoid common pitfalls that others have encountered in planning
initial network meetings. Four principles should be observed:
Start small. Be selective in inviting individuals to attend. It is easy to add individuals once
the needs and sources have been identified, and to change individuals based on the
strengths and interests of the members. In particular:
• Have clear, attainable objectives for the meeting. Avoid trying to overachieve 
at the beginning;
• Establish the agenda in coordination with other participants, so that they feel 
invested from the beginning;
• Give each participant a role to play and a contribution to make.
The first meeting should be organized to accomplish several objectives:
• Identify known and potential sources of data and information. Selected par-
ticipants can be asked to describe particular data sets and to prepare and
briefly present data from sources to which they have access;
• Review the types of data sources (indicators) accessed by other epidemiologi-
cal networks to determine if they might be obtainable in your area. If they are,
determine what steps should be taken to identify agencies and individuals
who can provide access to each of these sources;
• Assign participants to follow-up activities (after the meeting) and, if appro-
priate, make contacts to find out what types of data are available, how the
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data can be made available and who is most knowledgeable about the data
and the data sources;
• Determine how the information from the meetings should be recorded, report-
ed and disseminated, including to whom it should be sent. A full report with
all the information will prove useful for agency planners and staff associated
with the network member agencies. An executive summary that brings all the
information together in a quick-reference format will prove very popular with
the press and the general public;
• Identify current and potential sources of support for organizing and conduct-
ing the meeting, and producing and disseminating reports from the meeting.
The full report should be based largely on the papers prepared and presented
by participants along with data tables.
Surveillance networks need to remain focused on questions such as: What drugs are cur-
rently being used? Who is using them? Are drug use patterns changing from year to year?
If so, how?
Network parameters
There are four essential parameters of a successful network: size and breadth; short meet-
ings; an energetic coordinator; and the meeting procedures report.
Size and breadth 
Although broad representation is desired, it is also important that networks be small
enough to allow discussion. Members should ideally include representatives from a variety
of organizations with different perspectives on drug abuse in each area. The following
areas and types of expertise are commonly represented in network meetings: drug abuse
treatment; medical examiner or coroner; public health department biostatistician and
planner; university researcher or groups with access to survey data; any outreach worker
group that works with drug abusers on the street; and law enforcement.
Short meetings
The members of the network group more than likely will be very busy people; 
the meetings should therefore be kept as short as possible. Sufficient time should 
be allowed for:
(a) Every participant with data and a data report to present his or  her findings;
(b) After each presentation or group of presentations, discussion of what the 
data show;
(c) Follow-up on issues that may have been raised at earlier meetings;
(d) Discussion of the agenda, date, time, and place of next meeting.
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An energetic coordinator
Almost all successful networks have had an energetic coordinator who was thoroughly com-
mitted to the network process. Although once the networks are established they do not
require a great deal of work, establishing the network does involve time devoted to con-
tacting individuals, making up the agendas for meetings, keeping the meetings on time but
still allowing participants to play their roles, and overseeing the preparation of proceeding
reports for dissemination. Anyone beginning a network must recognize, first, that the ini-
tial time that he or she will devote to the network may be significant, but, secondly, that
much of the work, once established, can be designated and less time will be needed. 
Meeting procedures report
Many networks fail because there are no meeting reports prepared. When this happens,
participants have nothing to show their superiors, the network losses credibility, and inter-
est in the network declines. The meeting reports do not have to be elaborate. They can
consist of an executive summary, which is extremely important, and an annex that
includes all of the reports and tables submitted by network members. Their reports should
follow the same format, including an executive summary or narrative and tables.
It is very important to note that networks are confronted by common problems that need
to be addressed, including those outlined below:
(a) It should be recognized that network members have their own interests, different
training and different orientations. As such, they may not understand what is
expected of them. It is therefore important that a specific format for their presenta-
tion at the network meetings be sent to all members of the network prior to the
meeting;
(b) Everyone gets excited about his or her own area of expertise; therefore, when pre-
senting data about those areas, each presenter should remain focused on the topic
and keep to the schedule. All presenters should therefore be told in advance just
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CONTRIBUTIONS OF PARTICIPANTS
The present section has highlighted the importance of having an integrated drug
information system and described the components of such a system. The main con-
tributions of the participants are as follows:
(a) Knowledge about their domain, including health, research methods, treat-
ment of drug abusers, crime and seizures;
(b) Familiarity with others interested in drug abuse through their own or relat-
ed agencies and organizations;
(c) Skills-academic or research, political, policy, programmatic, planning and
front-lines or on-the-street experiences;
(d) Access to data sources and understanding their limitations and strengths.
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how much time they will have for their presentation. It will be difficult at first to
keep presenters to their time allotment, but the chair of the network must develop
a system to let the presenters know how much time they have remaining, and when
their time is up to go on to introduce the next presenter;
(c) Turnover of network participants is often a problem. Finding interested members to
take their places is sometimes a greater problem. Whoever coordinates the network
should realize that recruitment is an ongoing task. That again is why providing a
report that is useful to the member agencies is important. If an agency finds that the
network has worth, it will assign someone to work with the network. Keeping in
contact with agency directors on a regular basis to thank them for their involvement
with the network is also extremely helpful;
(d) Government and political support is also very important in many countries and hav-
ing the support of the drug coordinator (if one exists) or a representative from the
health ministry can be useful. However, it must also be remembered that the net-
work should be a technical rather than a political forum and should be led by its
technical members. This issue will vary greatly across countries. The key point is for
the network to be able to speak to a policy audience while remaining a technical
body. Having participation from the university and academic sectors is often very
useful in ensuring the appropriate balance.
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DEVELOPMENTAL STAGES OF A DRUG INFORMATION SYSTEM
Systems usually start small, building on a couple of existing data sets that are easy
to access and analyse. From there, other elements can be added to make the sys-
tem stronger. If there is absolutely no data available to start with, getting in touch
with the right people who have contact with drug users and who know about the
drug-using situation is a good starting point. Once a broad understanding of the
situation is developed, other potential methods for collecting data or obtaining
existing data will probably become clear. For example, such people can very easily
form a key informant network that can provide updates on the drug situation.
Below are some general examples of possible different stages during the develop-
ment of a network and the different components and activities that may occur dur-
ing the developmental stages.
Getting started
There would be a meeting of key stakeholders with a discussion of the available
data and potential data sources. This process can be done more formally through
an information, resources and needs analysis (INRA) to guide the development of
the network (see part II of the present toolkit  module).
There would be an analysis of some recent existing data, possibly including:
(a) Treatment demand data;
(b) Arrest data (that is, possession and use of illicit drugs);
(c) Review of any existing surveys of drug use (school surveys, specialized sur-
veys, general population, rapid assessments);
(d) Expert opinion-for example, gaining the views of those working with drug
users about the types of drug used and main drug problems and related-
issues.
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Identifying data sources and establishing databases
Gaining access to information requires making and maintaining contacts with sources.
The extent to which public organizations such as treatment agencies, hospitals and police
departments will make their data or information available on request varies considerably
between countries. Stressing that individuals will not be identified can help convince
agencies to participate. However, agencies such as private hospitals, which are not obli-
gated to provide information on request, may be difficult to access. In some parts of the
world, law enforcement agencies do not typically collaborate with health agencies and dif-
ficulties may arise in combining these different data sources. Since the aim will be to get
information from as many types of agencies as possible, it is important to convince
agency representatives that the inclusion of their information will benefit their agencies
or at lest not be detrimental to their interests. Political support can also be very helpful,
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(continued)
Intermediate steps
Once a network is established, the next step is to gradually improve the data
sources. This may involve refining existing data sources or adding a new source of
information by, for example:
(a) Developing a standardized form for collecting treatment data;
(b) Setting up a key informant network or survey;
(c) Holding regular (biannual or annual) meetings to analyse, interpret and dis-
cuss available data;
(d) Publishing a meeting report.
Further development
Networks are a dynamic process and they need to grow and change along with
other developments and changing patterns in drug consumption. It is therefore
important to always be considering how the network can further develop through
additional activities. Some examples of additional activities that the system/net-
work might undertake once it is up and running are:
(a) Conducting a school survey or undertaking specialized research on a specif-
ic drug issue;
(b) Developing a database for collating and analysing treatment data trends over
time;
(c) Expanding the coverage of the data collection activities and/or network par-
ticipation;
(d) Holding a training seminar to develop technical skills, such as analysing and
interpreting drug consumption data;
(e) Engaging in some inter-country or inter-regional collaboration by inviting
participation from a neighbouring network or system;
(f) Developing a regular reporting mechanism that serves the needs of a target
audience (for example, brief and easy-to-read updates on drug trends to sup-
plement meeting reports).
Development of an Integrated Drug Information SystemPart One
for example, a letter from the Ministry of Health endorsing the network activities can
open doors that would otherwise remain closed. Therefore, it is important to be fully pre-
pared before contacting the agencies. It is important to talk about the agency being rep-
resented and the reason why the agency is interested in the network and how the infor-
mation will be used and reported. It must also be clear that the project is one that
addresses a public health problem, and as such it is not necessary to have names or
addresses of individuals who use drugs, but their information is aggregated and quanti-
fied. This can be emphasized through a letter that may follow a telephone call or personal
visit. If possible, copies of reports or portions of reports from other networks can be
shared, so the agency contact could see how such information can be used. In addition,
of course, it is important to make an invitation to the agency contact to attend any net-
work meeting. To maintain their interest, they should also be placed on the network's
mailing list for reports and other materials.
Existing networks vary in their criteria for including data from a variety of sources into
their databases. Most of the criteria reflect various levels of scientific rigour as well as
availability. For instance, in some networks drug-abuse-related arrest data are included,
while in others it is not. There are inherent biases with almost all available data sets (a
discussion of these biases is presented below). For example, the mayor of a town may
want to show how effective his administration is by directing the police to arrest all per-
sons found in possession of marijuana. In this case, the data sets on arrests may show an
increase in the proportion of marijuana-related arrests. This increase may or may not be
associated with an increase in marijuana use in this particular town. On the other hand,
including drug-related arrest data with the added knowledge of administrative directives
or other artifacts associated with the collection of such data can be very helpful in the
long run, as such data will be collected over time and there will be periods when direc-
tives will either inflate or deflate numbers. Networks that include arrest data understand
these issues and have found that, over time, arrest data have been useful in understand-
ing the drug problem in their communities. These data are particularly important for
detecting new drugs entering the community, for it is often common for the more expe-
rienced drug users to have tried new drugs that become available.
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TIPS FOR ACCESSING DATA FROM AGENCIES
The following steps should be taken to access data:
(a) Convince the agencies that they can benefit from the exercise or that it will
not be detrimental to them;
(b) Fully explain the activities of the network and for what purpose the data will
be used;
(c) Acknowledge the contribution of agencies and respect their data ownership
by only using the information for agreed purposes;
(d) Build up personal relationships of trust;
(e) Get political endorsement for the network activities;
(f) Provide feedback and try to involve the agencies in the network activities
where possible.
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In many cases, existing data may not be readily available. Records of drug use patterns
may not be kept or those records that are available may be in the form of entries in log-
books or as case files. This will be a major challenge to each network. To make matters
more complicated, it is possible that in most communities, there will be different meth-
ods of data maintenance and access becomes difficult.
If data or reports are not available, there are two approaches that can be used to collect
information for the network. 
(a) If records are available, it is possible to select a short period such as two weeks each
quarter and transfer the record data to network data forms. This transcription can
be done by a network member or a member of the agency staff. In either situation,
it is important that the transcription be reviewed for accuracy; 
(b) Another technique that can be used, particularly if record information is not avail-
able or if the record information does not include reference to the use of drugs, is to
conduct face-to-face interviews with a sample of clients/patients. The sample could
be consecutive cases presented during a two-week period every quarter or some
other acceptable approach. 
Those two approaches are detailed below.
Description of available data
A brief summary of the sources and types of existing data that are collected by networks
is given below. In collecting information from any source, it is important to remember the
following:
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FOCAL POINTS AS A BASIS FOR A REGIONAL NETWORK–
THE CARIBBEAN DRUG INFORMATION NETWORK
Most regional information systems recognize the value of establishing national
focal points to ensure the continuity of activities. In the Caribbean, the Caribbean
Drug Information Network is based around focal points in each participating
country. Focal points act as the national coordinators for information collection,
represent the country in regional technical meetings, and prepare an annual
national reports. As some Caribbean countries participate in both the Inter-
American Drug Abuse Control Commission of the Organization of American States
monitoring activities for the Americas, within the framework of the Inter-
American Uniform Drug Use Data System and in the local Caribbean network, hav-
ing the same focal point for both sets of activities ensures coordination and the
best use of resources. Further synergy is ensured by adopting comparable meas-
ures so that the data collection tools used for network activities do not differ.
Focal points provide a useful role by acting as a centre for communication
between the different agencies engaged in data collection; they do not necessar-
ily have to collect the data themselves.
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(a) If there is a potential of identifying individuals, caution must be taken to protect
them wherever possible by having the agency aggregate or summarize information;
(b) Staff within the agencies who have access to information that the network needs
have other primary obligations and may not be cooperative in helping the network; 
(c) Although it may not appear as such, most agencies have limited resources and may
not be so interested in the network, unless they can see that it could help them gain
access to additional resources.
Existing agency data
Drug use treatment
One of the main indicators used as a basis for most information systems is reports from
specialized drug treatment services. As with health problems, when considering drug use
treatment resources, a list of places where drug users would go for treatment must be
developed. These could be programmes that specialize in the treatment of drug use and
may be free-standing clinics or centres, or they could be units of general psychiatric or
medical clinics and hospitals. Treatment programmes and medical and psychiatric hospi-
tal admission records would be good sources of information on drug use and drug users. 
Advantages. As drug treatment programmes focus on drug abuse, they are more likely to
collect detailed information about what drugs are being used by their clients and how
those drugs are used (for example, injecting, snorting or smoking). In some cases, clients
are even tested using urinalysis to determine their current use patterns. In addition, in
many cases, drug treatment programmes want to know what types of drug problems they
may need to address in treatment and therefore may be more forthcoming with informa-
tion, particularly within a network that includes representatives of other types of agencies.
Admission forms provide the best information about what drugs clients were using prior
to coming into treatment.
Disadvantages. In many situations, treatment records include “drug of choice” or “primary
drug problem” and may not ask about other drugs. Furthermore, it is important to get
information from both publicly and privately funded treatment programmes, as clientele
may use different types of drugs. As mentioned before, another disadvantage of drug treat-
ment information is that those in treatment may not represent the current patterns of
drug use; many treated users may be older and the drugs they use may not represent
emerging patterns of use. Not all treatment admissions are self-motivated and may be
referred from a number of other agencies, including law enforcement, for a number of rea-
sons specific to non-drug use, and therefore there may be inherent biases in the treatment
information. Another problem consists in distinguishing between new treatment demands
and long-time service users. As many drug users drop out of treatment or relapse after
receiving care, drug services often have a disproportion number of long-term and older
repeat attendees. The characteristics of this group may be different from those of new
clients entering treatment for the first time. Many treatment reporting systems therefore
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try to distinguish between first and subsequent treatment demands. As some people will
also visit more than one treatment service during a reporting period, methods have also
been developed to reduce the possibility of double counting. It is also important to remem-
ber that drug users typically seek help for a drug problem several years after they initiate
use. Treatment data are therefore considered a “lagged indicator” of incidence. For exam-
ple, when the drug treatment services in the United Kingdom of Great Britain and
Northern Ireland started to observe large numbers of heroin chasers seeking help in the
mid- to late 1980s, the epidemic of new users was already five or six years old, having start-
ed at the beginning of the decade if not earlier. Another factor that will influence the use-
fulness of such data is the level of development of treatment services in a country and the
range of services on offer. This issue is also important when the scale or nature of treat-
ment provision changes. Increased treatment demand may simply represent an increase in
capacity or the development of new services that prove more attractive to those with drug
problems. For example, the development of a new stimulant service may lead to increased
reports of treatment demand by stimulant users-regardless of patterns of use within the
wider community 
Recommendations. Understanding how people come to treatment and how information
regarding drug use is recorded is important to understanding the data that are collected.
Also it is important to show the treatment programmes that their participation in the net-
work may help them access additional resources as they can better document the drug
abuse situation in their communities. A good example of a treatment reporting protocol
that has been widely used in many cities is that of the Pompidou Group first treatment
demand format (http://www.coe.int/pompidou).
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TREATMENT DATA COLLECTION-THE MODEL OF THE SOUTH AFRICAN
COMMUNITY EPIDEMIOLOGY NETWORK ON DRUG ABUSE
The South African Community Epidemiology Network on Drug Abuse uses treat-
ment demand data as one of its core data sources for understanding patterns and
trends in drug consumption in South Africa. In this system, data are collected
manually using a standard treatment data form, similar to that used by other sys-
tems like the Pompidou Group first treatment demand format (see Exhibit 1). This
form is manually completed for each patient and then posted to a coordinator for
a designated geographic area, or province, who collates the data. The province
coordinator then hosts a meeting with representatives from treatment agencies
and other relevant information providers to discuss and interpret their data. A rep-
resentative from each province then reports, along with other relevant data and
information, to a forum at the national level to form a picture of what is hap-
pening in his or her province. 
This system works well in South Africa as most of the designated subregions, or
provinces, have sufficient specialized treatment centres for alcohol and other drug
use, but not so many that this manual system becomes cumbersome. Also, this
manual system overcomes the need for computers and specialized data entry soft-
ware at treatment centres-with a pencil and postal service being the minimum
resources required for participation in the network. 
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Hospital admissions and emergency department logs
General hospital data can also be used to collect information on drug consumption, but it is
usually a more complicated and demanding task than working with specialized drug treat-
ment centres. However, if specialized treatment centres do not exist or have very limited cov-
erage in a country then hospital data, especially that from psychiatric hospitals, may provide
a good starting point for obtaining information on the types of drugs for which people are
seeking help. Record-keeping in hospitals varies greatly from country to country. In some
countries, hospital admissions and discharges are reported centrally, so that hospitals will
have the information available. Elsewhere no central records may be available. If the
International Classification of Diseases is used to code the diagnosis associated with the
hospital stay, then this may allow the number of drug-related admissions to be assessed.
However, unless drug use is the primary, secondary or contributing diagnosis, it will not
appear on the reports. In addition, the individual drug type may not be listed, nor will other
useful information necessarily be available, such as the route of administration. 
Urgent or emergency medical care is generally provided in a facility for unscheduled serv-
ices to persons whose conditions require immediate attention. These would include trau-
ma cases as well as overdoses. In many countries, persons without access to medical serv-
ices (such as those in poverty or new immigrants) will use emergency facilities for less
urgent illnesses. Some emergency departments maintain admission logs that include the
reasons for visits and outcomes of visits. However, if the involvement of drugs is not obvi-
ous, unless emergency department personnel ask about the use of drugs, there will be no
record of such use available.
Advantages. There are a number of advantages of gathering information about drug users from
hospitals and emergency departments. Drug abuse epidemiologists believe that when new
drugs or new ways to use drugs occur, there will often be people who will have negative phys-
ical reactions to them and will either go on their own to the emergency departments or will be
taken there by others. In addition, there are many drug users who will not use drug use treat-
ment programmes or be arrested, but who will use the medical care system. Obviously, the
development of the health-care system and the ease with which those with drug problems can
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(continued)
The South African Community Epidemiology Network on Drug Abuse system is
now being expanded to other Southern African countries under the SENDU net-
work, although the relatively low coverage of specialized treatment facilities in
some of the Southern African countries has highlighted the need for capitalizing
on existing data from non-specialized treatment facilities for drug users, such as
psychiatric hospitals and general health-care settings. 
For further information on this treatment reporting system visit the SACENDU web
site http://www.sahealthinfo.org/admodule/sacendu.htm.
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access it greatly influence the potential of this information source. In countries with a tradi-
tion of medical reporting and where health-care provision is good, more potential will exist
than for those countries in which access to medical provision is restricted. 
Disadvantages. The major disadvantages of these resources are: (a) accessing the informa-
tion and (b) once accessed, the completeness of the information available. As with all of
the methods needed to gather information on drug use, particularly on a regular basis, a
great deal of “upfront” work needs to be done. Hospital and emergency department offi-
cials need to be convinced of the importance of collecting this information. It is suggest-
ed (National Institute on Drug Abuse [2]) that such information allows local hospitals to
document the expenditure of their resources for drug use treatment and will help the local
medical community understand the health care needs of drug users so that improved
strategies for medical care and for the treatment of drug use can be developed. If, however,
even basic medical provision is restricted, then it may be that priority is given to other
health needs. Where medical staff are under extreme pressure and resources are limited,
they may simple not be able to engage in monitoring activities, especially if these are not
viewed as a priority. The resources available for health care also may influence the will-
ingness of agencies to take part. For example, private hospitals may not wish to engage in
what they see as extra work unless remuneration is made. Confidentiality policies can also
make medical personal cautious or unwilling to provide information on their patients. This
problem can usually be addressed by asking for data in aggregate form and by stressing
that no personal identifiers are required and that individual data will be kept confidential.
If data can be accessed, it may be incomplete, with information on patterns of use, drug
type and route of administration missing or not collated in a standard fashion. These lim-
itations in data quality can make meaningful analysis of the data difficult 
Recommendations. Two major approaches have been used to collect this type of informa-
tion. One way is to select time periods over the calendar year and provide access to the
hospital discharge logs (discharge is preferable to admission, as during the hospital stay,
diagnoses are made based on test results) or emergency logs, and either select a random
sample of patients discharged or seen in the emergency department and abstract from
their medical records. A second method is again to select time periods over the calendar
year, but have research staff available 24 hours a day to interview patients about the rea-
sons for their visits and about their drug use. Costs in terms of manpower and training are
involved with each approach. It will be important to make sure that the times selected rep-
resent variations in season or climate, in special holidays etc., that the periods of data col-
lection will be sufficient to be able to detect drug use, and that the denominator of all
patients and their visits will be kept. This second method allows a standard reporting form
to be used prospectively, and therefore means that there is more chance that the descrip-
tive information of interest can be collected.
Public health reports of infectious diseases
In many communities and countries, there is a requirement to report diagnoses of infec-
tious diseases, including: HIV infection or acquired immunodeficiency syndrome (AIDS);
hepatitis A, B, C etc.; and sexually transmitted diseases that appear at higher rates in
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drug-using populations. For example, many countries participate in sentinel surveillance
systems that continuously monitor subpopulation groups, so that pregnant women may
be anonymously screened for HIV as a convenient sample to explore exposure in the
broader community. 
Advantages. Like the hospital and emergency department information, the advantage of
these reporting systems is that they will include drug users who may not appear in drug
use treatment or arrest databases. Furthermore, if it is noted that rates of drug users in
these systems are increasing, as they have in many countries, particularly in developing
countries, it will be important to target prevention and treatment efforts to limit the
spread of infection.
Disadvantages. The problem that these systems pose is that most reporting forms do not
require reporting drug use, or if they do, this information is either missing or inaccurate.
Recommendations. It is important to work with those who have responsibility for the
reporting requirements for these systems to convince them, first, to include information
on the reporting forms about drug use, and, secondly, to make sure that the information
requested regarding drug use is appropriate and relevant. For instance, just asking about
drug use is not helpful. Information is needed about types of drugs used, how drugs are
used (for example, by injecting, snorting, smoking or swallowing), frequency of use of
drugs and length of time using drugs. 
Poison control reports, forensic science and medical laboratories
Not every community has a central system for reports of poisonings. However, when these
are available, they can provide important information on both emergent drug use problems
and existing use. Where poison control centres exist, both medical personnel and the pub-
lic report negative health effects of drugs and other substances. For instance, in the United
States, it has been the poison control centers that brought the use of gamma-hydroxybu-
tyrate (GHB) and its precursor gamma-butyrolactone (GBL) to the attention of the members
of the Community Epidemiology Work Group. This drug is used along with Ecstasy in clubs
and at dance parties such as raves, and can cause death. Similarly, in Europe, an early warn-
ing system links reports from various sources, including forensic science laboratories, to
assess the availability and risk of new drugs reported in any one member of the European
Union. Other routine data sources may arise from medical laboratories, such as screening of
intoxicated drivers or subpopulations of drug users in treatment settings.
Advantages. The advantages of using the poison control centre reports are similar to the
above: detecting emergent drug use problems and getting information on drug users that
may not appear in other reporting systems. 
Disadvantages. Clearly the disadvantages are similar to the other medical-based reporting
systems: the reports are on drug use episodes and not necessarily on long-term drug users,
and may not have sufficient information regarding the specifics of drug use to understand
what population is represented in the reports. The number of acute poisoning cases may
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be low and, for some drug types, negligible. In many countries, forensic science systems
are not sufficiently developed to provide consistent poisons reports. Even where they are
well developed, difficulties may still exist in correctly identifying the substance responsi-
ble for the poisoning, especially when multiple substances are being consumed. When
using medical toxicology data, cases need to be de-identified or confidentiality must be
ensured, and sampling issues may present an obstacle for detecting trends in particular
drug types (for example, tests on intoxicated drivers may overrepresent stimulant drugs).
Recommendations. It is may be useful to work with the poison control centres and foren-
sic science laboratories to review and revise reporting forms to get the information on drug
use that would be needed for the data system on drug users being developed.
Medical examiners and coroners reports
In most locales, medical examiners and coroners are responsible for investigating sudden
(unexpected) or violent deaths. As legal issues are at stake, they must be able to compile
sufficient evidence to support their determination of cause of death. In many countries,
their reports of cause of death are an important part of the nation's vital statistics.
However, there is great variation in the training of medical examiners and coroners and in
their level of expertise and interest in issues such as drug use. Medical examiners and
coroners are not always trained medically or legally. The quality of reports of cause of
death is therefore likely to vary between areas. For example, in a recent review the prac-
tice of medical examiners was found to vary so greatly between European countries that
meaningful comparisons could often not easily be made even where the same internatio-
nal diagnostic criteria had been adopted. Furthermore, not all deaths are thoroughly inves-
tigated and, even in cases where all deaths are investigated, toxicological screens to deter-
mine the use of drugs are not always pursued. So it is important to know about these
issues when accessing death reports. In addition, in most cases, death data are not acces-
sible to the public and special arrangements need to be made to gather this information.
Drug users may die from a number of reasons. Cause of death may be directly linked to
drug use, such as in drug poisoning or overdose. Or cause of death may be indirectly linked
to drug use, but directly linked to the lifestyle of the drug user, or may involve homicide,
suicide, AIDS or some other infection (such as sepsis or bacterial endocarditis). Or a drug
user may die of natural causes and other diseases. Most drug use data systems include
information of the direct and indirect causes of death, but unless the information on drug
use is collected, information for deaths among drug users due to natural causes or other
diseases will not be included.
Advantages. This is another source of information, if toxicology or other screening is com-
pleted, on emergent drugs of abuse and of drug users that may not be found in the other
data sources.
Disadvantages. There will be many deaths due to drug use and among drug users that will
be missed. The lack of medical training, failure to conduct posthumous investigations and
drug testing, and the limitations as to which deaths are referred to a medical examiner or
coroner will have an impact on who is reported in this system. The comparability of data
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on drug deaths between countries is low, and even within countries considerable variation
may exist. Many drug users consume a range of substances, often including alcohol, and
coroner's reports often only report on this in a summary fashion, referring to “opiate
death”. It can also sometimes be difficult to distinguish deliberate poisonings (suicides)
from accidental drug overdoses.
Recommendations. A thorough understanding of what deaths are referred to the offices of
the medical examiner and coroner will clarify the limitations of the data. In addition, most
communities have a central reporting system for deaths. It is important to remember that,
although all of these data sources have limitations, taken together, they can provide an
excellent idea of drug use patterns within the population of the geographic area being con-
sidered. Arrangements can be made with the medical examiner and coroner to access their
records, or they can be made with the local public health agency that is responsible for
vital statistics to gain access to reports on a periodic basis. There are a number of techni-
cal resources on improving data quality, and international standards are being developed
in this area (see the EMCDDA web site for a review of the issue http://www.emcdda.org).
Law enforcement
The illegal nature of drug use in most countries will place drug users at risk of arrest.
Therefore, information from arrest records also provides information about people arres-
ted for drug use offences. In addition, many law enforcement agencies seize drugs and, in
some cases, analyse the seized drugs as to type of drug and purity levels. Law enforcement
agencies may also keep track of the street prices of drugs and have a better understanding
of how drugs are marketed. 
Advantages. Law enforcement agencies have access to information, such as price and pur-
ity levels, that most other agencies lack. They also have the potential, as with hospitals
and medical examiners, to acquire information on a broad range of population groups,
including members of the middle and upper socioeconomic classes, as they may be called
in cases of domestic disputes, and may make arrests for driving under the influence of
alcohol or drugs.
Disadvantages. As in the cases of the other agency data, law enforcement information is
subject to administrative decisions. If there is great public concern about drug abuse, the
police are more likely to step up their activities and arrest more drug abusers. Law
enforcement agencies may also feel the need to “prove” their worth during times when
budgets are being allocated and, at those times, more drug seizures may be made. In some
countries law enforcement agencies do not typically cooperate with health and social
agencies and may be reluctant to share their data. The categorization of arrest data may
also be misleading. For instance, many jurisdictions have laws against possession and
sales of drugs. Persons arrested for those reasons may not necessarily be drug users them-
selves. For that reason, it is important to distinguish between charges related to the use
of drugs, the selling of drugs and the trafficking of drugs. When seizure data is analysed,
it is particularly important to distinguish between those drugs intended for sale within
the country concerned, and drugs intended for consumption elsewhere. Furthermore,
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drug use carries great social stigma and those from the higher socioeconomic groups may
be less liable to arrest, or may be able to have their arrest records expunged or have the
reason for arrest altered.
Recommendations. Law enforcement agencies vary as to how they record arrest and seizure
information. In some areas, specific individuals or divisions are responsible for maintain-
ing data on arrests. As with all the other categories of agency-based data, it is important
to understand how the data are recorded and to know what political or social pressures
could be occurring that would influence what arrests are made.
It should be borne in mind that the objective of the network is not only to define the char-
acteristics of the drug abuse problem in the network's target area, but also to identify
emergent drug abuse patterns. For this reason, having data for sequential time periods,
quarterly, semi-annually or annually, is very important. Interpretation of any changes that
are observed must be cautiously made with a great deal of consideration of whether what
is being observed is an artifact of some administrative decisions or a real pattern change.
Networks are therefore encouraged to include information from a variety of agencies,
including at least a health agency, a law enforcement agency and a drug abuse treatment
programme. If there appears to be some consistency across those agencies in an emergent
pattern, the network members will be more confident about the observed trend. Having
similar information from a number of geographic areas will also strengthen their findings. 
Surveys
In general, three types of surveys are available to networks, covering the general popula-
tion, students, and special populations. General population surveys include either person-
to-person, telephone or mailed interviews with a representative sample of the general pop-
ulation usually in households. They vary by age range and whether certain subgroups are
oversampled, that is, whether the sample of persons being interviewed include larger
numbers of groups than actually appear in the general population. For instance, a natio-
nal household survey on drug abuse may over-sample specific ethnic groups to make sure
the number of people representing those groups is sufficient to make estimates of drug use
patterns for them. The general population survey can provide a good estimate of the num-
ber of persons in the population who use drugs at the time of the survey (indicating preva-
lence for some drug types). They perform less well for more stigmatized and low-preva-
lence behaviour (such as drug injecting or heroin use). While general population estimates
may be cost-effective and useful in large developed countries, that is not always the case
in developing countries. The value of this kind of exercise is particularly questionable in
countries that lack a tradition of public polling or where suspicion of the authorities is
high among the general public. The high cost of this kind of work and the technical
sophistication of the sampling methods required also mean that investing in this activity
may not yet be cost-effective for many developing countries.
Student surveys provide information on drug use patterns among young people. As drug use
is often initiated when people are in their teens, student surveys provide estimates of the
incidence of drug use (new cases). These surveys are generally self-administered within the
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school setting. What ages are targeted for these surveys depends on a number of factors:
what existing data and population surveys indicate are the ages of initiation of drug use; the
foci of drug abuse prevention programmes; and, of course, the reading and comprehension
levels of the students. Usually, student surveys are conducted with children aged 10 and
older. Module III of the GAP toolkit gives guidelines on conducting school surveys. An
increasing number of countries have conducted surveys of their student population, and the
data can be useful in making comparisons between countries (for further information, visit
the web site http://www.undcp.org/drug_demand_gap_m-toolkit.html). 
Special population surveys are generally conducted with well-defined population groups
meeting certain inclusion (and exclusion) criteria. These may include the homeless or
street children, users of specific drugs, representatives of special groups such as sex work-
ers, or young people who attend nightclubs or dance events. These community samples of
drug consumers can provide rich data about the behaviour of this group, which is difficult
to obtain by other means. However, interviewing drug users who are not in contact with
services is a challenging endeavour. The primary challenge of special population surveys
consists in estimating the denominator and the characteristics of the total population to
allow that the sample surveyed is indeed representative. Further sources of information on
the application of special population surveys is provided in the references to the present
GAP Toolkit Module 1.
All surveys are most useful if they are conducted on a regular basis to allow trend analy-
sis. Annual or biannual surveys using the same survey form, sampling approach and data
collection methodology can lead to detection of up and down trends that influence the
allocation of resources to either treatment or prevention services. 
Advantages. There are several major advantages of surveys over other data collection 
methods. If well designed, surveys provide the information needed to develop incidence
and prevalence rates with precision. They have broad coverage, including those popula-
tions of drug abusers who are able to maintain their habits without being arrested or 
hospitalized, perhaps seeking treatment from private clinics or practitioners. Other 
information can be added to a survey of the characteristics of drug users compared to 
non-drug users and of other factors that are of interest to those sponsoring the survey.
When surveys are conducted on a regular basis, every year or every other year, it is 
possible to monitor trends across time. 
Panel surveys (longitudinal, prospective studies), in which the same group of people are
interviewed on a regular basis, have the potential for identifying risk and protective factors
relative to initiation and involvement in drug abuse, documenting the progression of drug-
using behaviours, and specifying consequences of drug abuse and dependence.
Disadvantages. The major limitation of surveys is the failure to identify emergent drug use
trends (if you don't ask you won't find out) and their poor performance with stigmatized
and low-prevalence behaviour. Furthermore, if only a general population survey is con-
ducted without an oversample of young people, it will be difficult to ascertain new cases,
and information on the most affected populations (those who are arrested or live on the
streets) will not be available.
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The conduct of surveys requires special training and can be very expensive to complete. To
be successful, a survey must have high response rates across subpopulations so that the
results will not be biased in any way. School surveys are significantly cheaper and arguably
more practical and their completion is technically straightforward. For information sys-
tems in developing countries, school surveys are therefore usually a higher priority than
general population surveys. However, it must be remembered that: students will only be
likely to report drug use if they are convinced that their answers are confidential and will
not result in any negative consequences; low-frequency events will still require large sam-
ples to detect; and those young people who may be most at risk of using drugs may be
absent (truants, non-attendees etc.). Also, in some parts of the world, access to education
is limited or many pupils may leave school at an early age; this again will compromise the
usefulness of school surveys.
Recommendations. if the network is planning to use survey data, it will be important to
know the following:
(a) What population does the group of respondents represent? Does it include children
and adolescents? Adults and older people? Does it include men and women? Does
it represent urban and non-urban groups? The way to determine the answers to
those questions is to compare the proportions of the respondents within each of the
descriptive categories to the proportions of the total population. For example, if the
total population consists of 49 per cent males and 51 per cent females and the
respondent population consists of 58 per cent females and 42 per cent males, the
survey slightly underestimates drug use rates for males;
(b) How large is the sample selected for the survey? Is it large enough to ensure that
estimates of the rates of specific categories of drugs of interest are stable? A statis-
tician may be needed to assist in determining the answer to that question;
(c) What drug categories are included in the survey? Are those categories representative
of drugs used in the community? Are the categories of interest to the interpretation
of the survey results and to the network?
(d) What drug types are asked about, do they cover the areas of interest, and are the
questions posed in a clear and meaningful way—distinguishing between different
types of psychotropic substance?
(e) Were all possible measures taken to reduce the bias in responses by making the
respondents feel confident that their answers were confidential and not likely to
lead to negative consequences for them or their communities?
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School surveys are recognized as one of the easiest ways to make comparisons
between countries. They are also relatively inexpensive and methodologically
straightforward. This data source is often among the first to be systematically col-
lected by new networks. A good example of this is the approach adopted by the
Inter-American Uniform Drug Use Data System. The System is based upon a num-
ber of indicators, but participating countries are encouraged to conduct a school 
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Qualitative data
Qualitative information can be used in a drug information system either to complement
and aid the interpretation of other data collected or alone where only very limited data
are otherwise available. The main sources of qualitative data used include focus groups,
in-depth interviews, key informant surveys and more sophisticated ethnographic
approaches. The incorporation of qualitative data into a drug information system will
greatly aid the interpretation of trends in indicator data by providing more specific infor-
mation on what drug trends represent. For example, rapid assessment approaches often
incorporate qualitative methods along with existing data and specialized surveys on drug
use to facilitate interpretation of the later sources. Qualitative information also serves an
important function in providing information that cannot be pre-empted by a structured
survey questionnaire or through existing data sources, and in doing this can act as a 
sensitive warning of new drug trends that may require further investigation. The richness
of information provided on the broader context surrounding drug use (for example, 
cultural, social, economic and demographic factors) can be helpful in understanding the
antecedents and consequences of particular drug-using behaviours. As such, qualitative
information is very valuable when it comes to designing interventions in response a 
particular trend detected by a drug information system.
Advantages. One key advantage of qualitative data collection is that it does not depend on
the availability of infrastructure relating to drug problems. That is, it is a viable form of data
collection in situations where there are no specialized treatment agencies for drug depend-
ence, where there is no routine toxicology for illicit drugs, or where coverage of services for
drug-related morbidity are inadequate for monitoring purposes. Similarly, in a situation
where there is minimal existing knowledge about the drug situation, qualitative methods are
sufficiently flexible to provide a starting point for gathering information, which in turn can
provide direction for further data collection activities (for example, providing contact points
for snowball samples of drug users). Another advantage is that some methods of qualitative
data collection can be conducted with minimal cost and infrastructure and can be adapted
to existing structures (for example, key informant interviews can be conducted over the tele-
phone to overcome geographic barriers, and existing groups of people concerned with drug
issues could be used to form the basis of focus group discussions).
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survey as one of their early activities. A standardized method and short question-
naire is used to ensure the comparability of results and support is given to some
of the more technically difficult activities such as drawing the sample. Tools also
exist to allow the data to be easily entered and analysed. In this way, the Inter-
American Uniform Drug Use Data System is successfully generating a comparable
data set for countries in the region. As with other data sources, school survey data
have their weaknesses and do not provide a full picture of the drug problem.
Nonetheless, this method does provide extremely useful data that can be rela-
tively easily collected. By repeating the survey every few years using the same
methods, a data set that reflects changes over time can be assembled.
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Disadvantages. The open-ended or unstructured nature of data collected through these
methods means that considerable time and expertise is often required for data analysis.
Also, considerable training and experience are necessary to undertake some qualitative
data collection (for example, on the basis of ethnography), so that the applicability of the
methods depends on the availability of human resources to support data collection.
Obviously the applicability of the methods also depends on the availability of participants
who have good knowledge of the drug use situation, and their willingness to disclose this
information. Practicalities of interviewing people also need to be considered, such as social
and cultural factors affecting the group dynamics within focus group discussions. 
Recommendations. There needs to be clarity on the specific target group for the qualitative
research and the questions that need to be answered from the research. Methods of quali-
tative data collection need to be adopted that are clear, transparent and appropriate given
the available level of expertise and infrastructure to collect and analyse data (including the
choice of software). Methods chosen need to accommodate the local social and cultural fac-
tors that may impinge on the quality of data collected. People from whom qualitative infor-
mation is obtained should have adequate knowledge of the research question through con-
tact or experience with drug users. Similarly, one should consider the impact of social and
cultural factors on reporting in group situations (for example, gender, ethnicity and status)
and the method used for recording data (such as written records or tape recordings), and
methods should be chosen that minimize the adverse impact of those factors. 
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DRUG TRENDS—THE ILLICIT DRUG REPORTING SYSTEM
Specialized surveys of drug users feature in most systems in an ad hoc manner,
where they are used to investigate issues highlighted by existing data, or are
included where they already exist and provide relevant information. One system,
namely the Illicit Drug Reporting System in Australia, undertakes specialized sur-
veys of drug users as part of its routine data collection-these data actually form-
ing the core of this strategic early warning system. 
The Illicit Drug Reporting System uses convenience samples of injecting drug users
in capital cities as a sentinel population for monitoring trends in problematic
forms of drug use. Annual self-report data from this group provides a barometer
for trends in the type of drugs being injected, health-related issues (such as fre-
quency of injection, HIV risk-taking behaviour and overdoses) new forms of drug
use, and changes in the availability and marketing of drugs. 
Use of specialized surveys as a routine data source works well in Australia because
there is a substantive population of injecting drug users who have broad exposure
to the main drug types and who are often the first group to be exposed to changes
in drug availability and shifts in patterns of drug consumption. Also, this group is
readily accessible through the existing service providers and there is a strong tech-
nical infrastructure for researching this group. While this method provides a cost-
effective means of keeping a watchful eye on emergent drug trends in the
Australian context, it would require considerable investment in countries where
active survey research on populations of drug users was not commonplace.
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Definitions of data elements
To be useful in making comparisons across time and space, usually information systems
use standard definitions of data elements. The most common data elements and their def-
initions are presented below.
Basic concepts
Incidence 
Incidence may be defined as the proportion of people within a defined population resid-
ing in a defined geographic area who are newly diagnosed as having a specified health 
condition or problem in a given time period. For example, 5 per cent of persons living in
country X were newly diagnosed with condition Y in 1999, or 2 per cent of persons aged
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The key items are as follows:
(a) Coverage-city, country, region;
(b) Specification of drug categories;
(c) Data resources;
(d) Time period covered by data;
(e) Characteristics of drug users provided by data;
(f) Format of data-reports, hard copy in files, computerized.
Nevertheless, this system provides an example of how specialized surveys can pro-
vide valuable information to assist with understanding trends in drug consumption. 
Perhaps more relevant to developing regions is the supplementary data provided
to the Illicit Drug Reporting System through the application of routine key inform-
ant surveys. The collection of qualitative data from experts who have regular con-
tact with drug users through a semi-structured interview is inexpensive, requires
minimal infrastructure, and has been successfully applied in developing regions.
For example, the expert opinions of school counsellors have been incorporated
into the routine data collection activities of the Seychelles through a semi-struc-
tured questionnaire on drug trends among youth. Similarly, key informant inter-
views were used in Pakistan to map intra-country variation in drug consumption
patterns and service provision.
For more information on this system, visit the Illicit Drug Reporting System web
site http://ndarc.med.unsw.edu.au/ndarc.nsf/website/IDRS.
USING SPECIALIZED SURVEYS AND KEY INFORMANTS TO MONITOR
DRUG TRENDS-THE ILLICIT DRUG REPORTING SYSTEM (continued)
Developing an Integrated Drug Information SystemGAP Toolkit Module I
34 years and older residing in London reported having used marijuana for the first 
time in 2000.
Prevalence
Prevalence may be defined as the proportion of people within a defined population resid-
ing in a defined geographic area who are diagnosed as having a specified health condition
or problem in a given time period (includes newly diagnosed cases or persons who newly
initiated a problem behaviour and existing cases). For example, 15 per cent of persons liv-
ing in country X were diagnosed with condition Y in 1999, or 10 per cent of persons aged
34 years and older residing in London reported having used marijuana in 2000.
Time periods
In general, drug abuse researchers use the following four time periods when reporting
about drug use in a population or subpopulation.
(a) Lifetime refers to the use of a specific drug at least once in a lifetime;
(b) Annual refers to the use of a specific drug at least once in the prior year (12
months);
(c) Current refers to the use of a specific drug at least once in the prior month (30 days);
(d) Daily refers to the use of a specific drug 20 or more times within the prior month.
Drug categories
As with time periods, drug abuse researchers generally report on the incidence and
prevalence of drug use within a defined population for a specified time period by the
drug categories listed below. The drug categories are fairly inclusive, yet it is known that
many populations within certain geographic areas may use drugs not included in the list.
The following special categories are important and should be included in all reports 
on drug abuse:
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(a) Cannabis type. Includes marijuana and hashish;
(b) Opioids. Includes heroin, opium, and other opioids (for example, morphine, fentanyl
and buprenorphine);
(c) Cocaine. Includes powder (salt) cocaine, crack cocaine and other forms of cocaine;
(d) Amphetamine-type. Includes amphetamine, methamphetamine and Ecstasy-type
amphetamines;
(e) Sedatives and tranquilizers. Includes legally manufactured barbiturates and benzodi-
azepines;
(f) Hallucinogens. Includes lysergic acid diethylamide (LSD) and other hallucinogens;
(g) Solvents and inhalants. Includes a range of volatile substances such as
gasoline/petrol, adhesives, aerosol products (for example, paint sprays, air freshen-
ers, analgesic sprays), anesthetics (such as nitrous oxide), cleaning agents, solvents,
and room odorizers (for example, amyl nitrite, butyl nitrite);
(h) Other drugs. Any illicit substances that do not fall within the above categories, such
as gamma-hydroxybutyrate and anabolic-androgenic steroids. 
Age categories
Using standardized age categories helps compare trends for different groups over time both
across and between populations located in different cities, regions or countries. In most
countries, drug use patterns vary across age groups, with children using mostly inhalants
and solvents or marijuana, while those in their 20s and 30s may use drugs such as heroin
or cocaine. There are other age-related data elements that are of interest to drug abuse
researchers. These elements are more likely captured through surveys where self-adminis-
tered or face-to-face interviews are completed. In most data sets, age is collected as an open
category and summarized according to reporting needs. Age groupings often referred to in
summary statistics of drug data include:
(a) Adults. 15-64 years;
(b) Youth. 15-24 years;
(c) Adolescents. 15-16 years.
Route of administration
The harmful consequences of drug abuse vary not only by drug type but also by the way
the drug is consumed (route of administration). In particular, drug injecting is associated
with the most severe consequences such as transmission of HIV infection and an increased
risk of overdose and of drug dependence. Typical routes of administration include, oral
consumption (eating, drinking and swallowing), sniffing or snorting (inhaling up the
nose), smoking or inhaling sublimate (“chasing the dragon”) and injecting. Most infor-
mation systems attempt to differentiate data on drug users according to route of adminis-
tration, especially for those drugs that can be injected. Injecting behaviour is often con-
sidered so important that a separate question will be used to ask about lifetime and cur-
rent injecting experiences and possibly the extent to which the individual has shared
injecting equipment with others.
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Establishing a database
Information that is obtained by the network will appear in a variety of formats. It is impor-
tant that one format for the presentation of survey and agency-based data be used by net-
work members. This type of standardization will be helpful as the network maintains itself
over time. The problem with standardization is that it focuses on the lowest common denom-
inator, that is, those databases that have the least amount of information. It may be that sep-
arate formats are developed for each source of data. This means that the network may need
to have formats specific for treatment, for law enforcement, for emergency departments etc. 
The reference to “existing” data means data that are available in the form of tables or graphs
in reports or stored in data files that are computer-accessible and can be made into tables.
Putting data into tabular form enables information to be presented in a small amount of
space. Tables present information, or data, in an orderly fashion in rows (the horizontal lines)
and columns (vertical lines). The intersection of a row and a column creates a cell. 
Tables are structured as follows:
COLUMN 1 COLUMN 2 COLUMN 3 ...COLUMN N
CELL 1,1 CELL 1,2 CELL 1,3 CELL 1,N
CELL 2,1 CELL 2,2 CELL 2,3 CELL 2,N
CELL 3,1 CELL 3,2 CELL 3,3 CELL 3,N
CELL N,1 CELL N,2 CELL N,3 CELL N,N
The columns and rows represent different data items or characteristics. For example, a col-
umn may represent a drug category and the row may represent age groups. Then cell 1,1
would represent column 1-category and row 1-age group. If column 1 was heroin and row
1 was age group under 17, then cell 1,1 would be either a number or percent representing
people using heroin who are under 17.
In available tables, the data presented in a cell is either a number or a percentage. If it is
a percentage, it is important to note whether the 100% is the sum of percentages found in
the rows or columns or of both rows and columns combined. Below are three tables that
look at drug use by gender and age.
The first table shows what percentage of male and female current users of illicit drugs are
under 17 years of age, 17 to 24, 35 to 34 and 35 or older. The percentage then is: age
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group/gender, where the denominator equals the total number of males or females and the
numerator equals the total number of males within each age group. 
Table 1.   Distribution of current users of any illicit drug: gender by age, 1999
(Number and percentage)
Age groups
All ages <17 17-24 25-34 35+
Gender Number % Number % Number % Number % Number %
Male 350 100 100 28.7 175 50 25 7.1 50 14.2
Females 150 100 30 20 80 53.3 15 10 25 16.7
Total 500 100 130 26 255 51 40 9 75 15
Table 1 shows that the distribution of males and females by age groupings is similar. Half
of the male and the female drug users were aged 17 to 24. The next largest group for both
males and females are those under 17, then those 35 and older and lastly, those 25 to 34. 
Now table 1 will be turned around to determine what proportion of each age group were
males and females using the same numbers. In table 2, the denominator (100 per cent)
will be the same for all age groups.
Table 2.   Distribution of current users of any illicit drug: age by gender, 1999
(Number and percentage)
Age groups
All ages <17 17-24 25-34 35+
Gender Number % Number % Number % Number % Number %
Male 350 70 100 76.9 175 68.6 25 62.5 50 66.7
Females 150 30 30 23.1 80 31.4 15 37.5 25 33.3
Total 500 100 130 100 255 100 40 100 75 100
Table 2 shows whether the gender distribution of drug users within each age group is sim-
ilar to the overall distribution. Seventy per cent of drug users are male and 30 per cent are
female. In fact, males tend to dominate within each age group, although there seems to be
an over representation of males among those under 17.
Table 3.   Distribution of current users of any illicit drug by gender and age, 1999
(Number and percentage; total drug users = 500)
Age groups
<17 17-24 25-34 35+
Gender Number % Number % Number % Number %
Male 100 20 175 35 25 5 50 10
Females 30 6 80 16 15 3 25 5
Table 3 shows the distribution of all drug users by gender and age groups. Thirty-five per
cent of all drug users are males between the ages of 17 and 24, followed by males under
the age of 17, and then females aged 17-24. 
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The data that are important to include in the database by reporting source include:
(a) Type of drug by mode of administration;
(b) Age: actual age in years provided by the data source or converted from the date of
birth to the date of the report (for example, if the date of birth is 22 January 1964
and the date of admission to treatment is 17 December 17 2000, the age is 36 years).
For the network report, consistent age groups are used. To comply with the annual
reports questionnaire and to make the age groupings comparable to other systems,
use the following age categories: children (12 and under); young teens (13-14); late
teens (15-16); young adults (17-24); adults (25-34); and older adults (35 and older);
(c) Gender;
(d) Ethnic group, if applicable.
Examples of formats that are used to store data can be found in exhibits 1 and 2 below,
used by the Pompidou Group of Epidemiology Experts in Drug Problems and the
Community Epidemiology Work Group in the United States, which provide good models
for treatment data.
In addition to maintaining the charts in “hard copy”, it is possible to transfer the charts
from hard copy to computer. In this way, when the network begins to accumulate data over
time, it is possible to examine the data for trends. It is important to note that the trends
must be interpreted cautiously, since many external factors, such as those mentioned
extensively above as disadvantages of using existing data and information, need to be con-
sidered. Trends may actually represent not changing patterns but administrative practices. 
Exhibit 1 below provides an example of a treatment admission data-collection form 
adapted from the Pomidou Group first treatment demand format.
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Exhibit 1.   Form used for collecting treatment data
1. City [  ][  ] 2. Treatment centre [  ][  ][  ]----[  ][  ] 3. Client No. Internal code
City-specific centre Code number -type of centre
A. Treatment contact details
4. Date of treatment demand [   ][   ]-[   ][   ]-[   ][   ] 
Day    Month  Year
5. Type of contact with this centre (circle)
1. New client         2. Old client 9. Not known
6. (a) Ever previously treated, at any treatment 
centre (circle)
1. Never treated  2. Previously treated  9. Not known
(b) If previously treated, when last? [    ][    ][    ]
Number of months since left last treatment 
(or enter code) 888. Never previously treated  999. 
Not known
7. (a) In contact with other treatment centres 
(specify and circle)
____________________________________________
1. Yes 2. No 9. Not known
(b) Source of referral (specify, and circle code)
____________________________________________
1. Self/family/friends 5. Social services
2. Other drug treatment centre 6. Court/proba-
tion/police
3. General practitioner 8. Other
4. Hospital/other medical agency 9. Not known
B. Socio-demographic information
8. Sex (circle) 1. Male     2. Female     9. Not known
9. (a) Age [  ][  ] Years
(b) Date of birth [  ][  ]--[  ][  ]--[  ][  ]
Day    Month    Year
10. (a) Current living status (circle)
1. Alone 5. Institution
2. With parental family 6. Temporary/homeless
3. With friends 8. Other
4. With partner 9. Not known
(b) Living with drug misusers (circle)
1. Yes     2. No     9. Not known
11. (a) Resident of city (circle) 
1. Yes     2. No     9. Not known
(b) Area of residence within city (specify)
_____________________________________ [  ][  ]
12. (a) Nationality (specify and circle code)
_____________________________________ [  ][  ][  ]
1. National of this country
2. National of other country
9. Not known
(b) Ethnicity (specify) ____________________ [  ]
13. Employment status (circle code)
1. Regular employment
2. Unemployed/casual work
8. Other (specify) 
9. Not known
14. (a) Highest educational level (specify) [  ]
(b) Age left school [  ][  ] Years
(or enter code)
01. Never went to school    88. Still at school    99. Not
known
C. Problem drug use
(a) Drug name (b) Route of (c) Frequency (d) Age at 1st  (e) Duration of
(write in) administration past month use regular use
(enter code) (enter code) (years) (years)
15. Primary drug
16. Secondary (1)
17. Secondary (2)
18. Age 1st used any drug
(b) Route: 1. Inject, 2. Smoke, 3. Eat/drink, 4. Sniff, 9. Not known.
(c) Frequency: 1. 1 per week or less, 2. 2-6 days per week, 3. Daily, 4. Not used past month, 9. Not known.
[  ][  ] Years
D. Risk behaviour
19. (a) Currently injecting (circle)
1. Yes 2. No 9. Not known
(b) If injecting, shared past month (circle)
1. Yes 8. Not applicable (not injecting)
2. No 9. Not known
20. (a) Ever injected (circle)
1. Yes 2. No 9. Not known
20. (b) If ever injected, age 1st [  ][  ] Years
(c) If ever injected, ever shared (circle)
1. Yes 2. No 8. Not applicable (never 
injected) 9. Not known
21. HIV status (circle)
1. Tested-positive 4. Never tested
2. Tested-negative 9. Not known if tested
3. Tested-results unknown
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Exhibit 2 below provides an example of a treatment data collation form adapted from the
Community Epidemiology Working Group in the United States.
Exhibit 2 allows an examination of the characteristics of drug users within each drug cate-
gory. It shows what proportion of those admitted to treatment with a primary alcohol only
problem are men, how many are under the age of 17 etc. This is important information to
have. The percentages that are calculated all use the total number of persons within each
drug category (that is, alcohol only, alcohol-in-combination, heroin etc.) as the denominator. 
However, the network may want to address additional questions that would require the
denominator to be a different one. For example, they may want to know what proportion
of women admitted to treatment use alcohol. In this case, the calculation would use the
number of women admitted to treatment as the denominator and the numerator would be
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Exhibit 2.   Form used for collating treatment data
Reporting site__________
Characteristics of clients admitted to treatment
From __________________ To _____________________, 2001
Month Month
Total number of treatment admissions: _____________
Alcohol only Alcohol-in- Heroin Cocaine Marijuana Amphetamines
combination
Total N
(Use to derive %) 
Gender:
Male ________% ________% ________% ________% _______%  _______%
Female ________% ________% ________% ________% _______% _______%
Race/ethnicity:
White ________% ________% ________% _______% ________% _______%
Black ________% ________% ________% _______% ________% _______%
Hispanic_______% ________% ________% _______% ________% _______%
Age at admission:
17 & under__ __% ________% ________% _______% _______% _______%
17-24 ________% ________% ________% _______% ________% _______%
25-34 ________% ________% ________% _______% ________% _______%
35 + ________% ________% ________% _______% _______% _______%
Route of administration:
Smoking ______% _________% ________% _______% _______% ______% 
Sniffing _______% _________% ________% _______% _______% ______%
Injecting ______% _________% ________% ________% _______% ______%
Other ________% _________% ________% ________% _______% ______%
Secondary drug:
Type of drug # 
%_______ _______ _______ _______ _______ _______
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the number of women admitted to treatment with alcohol only (etc.) as their primary
problem. So using the same information but changing the base, that is, whether it is drug
category or gender, provides answers to two different but very important questions.
Exhibit 2 shows the tabular format that would provide the information where the
client/patient characteristic is the denominator.
Network meetings and interpretation of the data
The network meetings are the most important component in any integrated drug infor-
mation system. It is here that the data are presented and discussed. It is the proceedings
of the network meeting that forms the network report. There are three significant par-
ticipants at these meetings: the chair, the network members and a reporter. 
In these proceedings, the chair of the network meeting has several major roles that must
be played. The chair:
(a) Convenes the meeting and either develops the agenda or assigns this role to 
another network member;
(b) Makes sure that all members keep on schedule;
(c) Makes sure that each member has both the data in the appropriate format and has
a written report;
(d) Allows only a few minutes for questions after each individual report;
(e) Discourages discussion of the data presented until after all presentations are com-
pleted;
(f) Summarizes the key findings that were presented;
(g) Encourages discussion of the findings;
(h) Asks about other corroborating or additional information that is needed and assigns
network members to access this information and to present it at the next meeting;
(i) Assigns someone to write a proceedings report that would include the discussion
and establish a date when the draft is ready for review; 
(j) Assigns someone to disseminate the report;
(k) Every so often, reviews the dissemination list with network members.
The importance of having a short but lively network meeting was emphasized above. Each
network member also has a significant role to play. The members bring to the meeting
information in the form of data, but also in the form of their own expertise and familia-
rity with drugs and drug users within their own communities, whether treatment, out-
reach or law enforcement.
Once each network member has compiled the information from their data source in a stan-
dardized format, they need to write a presentation that: (a) summarizes the data; and (b)
discusses whether factors such as a police sweep or contamination of a widely distributed
drug may have affected the available data, that is, increased arrests for cannabis posses-
sion or increased numbers of emergency department episodes for heroin use.
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Once the network has a number of meetings and a database, the network members should
include another section that looks at trends over time.
Although questions may be raised by network members during their presentations, it is
probably more efficacious to save discussion until the end of the meeting. The chair or
other person assigned to this task should listen and take notes of each presentation, look-
ing for cross-cutting findings or issues. For instance, the network member presenting
information on arrests may mentioned that there appears to be an increase in arrests of
young people for possession of heroin, while the member presenting emergency depart-
ment visits may note that more people under the age of 21 are being seen for heroin over-
doses. Those two observations, when viewed individually, may not signify any changes, but
together they suggest that more young people are involved with heroin. 
When all the network members have made their presentations, the chair or designated
officer should present his or her observations. This should open the discussion about the
data that was presented. The discussion does not have to be limited in the types of obser-
vations made, but should focus on the question: “What do these data tell us about drug
use in our area?”
Having someone available to listen and take notes is very helpful to the group, particular-
ly in order to capture the questions and discussion on paper so that the information can
also be included in the proceedings report. 
For further information on the interpretation of data from drug information networks,
refer to other GAP toolkit modules on data analysis and interpretation
(http://www.undcp.org/drug_demand_gap_m-toolkit.html).
Preparation of reports
The foregoing discussion emphasized the need to clarify what questions the network is
asking of the data and then preparing the data to accurately address those questions. The
network may want to think of several types of reports. Certainly, the most important
report is the one that summarizes the information discussed at the network meeting. In
the introduction to the present toolkit, a description of the integrated drug information
system included a review of the importance of the network report, how it is disseminated
and to whom it is disseminated. In that description, it is suggested that the network report
should include an executive summary and a summary either by data source (agency) or by
drug type. If more than one geographic area is represented in the network, a section by
geographic area may be warranted. 
The report would usually contain simple narrative summaries with some presentation of
the data in table format (as shown above in tables 1-3) or in graphic form. For instance,
the data from tables 1 and 2 could be made into a bar chart. Figures II and III below rep-
resent the data from tables 1 and 2. The data from table 3 are graphically presented as a
pie chart in figure IV, where the entire circle represents all the current illicit drug users.
Presentations such as these graphs are helpful to readers who have more difficulty read-
ing tables. For this reason, graphs are used more often than tables in network reports.
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Figure II.   Distribution of current users of any illicit drugs, by gender and 
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Structure of the report
The size of the report depends on a number of factors, in particular, how many agencies
are included, how many drugs are being considered, whether time trends are included and
how many geographic areas are represented in the network. The following is a suggested
table of contents for two types of networks. The first network is one that just began in one
geographic area. It has met only once and does not have complete agency representation.
The second network has complete agency representation for a single geographic area and
has met for three years. A third type of network is one that consists of representatives from
multiple geographic networks.
New network report
Executive summary for “name of network”: indicate authors and contact name, agency,
address, telephone number and email address
I. Goals and objectives of network
A. Define the long-term purpose of the integrated drug information system 
B. Specify the objective of the current meeting 
C. Briefly describe future plans
II. Brief description of the geographic area being represented by the network
A. Boundaries
B. Demographics of population residing in the geographic area
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III. List agencies represented at the meeting, specify chair
IV. Brief narrative on types of drug patterns used in the area; if noted during 
meeting, describe differences by reporting source
V. Brief discussion on characteristics of drug users; if noted during meeting, 
describe differences by reporting source
VI. Summary of discussion by network members about the findings
Network report
I. Introduction
A. Objectives of the integrated drug information system
B. Composition of network; agency representation
C. Dates and place of meeting
II. Fuller description of geographic area
A. Total population size and demographics such as age, ethnicity, socio-
economic status
B. Discuss factors that may influence drug use patterns in the city such as 
homeless populations, changes in drug laws, influx of new drugs and 
increased prevention efforts
III. Data sources and time periods covered
A. Source of data-describe where the data included in this report came 
from; agency and type of data (for example, arrest information from 
precinct “A”)
B. Specify limitations of the data (for example, arrest data came from only 
one of the 10 precincts in the area)
C. What is the time period covered by each data source—for example, 
1 January 2000 through 31 June 2000
D. Introduce the data sources with a listing that represents the sequencing 
of the data as they are presented; any results from special studies, key 
informant interviews or ethnographic studies should be presented last
E. Data source presentations with exhibits, tables and graphs
IV. Summary of network comments and discussion giving an overall interpretation 
of the data presented. Include gaps in data and plans being made to fill the gaps.
V. Date, time and place of next meeting.
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Ongoing network
Follow the above outline but add trend data. Generally, the trend section is divided by
types of drug.
I. Drug “A"
A. Overall description of trends summarizing information from all sources 
of data
B. Trends by individual source of data; increases/decreases by specific 
population groups (for example, gender, age and ethnicity); new modes 
of administration (ranging from intranasal use to injecting); new drugs 
of abuse
C. Special studies
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A. Background (for example, functions and structure of network, 
meeting etc)
B. Summary of drug situation
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II. Information on drug consumption
A. Existing data sources
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C. Specialized/focused survey data
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A. Priority areas for future development
B. Identification of needs in order to address priority areas
C. Policy implications for drug demand reduction activities
IV. Conclusion and recommendations
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Other issues related to collecting and interpreting data
Ethical concerns
Collecting data on drug consumption presents particular ethical challenges due to the illi-
cit nature of drug-taking. Many countries have institutionalized procedures to protect the
rights of participants in medical research, which are enforced through obligatory compli-
ance with the World Medical Association Declaration of Helsinki, or locally developed eth-
ical frameworks that are consistent with the principles of the Declaration of Helsinki. The
Declaration of Helsinki can be found at http://www.wma.net. However, even the applica-
tion of these general guidelines to drug abuse epidemiology presents particular ethical
challenges. These challenges are detailed elsewhere, but the main themes centre around
maintaining confidentiality and anonymity of drug users, obtaining informed consent
from drug users (especially minors), and protecting the security and safety of both inter-
viewers and interviewees where data collection involves face-to-face interviewing.
Additional challenges remain for the application of general ethical principles to varied
social and cultural settings, especially in countries where procedures for regulating the eth-
ical parameters of medical research have not been institutionalized. For further discussion
of ethical principles relating to epidemiology, refer to the World Health Organization 
publications on this topic (http://www.who.int/dsa/cat98/ethic8.htm). The specific
application of ethical guidelines to drug abuse epidemiology is discussed by Fry and 
Hall in Bulletin on Narcotics, vol. LIV, No. 1 (2002) (see reference list annexed 
to the present toolkit module 1). An expansion of issues pertaining specifically to 
ethics in drug abuse epidemiology is planned as part of the GAP toolkit
(http://www.undcp.org/drug_demand_gap_m-toolkit.html).
Gender
Available evidence suggests that gender differences in drug use vary between countries
and regions, and are affected by factors such as the type of drug consumed, the pattern of
drug use, the age of the user and the regional and cultural setting. The reflection of gen-
der differences in patterns of drug use, particularly those based on agency data, will be
strongly affected by any gender differences in access to services (that is, health data), in
the likelihood of being apprehended for drug-related crimes (that is, arrest data), or in the
likelihood of being recruited into surveys. Further, the cultural, social and economic con-
text may differentially affect the ability and willingness of males and females to disclose
and discuss drug use (for example, social acceptability of use), or their drug use being
picked up by routine data sources (for example, abuse of prescription medications). If
interventions are to be properly informed by data, then sound data on patterns of drug use
in both males and females need to be collected, analysed and interpreted. In practical
terms, this means disaggregating data by gender, where possible and relevant. Gender dif-
ferences in drug consumption patterns found in data collected must be interpreted in light
of the potential biases in the data (for example, differential access to service), as would be
the case with interpreting drug-related indicator data in any situation. School-based sur-
veys and general population surveys are a good way to get a rough idea of gender differ-
ences in drug consumption, although results from these will still be affected by the social
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acceptability of drug use. Such services may also not provide good data on problem drug
use, the data providing information on problem drug use often being biased for the rea-
sons noted above. Where information on drug use is particularly scarce, a specialized sur-
vey on males or females alone, or analysis of existing data on services targeting either
males or females, could provide a starting point for understanding the type of drug con-
sumption patterns that are particular to either gender. For notes on gender issues in drug
consumption and related harms, refer to http://www.nida.nih.gov/NIDA_Notes/
NNVol15N4/tearoff.html, and for an example of a gender-specific analysis of drug use, see
Ministry of Social Justice and Empowerment of India and UNDCP, “Women and Drug
Abuse: the Problem in India” (New Delhi, 2002).
Concluding remarks
Drug information systems have been found in many countries to be effective tools for mon-
itoring drug consumption. In most contexts, they represent a cost-effective means of bring-
ing together the available data and expertise on patterns and trends in drug consumption.
These systems, which have been found effective in many developed regions, are also prov-
ing successful in developing regions. Without doubt, one of the key advantages of the sys-
tems is their ability to instigate communication and cooperation between different bodies
with an interest in drug consumption. Providing a multidisciplinary platform for the shar-
ing and discussion of drug consumption data greatly enhances the capacity to develop data
collection and the accurate interpretation of trends. Open dialogue between policy mak-
ers, researchers, epidemiologists and practitioners also provides a bridge for using data on
drug consumption to guide policy and the implementation of demand reduction activities
(that is, treatment, prevention and reducing the adverse social and health consequences
of drug consumption). The present guide has provided a starting point for the develop-
ment of such a system, emphasizing the key element of human networks. The annex pro-
vides a list of further resources to assist with development of a drug information system,
while other modules of the GAP toolkit provide further guidance on developing core data
collection activities.
Finally, it is critically important to remember one point: developing an information system
is a practical accomplishment, the success of which is dependant on ensuring that the
methods used are appropriate to the local conditions. The present toolkit provides only a
general guide based on what has been learned from working elsewhere. These guidelines
must be adapted to individual circumstances. Whom to invite to participate in a network,
what are the best information sources to use and how to report them will vary both
between and within countries. Furthermore, developing comprehensive information is a
long-term endeavour. Accordingly, the guidelines on information, needs and resources
analysis presented in the present toolkit suggest a method for defining a development
strategy complete with short-, medium- and long-term goals. One of the common obser-
vations of those working in this area is that even when formal information sources are
poor, considerable knowledge still exists, and valuable insights can be gained from form-
ing a network where different perceptions of the drug phenomenon can be shared can be
shared.
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References: Selected documentation and
resources
Below is a selected list of relevant resources and documentation to assist in the develop-
ment of a drug information system. Web-based resources are provided where possible. This
list is not comprehensive, but is intended to assist the reader by providing guidance to a
few key resources as a follow-up to the present toolkit module, and a basis from which the
reader can gain the broader exposure to the body of literature on drug abuse epidemiology.
General guidelines on Drug Abuse Epidemiology
UNDCP Global Assessment Programme on Drug Abuse methodological toolkit:
The GAP toolkit consists of interlinked resources on prevalence estimation, school sur-
veys, data analysis and interpretation, ethics and other core spheres of drug abuse data
collection. Updates on guidelines available can be obtained by emailing gap@undcp.org, or
writing to the Global Assessment Programme, Demand Reduction Section, UNDCP, P.O.
Box 500, A-1400 Vienna, Austria. 
http://www.undcp.org/drug_demand_gap_m-toolkit.html
World Health Organization, Guide to Drug Abuse Epidemiology (Geneva, 2000)
http://www.who.int/substance_abuse/pubs_psychoactive_drugs.htm
National Institute on Drug Abuse, Assessing Drug Abuse within and across 
Communities: Community Epidemiology Surveillance Networks on Drug Abuse
(Baltimore, Maryland, Department of Health and Human Services, National
Institutes of Health, 1998)
Ethical and gender issues
Ethics
Guidelines documents on ethics in epidemiology
http://www.who.int/dsa/cat98/ethic8.htm
Nuffield Council on Bioethics, “The ethics of research related to healthcare in 
developing countries”.
http://www.nuffieldbioethics.org/publications/pp_0000000013.asp
Fry and Hall, “An ethical framework for drug epidemiology-Identifying the issues”,
Bulletin on Narcotics. Vol. LIV, No. 1 (2002) 
http://undcp.org/bulletin_on_narcotics.html
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World Medical Association Declaration of Helsinki
http://www.wma.net, or in English: http://www.wma.net/e/policy/17-c_e.html
Gender
National Institute on Drug Abuse notes on gender issues in drug consumption and
related harms http://www.nida.nih.gov/NIDA_Notes/NNVol15N4/tearoff.html
Ministry of Social Justice and Empowerment of the Government of India and
UNDCP, Women and Drug Abuse: The Problem in India (New Delhi, 2002)
Women and Drugs, Symposium, Prague, November 1993 
http://www.coe.int/T/E/SocialCohesion/pompidou_group/5_2EPublications/List
_of_publications/prague_eng.asp#TopOfPage
Data collection
Global mechanisms of data collection on drug abuse and related issues
UNDCP Global Assessment Programme on Drug Abuse
http://undcp.org/drug_demand_gap.html
Report by the Secretariat on the world situation with regard to drug abuse, in par-
ticular the spread of human immunodeficiency virus/acquired immunodeficiency
syndrome (HIV/AIDS) through drug injection (E/CN.7/2002/2). 
http://undcp.org/cnd_session_45.html
Drug information systems: Principles, structures and indicators
(E/CN.7/2000/CRP.3)
http://www.undcp.org/pdf/drug_demand_gap_lisbon_consensus.pdf
Global Workshop on Drug Information Systems: Activities, Methods and Future
Opportunities, 3-5 December 2001, Vienna. 
http://undcp.org/drug_demand_gap.html
UNDCP Annual Reports Questionnaire Part II: Extent, patterns and trends of drug
abuse http://undcp.org/drug_demand_gap_datacollection.html
http://undcp.org/cnd_questionnaire_arq.html 
Surveys
General population surveys
http://www.emcdda.org/situation/themes/drug_use_general_population.shtml 
http://www.samhsa.gov/oas/oas.html
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School surveys
GAP methodological toolkit module on school surveys
http://www.undcp.org/drug_demand_gap_m-toolkit.html
Monitoring the Future project
http://monitoringthefuture.org
Hibell and others, European School Survey Project on Alcohol and Other Drugs
Report (Stockholm, Swedish Council for Information on Alcohol and Other Drugs,
2000)
General survey issues and specialized surveys
Journal of Drug Issues, Substance use survey data collection methodologies and
selected papers, vol. 31, No. 3 (Tallahassee, Florida State University, 2001) 
Group of Epidemiology Experts in Drug Problems of the Pompidou Group,
Handbook on Snowball Sampling (Strasbourg, Council of Europe, 1997)
World Health Organization Guide to Drug Abuse Epidemiology (Geneva, 2000)
Qualitative data collection
European Monitoring Centre for Drugs and Drug Addiction Scientific Monograph
No. 1, Estimating the Prevalence of Problem Drug Use in Europe (Lisbon, December
1997) 
European Monitoring Centre for Drugs and Drug Addiction, Scientific Monograph
No. 4, Understanding and Responding to Drug Use: the Role of Qualitative Research
(Lisbon, July 2000)
Rapid situation assessment
Rapid assessment and response
http://www.rararchives.org/index.html
"Rapid Assessment and Response Guide on Injecting Drug Use” (IDU-RAR), 1998
(unpublished), and the “Rapid Assessment and Response Guide on Psychoactive
Substance Use among Especially Vulnerable Young People” (EVYP-RAR), 1998
(unpublished), WHO/PSA and UNICEF in collaboration with UNDCP/UNAIDS
http://www.who.int/substance_abuse/pubs_psychoactive_drugs.htm
Drug Abuse Rapid Situation Assessments and Responses (United Nations publica-
tion, Sales No. E.00.XI.12)
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“Special issue: rapid assessment and response, International Journal of Drug Policy,
(2000)
Bulletin on Narcotics, Special issue on rapid assessment of drug abuse, vol. XLVIII,
Nos. I and 2 (United Nations publication) 
Drug information systems
National drug information systems
Community Epidemiological Work Group
http://165.112.78.61/CEWG/CEWGHome.html
Illicit Drug Reporting System
http://ndarc.med.unsw.edu.au/ndarc.nsf/website/IDRS
South African Community Epidemiology Network on Drug Use
http://www.sahealthinfo.org/admodule/sacendu.htm
Canadian Community Epidemiology Network on Drug Use
http://www.ccsa.ca/ccendu/index.htm
Regional drug information systems
The Pompidou Group of the Council of Europe
http://www.coe.int/pompidou
European Monitoring Centre for Drugs and Drug Addiction
http://www.emcdda.org
Inter-American Drug Abuse Control Commission and the 
Inter-American Uniform Drug Use Data System
http://www.cicad.oas.org/en/Observatory/Main.htm
Caribbean Drug Information Network
http://www.carec.org/projects/caridin_daess/caridin_daess.htm
Southern African Development Community Epidemiology Network on Drug Use
http://www.sadc.int/index.htm
East African Drug Information System 
http://undcp.org/drug_demand_gap_activities_easternafrica.html
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National and regional reports from drug information systems
Community Epidemiological Work Group reports
http://165.112.78.61/CEWG/Reports.html
European Monitoring Centre for Drugs and Drug Addiction annual report 
http://annualreport.emcdda.org/
Selected European national reports
http://www.emcdda.org/infopoint/publications/national_reports.shtml
South African Community Epidemiology Network on Drug Use
http://www.sahealthinfo.org/admodule/sacendu.htm
Peer-reviewed journal articles on drug information systems
Bulletin on Narcotics, Special issue on drug abuse epidemiology: science and prac-
tice, vol. LIV, No. 1 (2002)
Griffiths and others, “Drug information systems, early warning and new drug trends:
can drug monitoring systems become more sensitive to emerging trends in drug con-
sumption?", Substance Use and Misuse, vol. 35 (2000) pp. 811-44.
Parry and others, “The South African Community Epidemiology Network on Drug
Use (SACENDU): description, findings (1997-1999), and policy implications”,
Addiction, vol. 97 (forthcoming).
Hando and others, “The development of an early warning system to detect trends in
illicit drug use in Australia: the Illicit Drug Reporting System”, Addiction Research,
vol. 6, (1998), pp. 97-113.
S. Darke, S. Kaye and L. Topp, “Cocaine use in New South Wales, Australia, 1996-
2000: 5-year monitoring of trends in price purity, availability and use from the illic-
it drug reporting system”, Drug and Alcohol Dependence, vol. 67 (2002), pp. 81-88.
Darke and others, “Heroin use in New South Wales, Australia, 1996-2000: 5-year
monitoring of trends in price, purity, availability and use from the Illicit Drug
Reporting System (IDRS)”, Addiction, vol. 97 (2002), pp. 179-186.
Access to further academic journal articles online
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi
http://www.nlm.nih.gov/medlineplus/substanceabuse.html
http://www.bireme.br/
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www.healthinternetwork.net
http://www.tandf.co.uk/addiction-abs/
United Nations International Drug Control Programme resources
Terminology and Information on Drugs (United Nations publication, Sales No.
E.99.XI.7)
Demand Reduction. A Glossary of Terms (United Nations publication, Sales No.
E.00.XI.9)
Drug Abuse Rapid Situation Assessments and Responses (1999) (United Nations
publication. Sales No. E.00.XI.12)
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ANNEX
Writing a report: content 
and formatting guidelines
This annex is also provided in Word
and PDF formats
  
 
 
 
Name of Drug Information System 
 
  
 
 Annual Meeting Report 2002 
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Location of meeting 
Country 
 
 
 
 
 
 
 
(Insert Logos here) 
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Author, M. S. 
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Drug Abuse Unit 
Our city Department Of Public Safety 
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 The contents of this report represent the proceedings of the (insert meeting name), held in (insert 
meeting venue and date), which was supported by (insert funding and technical support agencies). 
 
 For further information, contact: (insert contact details for network coordinator). 
 
 (Insert details of the authors and/or name of organization producing the report, publisher and the 
place and year of printing.) 
 
For further information and resources on drug information systems, visit the UNDCP Global 
Assessment Programme on Drug Abuse web site at www.undcp.org, email gap@undcp.org, or contact: 
the Demand Reduction Section, UNDCP, P.O. Box 500, A-1400 Vienna, Austria. 
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Executive summary 
 
 
 The executive summary of the report should contain a brief introduction to the network and 
meeting report, a general statement summarizing the main findings of the meeting and a brief review of 
specific trends for each drug category and other drug-related issues (for example, the number of AIDS 
diagnoses, HIV or Hepatitis B and C infection rates, deaths due to drugs and drug-related accidents). 
This should then be followed by a summary of recommendations and follow-up action for the network. 
 
 If the network meeting report is very brief, it may be more appropriate to provide an abstract 
rather than an executive summary. An abstract should be about 150 words in length. It should contain 
a general statement of the findings, followed by a one-sentence statement for each drug category and for 
any other relevant observations, such as the number of AIDS diagnoses, HIV or Hepatitis B and C 
infection rates, deaths due to drugs and drug-related accidents. There should also be a sentence or two 
on the main conclusions and recommendations of the meeting. 
 
 The structure of the executive summary is reflected in the section headings listed below. 
 
 
A. Background  
  
B. Summary of the drug situation 
  
C. Recommendations 
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I. Introduction 
 
 
A. Country or city information 
 
 
 This should be a short section that describes factors unique to the city or country concerned. It 
can include population demographics, based on such factors as age, gender, race and ethnicity, and 
briefly describe relevant geographic features and political, economic or social events. Any factors that 
could be related to the drug abuse problems should be included. 
 
 
B. Background to network  
 
 
II. Information on drug consumption 
 
 
 List the sources and types of data used in the report. Wherever possible, explain any limitations 
or caveats on the data elements. For each source, define two time periods that the data cover: the latest 
reporting period and the comparison reporting period. 
 
 Establish an order for reporting findings from each data source. This order will be used for each 
report. The range of data would include the following: 
 
 (a) Treatment admissions; 
 (b) Arrests; 
 (c) Deaths; 
 (d) Emergency department episodes; 
 (e) School or other surveys; 
 (f) Availability, price and purity; 
 (g) Seizures; 
 (h) Trafficking and distribution; 
 (i) Ethnographic studies, key informant surveys and focus groups; 
 (j) Special studies. 
 
A suggested order for the presentation of findings is reflected in the headings below. 
 
A. Survey data 
 
 
1. General population surveys 
 
2. School or youth surveys 
 
3. Specialized or focused surveys 
 
 
B. Existing data sources 
 
 
1. Treatment data 
 
2. Arrest and seizure data 
 
3. Other existing data 
 
 
C. Qualitative data 
 
 
1. Key informant surveys 
 
2. Focus groups 
 
3. In-depth interviews 
 
4. Ethnographic studies 
 
5. Other 
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D. Overview of drug situation and trends 
 
 
1. Introduction 
 
 This section could be used to give an overall summary of illicit drug use, or of a particular drug 
that has become a significant problem, or of one important aspect of the data, such as drug-related 
accidents. 
 
2. Primary drug problem  
 
 Begin with a statement providing an overview of all indicators and, if possible, of the general 
direction of any trend. Elaborate with any qualitative information available, from key informants, focus 
groups or ethnographic studies. 
 
 Each subsequent paragraph could discuss the data from each data source. For consistency, the 
order of the paragraphs could follow the listing of the data sources mentioned above. It would be 
helpful to the reader to refer to any tables, charts or other exhibits included in the report. 
 
 In addition, a summary of any special studies could be included.  
 
3. Second most important drug (and subsequent drugs) 
 
 The same format should be followed as that given above. A description of special studies and 
findings would add more detail about some aspect of the drug abuse problem in the city where the 
studies occur. University and government researchers in the city who are not part of the integrated drug 
information system network may be asked to contribute to this report. Credit for the research and any 
funding associated with the studies should be provided.  
 
 For the convenience of the reader, all tables, charts and other exhibits should be numbered and 
titled. The title should reflect the drug involved, the source of the data, the characteristics studied and 
the time period covered.  
 
4. Summary of main trends 
 
 
III. Future directions 
 
 
A. Priority areas for future development 
 
 
B. Identification of needs in order to address priority areas 
 
 
C. Policy implications for drug demand reduction activities 
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IV. Conclusion and recommendations 
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III. Completed annual reports questionnaire and/or regional 
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Annual Reports Questionnaire 
Part II
Drug Abuse
Extent, patterns and trends of drug abuse
Name
Title/position
Address
Telephone Telex
Fax E-mail
Name
Title/position
Address
Telephone Telex
Fax E-mail
Name, address, telephone, telex, fax and e-mail of the person responsible for 
national drug abuse data in the country.
Name, position, address, telephone, telex, fax and e-mail of the technical person 
responsible for the completion of Part II, if different from above.
Report of the Government of
Reporting Year
E/NR/2001/2
E/NR/2001/2
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Structure of the questionnaire
This questionnaire contains the following sections:
1
Prevalence of drug abuse among the general population,
pages 4-7, questions Q1-Q9 
2
Prevalence of drug abuse among the school (youth)
population, pages 8-9, questions Q10-Q14 
3
Injecting drug abuse, pages 10-11, questions Q15-Q22
4
Severe drug abuse, page 12, questions Q23-Q28
5
New developments in prevalence and patterns of drug
abuse, pages 13-14, questions Q29-Q32
6
Drug-related morbidity, page 15, questions Q33-Q38 .
7
Drug-related mortality, pages 16-17, questions Q39-Q47
8
Drug treatment, pages 18-19, questions Q48-Q58  
9
Data collection capacity, page 20, questions Q59-Q61
The sections ask for information at two distinguished
levels, which recognises the fact that at present many
countries do not yet have detailed data on these topics.
• Summary expert opinions
The questions at this level ask for broad general
‘qualitative’ information. All questions refer to the past
year, being the reporting period.The questions do not
require actual data; if you have no data based on surveys,
registers or formal estimation methods, the questions can
be answered on the basis of the opinions of informed
experts. This should allow all countries to respond.
• Quantitative estimates
The questions at this level ask for quantitative statistical
estimates. The ARQ includes standardized response
categories  –  the  Global Standardized Data-set  (GSD).
However, should your data not conform to these
categories they can still be included. Please simply
indicate the categories used (for example age-range, 
drug category) in the space provided.
Estimates should be provided for the reporting year. Where
this is not possible please include the most appropriate
recent ﬁgures available. You should always specify the
year of the estimate.
If you do not have a national estimate you can specify an
estimate for a part of the country or for a sub-population. 
If you have more than one of such partial estimates, you
should take the estimate that in your opinion is the best
alternative for a recent national estimate. In such case you
should also specify the geographical or population
coverage of the estimate as simply but explicit as possible,
as well as the size of the reference population. 
For easy recognition a different background colour is used
for quantitative estimates. 
E/NR/2001/2
E/NR/2001/2
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General instructions for completion
• Many questions have pre-coded response categories and
you only have to mark the appropriate boxes. Most other
questions require to ﬁll in rank order numbers, numbers or
percentages. 
• Several questions relate to drug classes or drug types. 
Whenever applicable, it is important that the information
requested is reported for individual drugs. Although we
have taken care to include all major drugs relevant for the
topic concerned, the pre-coded lists might not fully suit the
interests of your country. We therefore provide in each list
the opportunity to add other drug classes or drug types.
You may use these open categories also to insert
alternative aggregate groups of drugs.
For example: some questions list ‘heroin’ and ‘other
opioids’; if you only have information on opioids without
speciﬁcation of types, you should specify ‘any opioids’ as
‘other drugs’.
• In all tables you should leave cells blank if you do not 
know the answer or cannot provide the required ﬁgure. 
All empty cells will be interpreted as ‘no information
available’. If a ﬁgure would result in the value zero, please
specify this as 0. 
• Instructions for speciﬁc questions are provided in 
boxes alongside the questions. In several places in the
questionnaire we have provided open text boxes to add
remarks and comments on the topic. For this purpose 
you can also use the empty pages at the end of the
questionnaire.
• For further notes and deﬁnitions of technical terms used 
in this form please refer to the accompanying  ‘The ARQ, 
a Lexicon of Terms and Guidance Notes’.
E/NR/2001/2
E/NR/2001/2
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Prevalence of drug abuse 
among the general population SUMMARY EXPERT OPINIONS
Cannabis type  
Marijuana (herbal)   
Hashish (resin)
Opioids 
Heroin 
Opium
Cocaine type 
Powder (Salt) 
Crack 
Amphetamine type 
Amphetamine
Methamphetamine
‘Ecstasy’ type 
Sedatives & Tranquillisers* 
Barbiturates
Benzodiazepines
Hallucinogens 
LSD
Solvents & inhalants
Other drugs 
Ranking of drugs: 
Start in Q2 with 1 for the most
prevalent class of drugs, 2 for the
second most prevalent class, etc. 
If necessary, you can assign
equal rank numbers to more than
one class of drug. 
Continue with ranking individual
drug types in Q3 in order of
prevalence within each drug
class separately.
Q1
Have the
drugs
below
been used
in your
country in
the past
year? 
NO               YES
Q2
How are main
drug classes
ranked in
order of
prevalence?
Put in numerical
order
Class of drugs    
Type of drugs
Q3
Within each
drug class
separately,
how are drug
types ranked 
in order of
prevalence?
Put in numerical
order
Other
Other
Other
*Non-prescribed / non-therapeutic use only
Complete Q2 and Q3
only when there has
been use of the drug
in the past year 
(Q1 = YES)
E/NR/2001/2
E/NR/2001/2
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Q5
What has been  the trend over the
past year in prevalence of each
drug type?
Q4
Large 
increase
Some
increase
No great
change
Some
decrease
Large 
decrease
Large 
increase
Some
increase
No great
change
Some
decrease
Large 
decrease
What has been the trend over the
past year in prevalence of each
drug class?
Cannabis type  
Marijuana (herbal)   
Hashish (resin)
Opioids 
Heroin 
Opium
Cocaine type 
Powder (Salt) 
Crack 
Amphetamine type 
Amphetamine
Methamphetamine
‘Ecstasy’ type 
Sedatives & Tranquillisers* 
Barbiturates
Benzodiazepines
Hallucinogens 
LSD
Solvents & inhalants
Other drugs 
Class of drugs    
Type of drugs
Other
Other
Other
*Non-prescribed / non-therapeutic use only
Complete Q4 and Q5
only when there has
been use of the drug
in the past year 
(Q1 = YES)
Prevalence of drug abuse 
among the general population SUMMARY EXPERT OPINIONS
E/NR/2001/2
E/NR/2001/2
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Q6
Do you have an estimate of drug
prevalence among the general
population?
Tick ONLY ONE
Q7
For which year does the estimate apply?
Which part of the country or the population is covered by
the estimate?
Year of the national estimate
Year of the partial estimate
Part of the country or sub-population for which the estimate applies
No Proceed to Q10
Yes
an estimate for the country 
as a whole
Yes
an estimate for a part of the country
or a sub-population
Estimated size of the
reference population for
which the estimate applies
Prevalence of drug abuse 
among the general population QUANTITATIVE ESTIMATES
E/NR/2001/2
E/NR/2001/2
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All ﬁgures should be rates
per 100 of population. 
You do not need to add %
after your ﬁgures.
Provide decimal ﬁgures. 
If an estimate results in 
a zero prevalence rate
please note as 0.
Please complete
questions Q8 – Q9 for
the estimate speciﬁed
in Q7 above
If you have an estimate of
the NUMBERS of users,
please convert these into
rates per 100 of the
reference population.
If you do not have ﬁgures
for the preferred age
range, you should specify
the age ranges that apply
to your estimates. 
If you do not have 
ﬁgures for the preferred
prevalence measure for
the reporting year, you
should specify the
prevalence measure
used for your estimate.
Cannabis type  
Opioids 
Heroin 
Opium
Cocaine type 
Powder (Salt) 
Crack  
Amphetamine type 
Amphetamine
Methamphetamine
‘Ecstasy’ type 
Sedatives & Tranquillisers* 
Barbiturates
Benzodiazepines
Hallucinogens 
LSD
Solvents & inhalants
Other drugs
Other
Other
Other
Preferred prevalence 
measure
Prevalence measure used
Preferred age range
Age range used
15-64 years
Q9
All % Females %
What is the estimated 
prevalence rate per 100
among the general
population in the
REPORTING YEAR?
Specify separately  for
the female population
All % Females %
15-64 years
Last 12 months
Q8
What is the estimated
LIFETIME prevalence
rate per 100 among the
general population?
Specify separately  for
the female population
Prevalence of drug abuse 
among the general population QUANTITATIVE ESTIMATES
*Non-prescribed / non-therapeutic use only
E/NR/2001/2
E/NR/2001/2
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Prevalence of drug abuse 
among the school (youth) population QUANTITATIVE ESTIMATES
Q10
Do you have an estimate of drug 
prevalence among the 
school (youth) population?
Tick ONLY ONE
Q11
For which year does the estimate apply?
Which Part of the country or sub-population is covered by the
estimate?
Year of the national estimate
Year of the partial estimate
Part of the country or sub-population for which
the estimate applies
No Proceed to Q15
Yes
an estimate for the country 
as a whole
Yes
an estimate for a part of the country
or a sub-population
Estimated size of the
reference population for
which the estimate applies
E/NR/2001/2
E/NR/2001/2
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Please complete
questions Q12 – Q14
for the estimate
speciﬁed in Q10
Q14
All % Females %
What is the estimated 
prevalence rate per 100
among the school
(youth) population in
the REPORTING YEAR?
Specify separately  for
the female population
All % Females %
Last 12 months
Q13
What is the estimated
LIFETIME prevalence
rate per 100 among 
the school (youth)
population?
Specify separately  for
the female population
15-16 years
Q12
All % Females %
What is the estimated 
prevalence rate per
100 among YOUNG
ADOLESCENTS
population in the
REPORTING YEAR?
Specify separately  for
the female population
 
Last 12 months
Prevalence of drug abuse 
among the school (youth) population QUANTITATIVE ESTIMATES
*Non-prescribed / non-therapeutic use only
All ﬁgures should 
be rates per 100 
of population. 
You do not need 
to add % after
your ﬁgures.
Provide decimal
ﬁgures. If an
estimate results
in a zero
prevalence rate
please note 
as 0.
If you have an
estimate of the
NUMBERS of
users, please
convert these
into rates per 100
of the reference
population.
You should
always specify
the age ranges
used for the
estimates.
If you do not have
ﬁgures for the
preferred age
range of young
adolescents, you
should specify
the age range
that applies to
your estimates. 
If you do not 
have ﬁgures for
the preferred
prevalence
measure for the
reporting year,
you should
specify the
prevalence
measure used for
your estimate.
Cannabis type  
Opioids 
Heroin 
Opium
Cocaine type 
Powder (Salt) 
Crack  
Amphetamine type 
Amphetamine
Methamphetamine
‘Ecstasy’ type 
Sedatives & Tranquillisers* 
Barbiturates
Benzodiazepines
Hallucinogens 
LSD
Solvents & inhalants
Other drugs
Other
Other
Other
Preferred prevalence 
measure
Prevalence measure used
Preferred age range
Age range used
E/NR/2001/2
E/NR/2001/2
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If there has been no
practice of injecting
(Q15, Any drugs = NO),
proceed to Q23.
Any drugs (type unspeciﬁed)
Heroin 
Other opioids  
Cocaine type  
Amphetamine  
Methamphetamine  
‘Ecstasy’ type
Other drugs
Q15
Has there 
been practice
of injecting
among drug
users in the
past year?
NO               YES
Q17
Has there been practice of sharing
needles or syringes among drug
injectors in the past year?
No Proceed to Q19
Q18
What has been the trend over
the past year in sharing
needles or syringes among
drug injectors?
Yes
Q16
What has been the
trend in injecting over
the past year?
With ‘sharing’
needles or syringes
we mean ‘using a
needle or syringe
that has been used
previously by
someone else’.
Injecting drug abuse SUMMARY EXPERT OPINIONS
Large 
increase
Some
increase
No great
change
Some
decrease
Large 
decrease
Large 
increase
Some
increase
No great
change
Some
decrease
Large 
decrease
E/NR/2001/2
E/NR/2001/2
98
Please complete
question Q21 for the
estimate speciﬁed in
Q20
Q22
What is the estimated
PERCENTAGE of active drug
injectors who report to have
shared needles or syringes
the last time they injected
drugs?
Q19
Do you have an estimate of the
percentage or number of drug injectors
among all drug users?
Tick ONLY ONE
Q20
For which year does the estimate apply?
Which part of the country or subgroup of drug users 
is covered by the estimate?
Year of the national estimate
Year of the partial estimate
Part of the country or subgroup of drug users for which the
estimate applies
Estimated size of the
reference population
for which the
estimate applies
No Proceed to Q23
Yes 
an estimate for the country as a whole
Yes
an estimate for a part of the country or
a subgroup of drug users
If there has been no practice
of sharing (Q17 = NO),
proceed to Q23
Injecting drug abuse QUANTITATIVE ESTIMATES
Any drugs (type unspeciﬁed)
Heroin 
Other opioids  
Cocaine type  
Amphetamine  
Methamphetamine  
‘Ecstasy’ type
Other drugs
Q21a
What is the
estimated
PERCENTAGE of
drug injectors
among all 
drug users?
Q21b
What is the
estimated
NUMBER 
of drug
injectors?
E/NR/2001/2
E/NR/2001/2
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Severe drug abuse SUMMARY EXPERT OPINIONS
Q23
Does your country make a distinction
between drug users in general and drug
users who are considered particularly
problematic, chronic or in need of help?
Q24
What has been the trend over 
the past year in “severe /
problematic” drug use?
No Proceed to Q29
Yes
Please complete
questions Q27 – Q28
for the estimate
speciﬁed in Q26
Large 
increase
Some
increase
No great
change
Some
decrease
Large 
decrease
Q25
Do you have an estimate of drug users,
who are considered particularly
problematic, chronic users or in need 
of help?
Tick ONLY ONE
Q26
For which year does the estimate apply?
Which part of the country or which subgroup of drug users
is covered by the estimate?
Year of the national estimate
Year of the partial estimate
Part of the country or subgroup of drug users for which the
estimate applies
Estimated size of 
the reference
population for which
the estimate applies
No Proceed to Q29
Yes 
an estimate for the country as a whole
Yes
an estimate for a part of the country or
a subgroup of drug users
Q28
Which deﬁnition of “severe / problematic users”
applies to the estimated number of Q27 and how is
the estimate calculated?
Q27
What is the estimated number of 
“severe / problematic” drug users?
Severe drug abuse QUANTITATIVE ESTIMATESSevere drug abuse QUANTITATIVE ESTIMATES
E/NR/2001/2
E/NR/2001/2
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Q29
Have new drugs or new patterns of drug
use been reported in the past year?
Q30
Which new drugs or new patterns of use
have been reported?
New developments in prevalence and 
patterns of drug abuse SUMMARY EXPERT OPINIONS
No Proceed to Q31
Yes
Q32
Which new groups of drug users have been
reported and in relation to which types of drugs?
No Proceed to Q33
Yes
Q31
Have new groups of drug users been
reported in the past year?
E/NR/2001/2
E/NR/2001/2
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New developments in prevalence and 
patterns of drug abuse SUMMARY EXPERT OPINIONS
Please use the space below to document any other  developments in prevalence and patterns
of drug abuse  in your country over the past year. 
E/NR/2001/2
E/NR/2001/2
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Drug-related morbidity SUMMARY EXPERT OPINIONS
Q34
What has been the trend over 
the past year in prevalence of
infections among drug injectors?
Please complete
questions Q37 – Q38
for the estimate
speciﬁed in Q36
Large 
increase
Some
increase
No great
change
Some
decrease
Large 
decrease
Q35
Do you have an estimate of drug
injectors having any of the infections
mentioned in the table above?
Tick ONLY ONE
Q36
For which year does the estimate apply?
Which part of the country or which subgroup of drug
injectors is covered by the estimate?
Year of the national estimate
Year of the partial estimate
Part of the country or subgroup of drug injectors for which
the estimate applies
Estimated size of the
reference population
for which the
estimate applies
No Proceed to Q39
Yes 
an estimate for the country as a whole
Yes
an estimate for a part of the country or
a subgroup of drug injectors
Q38
What is the estimated PERCENTAGE of
infected persons among drug injectors?
Q37
What is the estimated NUMBER of
infected drug injectors?
Drug-related morbidity QUANTITATIVE ESTIMATES
Q33
Have there been
reports about
prevalence of
infections among
drug injectors in 
the past year?
NO               YES
Hepatitis B  
Hepatitis C 
HIV
Hepatitis B  
Hepatitis C 
HIV
E/NR/2001/2
E/NR/2001/2
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Q40
How are drugs
ranked in order
of the primary
cause in drug-
related deaths?
Put in numerical order
Ranking of drugs as primary cause in
drug-related deaths:
Start with 1 for the drug most frequently
the primary cause in drug-related deaths,
2 for the second most frequent primary
cause, etc. If necessary, you may assign
equal rank numbers to more than one
drug.
Any drugs (type unspeciﬁed)
Heroin 
Other opioids  
Cocaine type  
Amphetamine  
Methamphetamine  
‘Ecstasy’ type
Other drugs
Q39
Have there been
reports about
drug-related
deaths in the
past year?
NO               YES
Q41
What has been the trend over
the past year in drug-related
deaths?
Large 
increase
Some
increase
No great
change
Some
decrease
Large 
decrease
Drug-related mortality SUMMARY EXPERT OPINIONS
E/NR/2001/2
E/NR/2001/2
104
Drug-related mortality QUANTITATIVE ESTIMATES
Q42
Do you have an estimate of the number
of drug-related deaths?
Tick ONLY ONE
Q43
For which year does the estimate apply?
Which part of the country or sub-population is
covered by the estimate?
Year of the national estimate
Year of the partial estimate
Part of the country or sub-population for which 
the estimate applies
Estimated size of the
reference population
for which the
estimate applies
No Proceed to Q48
Yes 
an estimate for the country as a whole
Yes
an estimate for a part of the country or
a sub-population
Please complete
questions Q44 – Q47
for the estimate
speciﬁed in Q43
Any drugs (type unspeciﬁed)
Heroin 
Other opioids  
Cocaine type  
Amphetamine  
Methamphetamine  
‘Ecstasy’ type
Other drugs
Q44
What is the
estimated
TOTAL
number of
drug-related
deaths?
Q45
What is the
estimated
number of
FATAL DRUG
OVERDOSES
ONLY?
Q46
What is the
estimated
number of
drug-related
AIDS
DEATHS?
Q47
What is the
estimated number
of drug-related
OTHER DEATHS
(excluding fatal
drug overdoses
and AIDS deaths)?
E/NR/2001/2
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Q49
How are drugs
ranked in order
of the primary
cause of
receiving
treatment?
Put in numerical order
Ranking of drugs as
primary cause of
treatment:
Start with 1 for the
drug most frequently
the primary cause of
treatment, 2 for the
second most
frequent primary
cause, etc. If
necessary, you may
assign equal rank
numbers to more
than one drug.
Any drugs (type unspeciﬁed)
Cannabis type
Heroin 
Other opioids  
Cocaine type  
Amphetamine  
Methamphetamine  
‘Ecstasy’ type
Other drugs
Q48
Have people
received
treatment for
drug problems
in the past
year?
NO               YES
Q50
What has been the trend over
the past year in the numbers of
people receiving treatment?
Large 
increase
Some
increase
No great
change
Some
decrease
Large 
decrease
Q51
Do you have an estimate of the number
of people receiving treatment for drug
problems?
Tick ONLY ONE
Q52
For which year does the estimate apply?
Which part of the country or selection of treatment
facilities is covered by the estimate?
Year of the national estimate
Year of the partial estimate
No Proceed to Q59
Yes 
an estimate for the country as a whole
Yes
an estimate for a part of the country or
a selection of treatment facilities
Drug treatment SUMMARY EXPERT OPINIONS
Part of the country for which the estimate applies
Types of treatment facilities included and/or excluded 
in the estimate
Drug treatment QUANTITATIVE ESTIMATES
E/NR/2001/2
E/NR/2001/2
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Please complete
questions Q53 – Q58
for the estimate
speciﬁed in Q52
Any drugs (type unspeciﬁed)
Cannabis type
Heroin 
Other opioids  
Cocaine type  
Amphetamine  
Methamphetamine  
‘Ecstasy’ type
Other drugs
Q53
What is the
estimated
NUMBER 
of people
receiving
treatment 
for drug
problems?
Q54
What is the
estimated
PERCENTAGE
of people
receiving
treatment for
the FIRST 
TIME EVER
among people
in treatment?
Q55
What is the
estimated
PERCENTAGE
of FEMALES
among people
in treatment
Q56
What is the
estimated
MEAN AGE 
of people in
treatment?
Q57
What is the
estimated
PERCENTAGE
of DRUG
INJECTORS
among people
in treatment?
Drug treatment QUANTITATIVE ESTIMATES
If estimates for ‘all drugs’ in Q53-Q57 above include also treatment for alcohol problems,
please tick here 
Q58
All people receiving treatment
during the year 
People STARTING treatment
during the year
People in treatment at CENSUS
DATE in the year
People discharged from
treatment during the year
Other
Tick as
Appropriate   
Tick as
Appropriate   
Tick as
Appropriate   
Tick as
Appropriate   
Tick as
Appropriate   
Which deﬁnition of ‘people treated for drug problems’
applies to the ﬁgures in the columns of Q53 –Q57  above? 
Q53 Q54 Q55 Q56 Q57
E/NR/2001/2
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Data collection capacity
Q60
Poor Moderate Good
How would you qualify
the present suitability 
of these instruments 
for making national
estimates about the 
drug situation?
Q59
Has your country
capacity with
regard to data
collection
instruments
speciﬁed below?
Q61
If applicable, what are the main obstacles for implementation or improvement of data
collection instruments suitable for making national estimates about the drug situation?
Registers
Specialised treatment register 
Registers on drug-related morbidity
Registers on drug-related mortality
Survey instruments
Prevalence surveys among  the general
population
Prevalence surveys among school
populations
Surveys among drug users
Qualitative research instruments
Rapid Situation Assessment
Other
NO               YES
E/NR/2001/2
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Please list below relevant national reports or major studies about the extent,
patterns or trends in drug abuse in your country, published in the past year. 
Specify author, title and year of publication. Attach copies of documents and
reports if possible. 
Reports
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
E/NR/2001/2
E/NR/2001/2
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Please use the space below to add notes of clariﬁcation to any of the
information contained in this questionnaire or to document any issue that you
wish to draw to the attention of UNDCP.
Additional information
E/NR/2001/2
E/NR/2001/2
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Additional information (continued)
E/NR/2001/2
E/NR/2001/2
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The completed questionnaire should be addressed to:
The Secretary-General
United Nations International Drug Control Programme
Vienna International Centre
PO Box 500
A-1400 Vienna, Austria
E/NR/2001/2
E/NR/2001/2
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PART TWO
Information, Needs and
Resources Analysis 

Introduction
Background
The information, needs and resources analysis is the first step in estab-
lishing a drug information system. It is the groundwork on which to base
the development of an integrated drug information system. This inventory
is an important first step in the development of an integrated system, as it
will:
(a) Establish the baseline information available on drug use in each
country;
(b) Determine which data sources are available to contribute to an inte-
grated drug information system;
(c) Determine what resources already exist in each country that can be
used to support such an integrated system;
(d) Identify priority infrastructure and training needs in order to deve-
lop an integrated system;
(e) Establish communication between relevant stakeholders who will
form part of the integrated system;
(f) Involve all relevant agencies and individuals in the development of
the integrated drug information system.
That is, the integrated drug information system will provide the necessary
information to help decide who should be involved in the analysis, what
data can contribute to the analysis, what should be the focus of the analy-
sis (that is, geographic coverage and types of drugs covered), potential
methods of communication for the integrated drug information system,
and what each agency/or individual in the country can contribute to an
integrated system in terms of both skills and data/information. It will also
begin to establish the necessary communication of information between
relevant stakeholders, help establish local ownership of the network, and
gain government support for the development of the integrated system.
The information, needs and resources analysis comprises several stages.
First, baseline information that already exists in the country needs to be
established. Secondly, the existing resources that could support an inte-
Chapter I
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grated system need to be identified. Thirdly, gaps in resources and information need to be
identified. And finally, this information must be assimilated in a strategic analysis, where-
by a framework for an integrated system is established and specific development goals are
set. The purpose of each step is explained below.
The baseline information gathered during the information, needs and resources analysis
can provide a rough guide to the drug abuse situation in the country, act as a catalyst for
stimulating discussion of drug trends, and provoke support for the more comprehensive
and ongoing integrated system to monitor drug trends. Using the baseline information
obtained in the analysis will make it possible to focus the integrated system on locally rel-
evant drug issues, and to undertake ongoing drug abuse monitoring in a way that is appro-
priate and sensitive to local conditions.
The identification of resources (that is, infrastructure and skills) for supporting an inte-
grated drug information system in the country will ensure maximum utilization of exist-
ing structures and ensure that capacity is built around existing. This should improve the
sustainability of the integrated system and make sure that resources are not wasted dupli-
cating existing structures. 
The information, needs and resources analysis will also assist in identifying the gaps,
needs, within the country in order to develop an integrated drug information system. For
example, the information, needs and resources analysis might identify training in the
analysis of existing indicator data as a priority area for development, or a need for a cen-
tral coordinating body for the integrated system and associated infrastructure. These
needs can be addressed by the integrated system once it is established, or may need to be
addressed prior to or during the formation of an integrated system.
Finally, the information, needs and resources analysis will prioritize the needs with a
strategic analysis and associated action plan, which, when implemented, will initiate the
development of an integrated drug information system. This strategic plan should propose
which individuals and agencies could be involved in the integrated system, and at what
level (for instance, expert advisory group for the intregrated system, data gatherers, pre-
senters, coordinating functions and communication with policy makers), what resources
are needed to support the network, and which data sources could be given priority for
development and inclusion in the integrated system.
STRUCTURE OF THE INVENTORY
The inventory is a preliminary step that must be taken before starting an integra-
ted drug information system, because the outcome of the inventory will guide the
development of the integrated system. There are five main steps involved in build-
ing the integrated system, which are indicated below.
STEP 1
Identifying relevant individuals and institutions
Information, Needs and Resources AnalysisPart Two
117
Carrying out the information, needs and resources analysis
Compiling the inventory of resources involves an audit of existing and potential informa-
tion sources on drug abuse in the country. This audit is called an “information, needs and
resources analysis”. It aims to: 
(a) Establish what information exists on drug abuse in the country;
(b) Establish what resources exist to support a drug information system;
(c) Develop a strategic framework for a drug information system.
The following steps are required to achieve those aims: 
(a) First, people and institutions that have access to information on drug abuse (or key
stakeholders) must be identified;
(b) Secondly, the nature and extent of information available from those persons and
institutions must be assessed;
(c) Thirdly, the resources needed to develop a drug information system need to be iden-
tified;
(d) Finally, the information obtained through the three above-mentioned steps must
then be assimilated in a strategic analysis to form a framework and development
strategy for an integrated drug information system.
The report of the information, needs and resources analysis
The purpose of the information, needs and resources analysis is to produce a report that
can serve as a resource for discussion when developing an information system on drug
abuse. A format for this report is provided in annex I. The report of the information, needs
and resources analysis is intended to help establish a sound information base, as the first
step in establishing ongoing drug abuse surveillance. The data sources and resources
STRUCTURE OF THE INVENTORY (continued)
STEP 2
Assessing information and resources available
STEP 3
Identifying resources and needs
STEP 4
Strategic analysis
STEP 5
Writing the report of the information, needs and resources analysis
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reported are not intended to be exhaustive, but to provide a starting point, directing the
reader toward potential data that can be used to monitor drug abuse.
Building a resource library
A second requirement is to build a library of resources pertaining to the integrated drug
information system. These resource files are to be contained in the annexes to the report
of the information, needs and resources analysis. Ideally, the resource files should contain
information on potential network members, existing reports on drug abuse, existing data
sources on drug abuse and methods used for collecting and collating data. The reference
library should be used to keep track of resources available in the country and to ensure
that information collected is available for reference at a later date. The resource library can
be updated at regular intervals based on new information that becomes available, and
used by people within the drug information system as a reference for drug abuse infor-
mation in the country.
Updating the information, needs and resources analysis
Auditing resources for the integrated drug information system should be done at regular
intervals. In keeping with the nature of drug abuse, monitoring information on drug abuse
is a dynamic process. Members of a network need to revise their approach to data collec-
tion according to the demands of the situation. The most important thing to remember
when developing data sources is to work with the resources currently available, and to
build on them gradually within the means available.
Adapting an integrated drug information system to the country
Focus of the system
Different countries will have different focuses for their integrated drug information sys-
tem, depending on the country situation. The country context will have a strong bearing
on the objectives of drug abuse surveillance, and the means by which drug abuse surveil-
lance can be achieved. The kind of country factors that need to be considered include:
(a) Geography, population, urbanization, ethnicity, religion and language;
(b) Economic development, political situation and priority issues in the country;
(c) Broad perceptions of drug abuse in the country.
Thus, the first thing that should be done before embarking on the information, needs and
resources analysis, is reflect on the country situation. This information should be docu-
mented in the report of the information, needs and resources analysis under the “Country
information” section, to provide the reader with a context to interpret the drug abuse
information sources and networking.
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Coverage of the system
Having reviewed the country situation, it must be considered at what level the integrated
drug information system is to operate. In other words, is it going to be a national system,
a regional system, or a local or city system? The present guide focuses on development of
a national or city-based system.
As already noted, there are several levels at which drug information systems operate, and
comprehensive systems are usually built on smaller subsystems at a city or regional level.
Other systems may focus on sentinel drug-abusing areas, for example, major cities where
problematic drug abuse is apparent. Factors such as accessibility, resources and popula-
tion distribution may affect the coverage of the system. 
Once the level of the information system has been decided, the next steps would be taken
according to the resources available within the level chosen for the drug information sys-
tem (that is, resources available within the entire country, if the national level is chosen).
If it is not certain what level of information system is needed, the next steps should be
taken using all available information in the country to determine what level of information
system would be most easily built using the resources available. 
Establishing information on drug abuse
The first step of the information, needs and resources analysis involves establishing what
information currently exists on drug abuse in the country. This will provide baseline infor-
mation on what data sources can form the input for the drug information system. Thus,
the present section considers a fact-finding mission to establish what information sources
on drug abuse exist in the country. It is divided into two steps, the first designed to iden-
tify people that have access to information on drug abuse, and the second designed to
meet with these people and obtain that information.
Preparatory work
Because the information, needs and resources analysis serves as a preliminary step to
establishing an integrated drug information system, it is important to involve all key stake-
holders in the process, and build a sense of local ownership of the analysis and resulting
integrated system. This means informing stakeholders in advance about the analysis and
the integrated system, establishing open communication between all involved in the
process, and maintaining transparency while conducting the analysis.
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TIP:
Begin with a manageable area, such as the capital city of the country
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Government approval. The initiation of the information needs and resources analysis
should have Government approval in order to ensure ongoing support and successful coo-
peration with local authorities and staff of relevant services as well as to gain access to var-
ious levels of information.
Advisory group. In order to achieve those aims, it is important to establish and independ-
ent advisory body to oversee the analysis and the subsequent development of the network.
This advisory body should include representatives from the following agencies and organ-
izations where they exist:
(a) Data providers (non-governmental organizations, hospitals, specialized treatment
agencies, law enforcement etc.);
(b) Government ministries, especially those that oversee data providers;
(c) National drug control authorities;
(d) University or research institutions, particularly social research and statistical units,
or equivalent bodies;
(e) Health institutions that are responsible for drug demand reduction activities (that
is, prevention, treatment and reducing the adverse consequences of drug abuse).
The execution of the information, needs and resources analysis and subsequent report
should be done under the guidance of the expert advisory committee. 
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Guidelines
Step 1: identifying relevant individuals and 
institutions
(See annex I, working sheet — step 1)
In order to establish what information is available on drug abuse in the
country, the people and institutions that have access to the relevant infor-
mation on drug abuse must first be identified. This may involve making
contact with one or two key people in the country who are dealing with
drug abuse, and seeking their referral to other individuals and agencies. If
there is no obvious initial contact point in the country, it may be necessary
to investigate a range of agencies that, through their work, may come into
contact with drug abusers or collect data relating to drug abuse.
Below is a list of agencies that may be able to provide information on drug
abuse and related issues. This list is intended as a starting point, and, when
approached, the agencies concerned may refer the inquirer to other sources
of information, such as drug user groups, individual experts or other serv-
ices for drug abusers (for example, needle exchange services or telephone
helplines).
Essentially, agencies that drug abusers come into contact with must be
sought out. It has to be decided which agencies in the country may be able
to provide information on illicit drug abuse. The next step (step 2) is to
convene a meeting with those agencies to establish what information they
can offer to an integrated drug information system.
Chapter II
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TIP:
Where there are too many agencies to cover, canvass existing serv-
ices through an initial introductory letter or phone call to identify
the most relevant or representative services to include in the INRA
process. Alternatively, hold a meeting of agency representatives to
establish the status of data collection and possible ways of moving
forward.
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Step 2: assessing information and resources available
(See annex I, working sheet — step 2)
Step 2 involves convening a meeting with the organizations and institutions that may be
able to provide relevant information on drug abuse. This can be done as a joint meeting
between all agencies, or, if time permits, one person can make site visits to each agency
individually. In either case, one person must be delegated to lead the process, organize
meetings, take notes, and keep records of the information obtained. The type of questions
to be answered through meetings with the agencies include the following:
(a) Does you country have a national household survey of drug abuse among the gen-
eral population?
(b) Have any school surveys or youth surveys on drug abuse been conducted?
(c) Have any specialized research studies (including rapid situation assessments) been
undertaken on drug abuse?
(d) Is there a registry of treatment admissions relating to drug abuse?
(e) Is there a registry of hospital and emergency admissions relating to drug abuse?
(f) Does you country keep a database of deaths relating to drug abuse?
(g) Do police keep statistics on arrests relating to illicit drugs?
(h) Are there any telephone help lines that take calls relating to illicit drug abuse?
(i) Are there any outreach services or individuals who have regular contact with drug
abusers?
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POTENTIAL CONTACT PEOPLE FOR INFORMATION ON DRUG ABUSE
Government departments of health and welfare
National drug councils and authorities
Universities and research centres
Non-governmental organizations that have contact with illicit drug abusers
International agencies that may be involved with substance use or related issues
(for example, UNDCP, the Joint United Nations Programme on HIV/AIDS and the
World Health Organization)
Drug treatment centres
Outreach services for at-risk groups (such as street people, sex workers or youth)
Police headquarters and local police stations
Prisons and the judicial system
Hospitals and emergency rooms
Psychiatric facilities
Ambulance service
Forensic laboratories and coroners
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At the meeting(s), it is important to introduce the process of the information, needs and
resources analysis and to explain the role of the investigator and the relationship between
the analysis and the development of an integrated drug information system. That done,
the next step is to obtain any available information on drug abuse from the agency, find
out the methods used to collect this information, and identify any barriers to data collec-
tion. Where possible, inspect databases, obtain copies of forms used for data collection,
and reports that have been written on drug abuse or associated data collection activities.
When obtaining information on drug abuse data collection activities, it is important to
enquire about the issues listed below.
The information obtained during the meetings should be summarized under the
“Information sources” section of the report. Obtain the contact details of individuals and
agencies associated with information sources and note these in annex I of the report.
Notes from the meetings, along with any questionnaires or reports obtained, should be
included in the Resource Library so that can be accessed in the future. 
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THE FOLLOWING IMPORTANT QUESTIONS SHOULD BE ASKED:
How is the data collected?
What is the coverage of data collection (that is, age, gender and geographic area)?
What sampling methods were used to obtain the data?
How are the data recorded (computer database, written records, log book etc.)?
How up-to-date are the data?
How frequently is the data entered into a central database and collated?
What data categories are kept in the records (for example, age, gender or drug
type)?
What drug categories are used? Do they conform to the annual reports question-
naire?
What definitions are used for data categories?
What age group is covered by the data?
How are data reported and disseminated?
What are the barriers to data collection; collation and dissemination?
What resources are needed to develop data collection activities? 
NOTE:
For each of these data collection possibilities, it is important to assess the scope of
the data (for example, coverage, sampling and reporting), which can be done using
the questions listed below.
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CHECK DATA AGAINST STANDARD DATA DEFINITIONS AND 
PARAMETERS
Drug Categories
• Cannabis-type
• Opioids
• Cocaine
• Amphetamine-type
• Sedatives and tranquilizers
• Hallucinogens
• Solvents and inhalants
• Other drugs
Age
Age is usually coded as an open category to allow for analysis and reporting of spe-
cific age categories at a later time (for example, adolescents aged 15-16).
Time period
• Lifetime-used a specific drug at least once in one's lifetime
• Annual-used a specific drug at least once in the prior year (12 months)
• Current-used a specific drug at least once in the prior month (30 days)
• Daily-used a specific drug 20 or more days within the prior month
NOTE:
The above categories confirm to the annual reports questionnaire, part II, “Extent,
patterns and trends of drug abuse”. For further information on the annual reports
questionnaire, part II, visit http://undcp.org/drug_demand_gap_datacollection.
html#arq; to download the questionnaire, visit http://undcp.org/cnd_question-
naire_arq.html. For more detailed information on drug categories and terminology,
refer to UNDCP publications Terminology and Information on Drugs and Demand
Reduction: A Glossary of Terms (see the selected documentation and resources
annexed to part I of the present toolkit module for publication details). 
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Step 3: identifying resources and needs
(See annex I, working sheet — step 3)
What resources exist to support the integrated drug information system?
Using the information obtained in the meetings with agencies discussed under step 2,
describe what infrastructure and resources are available to establish a drug information
system. The type of resources that should be considered include:
(a) People available to partake in a network;
(b) Data sources that could contribute to a network;
(c) Expertise and technical skills that are needed to develop the data collection;
(d) Universities and research institutes that could offer technical support to epidemio-
logical activities;
(e) Infrastructure available to undertake data collection activities and networking (com-
puters, database software, stationery, Internet/email, communications);
(f) Level of staffing and financial support for a network.
The information from this exercise should be summarized in the “Resource” section of the
report of the information, needs and resources analysis.
Identifying gaps in resources, or needs
Once the existing resources in the country have been established, the gaps in resources
that need to be developed should be identified. Use the information obtained during 
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WHEN OBTAINING INFORMATION FROM KEY INFORMANTS 
AND OTHER EXPERTS ON PATTERNS OF DRUG ABUSE ASK ABOUT 
THE FOLLOWING:
Questions to ask key informant
• Types of drug abused
• Demographic characteristics of drug abusers
• Frequency of use 
• Route of administration
• Context of use (e.g., where and with whom do they use drugs)
• Problems associated with use
• Service utilization and barriers to accessing services
• Risk-taking behaviour among drug abusers (for example, needle sharing)
• New trends
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step 2 (meetings with agencies and individuals) regarding barriers to data collection,
together with the assessment of existing resources to identify resource needs, including
human resources, and training. For instance, a barrier to networking may be a lack of com-
munication between agencies because they are located in different cities. One solution to
this problem might be to distribute a list of contact details or set up a mailing list. In this
case, minimal resources would be required, such as temporary access to a computer to
develop an electronic mailing list and a functional postal service. A second example would
be where data on hospital admissions relating to drug use were recorded in a database, but
could not be readily retrieved and analysed. In this case, the resource needed might be
training in data entry and analysis. Obviously, the identification of resources and needs
must be realistic within the resource constraints of the city or country. For example, it
would not be realistic to plan email communication for a network if none of the network
members had access to a computer. Document your assessment of resources needed in the
“Needs” section of the report of the information, needs and resources analysis.
Step 4: strategic analysis
(See annex I, working sheet — step 4)
The previous sections dealt with compiling the information on drug abuse that already
exists in the country (for example, arrest data and treatment data), the resources that
exist in the country, and what resources were needed to develop potential data sources (for
example, development of a standardized data collection form or a computer database). 
The purpose of this section is to prioritize developments needs and establish a set of real-
istic goals for developing an integrated drug information system. When setting goals, it is
important to consider the objectives and focus of the network and the development of the
country. It is better to set achievable goals than set ambitious goals that cannot be realized.
The present section is divided into three parts. The first part involves evaluating the infor-
mation sources in the country, the second involves forming a framework for the planned
integrated drug information system, and the third involves formulating a strategic devel-
opment plan with specific goals.
Analysis of data sources
Use the information obtained from the “fact-finding mission” on information sources to
assess each data source. The following table format should be used as a guide, and the
requested information should be filled in for each data source. This information should go
into the “Analysis of data sources” section of the report of the information, needs and
resources analysis.
Once the analysis of each data source has been completed using the table format below,
summarize data sources in order of their potential contribution to an integrated drug infor-
mation system considering priority, sustainability and development potential. Also, sum-
marize the main type of resources needed to develop these data sources.
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DATA SOURCE (INSERT DATA SOURCE, FOR EXAMPLE, 
TREATMENT ADMISSIONS)
Current development
Coverage
Compatibility with the
annual reports question-
naire
Development potential
Priority
Sustainability
Training and support
needs
Describe which aspects of the data collection already
exist, and which areas need further development.
Example: Data collection is well developed at an agency
level, but not collated centrally.
National, regional, local/city; describe the proportion of
the population and/or geographic area covered by the
data source.
Example: National coverage-includes all cases recorded
in the country; or includes all major urban 
centres within a particular region.
Indicate to what extent the data categories (drug cate-
gories, age categories and gender) are consistent with
reporting in the annual reports questionnaire, and to
what extent this data can assist in answering the ques-
tionnaire.
Consider what resources are needed to develop the data
source and indicate whether the development of the
data source could occur in the short, medium or long
term.
Rate the relevance and need for the data source as high,
medium or low.
Consider the resources needed to maintain data collec-
tion over the long term, and rate whether this data
source has a high, medium or low potential of being
maintained.
Identify main training and support needs to build the
data collection activity.
Example: Need training and support to develop a form
to collect treatment data.
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Analysis of the epidemiological network
The purpose of the exercise is to bring together the information on data sources with the
resources available for the network. The first step is to assimilate the information in order
to come up with a framework for the network that includes the main people involved, the
main data sources and the means of networking (coordinating the network, communicat-
ing and disseminating information).
Use the information obtained thus far to develop a framework for the network. Specifically,
the following steps should be taken:
(a) Describe potential focal points for coordinating the network in the country and
attending regional network meetings, taking into account the geography of the
country and the objectives and focus of the network;
(b) Identify data sources that could readily form the basis of the drug information sys-
tem. Consider the relevance of each data source to the country, the coverage and reli-
ability of the data sources, and the practicality and cost-efficiency of developing the
data source; 
(c) Identify potential methods of disseminating information, considering who needs to
be informed, and what communication methods are feasible within the country.
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DATA SOURCE (INSERT DATA SOURCE, FOR EXAMPLE, 
TREATMENT ADMISSIONS) (continued)
Infrastructure needs
Key institutions
Proposed development
strategy
Identify hardware or infrastructure needed to develop
data collection
Example: Computer, database software, printed forms
for data collection.
List the institutions that would be directly involved in
data collection.
Suggest necessary measures that need to be taken to
make the data source operational to improve it.
Example: Develop a standardized data collection form
and corresponding data definitions. Provide training to
treatment facilities on completion of the standardized
data collection form, and data definitions. Provide data-
base software and training in data entry and analysis.
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Other factors to consider
Other network factors to consider include the geographical coverage of the network, the
frequency of data collection and collation and the main drugs covered by the system.
Writing a proposal for strategic development
The purpose of this section is to develop a strategic action plan, setting specific goals for
the short-, medium- and long-term. Based on the information set forth in previous sec-
tions, briefly explain the planned integrated drug information system. For example,
explain the coverage of the planned system, its focus, objectives and output. Then identify
short-, medium- and long-term goals based on the sections below. For each goal, the
actions that need to be taken to achieve that goal should be listed. This information
should go into the report of the information, needs and resources analysis under “Proposal
for strategic development”. 
Example of a short-term goal
Goal: develop an epidemiological network using the following information sources:
(a) Police data on arrests;
(b) Treatment data from each treatment centre;
(c) Survey research (for example, youth survey) conducted by the Institute of Health.
Example of a medium-term goal
Goal: Development of a centralized data collection system for drug treatment, specifically
including steps to:
(a) Develop a core set of treatment indicators;
(b) Standardize data definitions used to collect the core treatment indicators;
(c) Develop a procedure for collecting treatment indicators; 
(d) Build a database to collate core indicator data obtained from treatment agencies.
Example of a long-term goal
Goal: Develop an accurate recording system for drug-related deaths, in particular opioid-
related deaths. Implementation of this goal will require the following actions: 
(a) Increasing staff time available to study toxicology and illicit drugs;
(b) Educating coroners and relevant medical officers on how to identify and classify
drug-related deaths; 
(c) Adding categories for drug-related deaths into the existing database.
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EXAMPLE 1: ASSESSING TREATMENT DATA
Step 1: Obtain information on data collection from drug treatment centre
Action: Visit all treatment centres, examine data collection forms, obtain data
categories used and definitions used for data collection categories where they
exist.
Step 2: Assessment of data
Outcome: Treatment centres have different methods for collecting their data and
the data from treatment centres is not centrally collated.
Resources available: All centres collect client data, but most have different cate-
gories for different data, and there are no standard data definitions. All centres
have access to computers and basic data entry software (for example, Microsoft
Excel) to collate and analyse their data.
Step 3: Strategic analysis 
Priority development need: Development of a centralized data collection system
for drug treatment.
Actions:
(a) Develop a core set of treatment indicators;
(b) Standardize data definitions used to collect the core treatment indicators;
(c) Develop a form to collect treatment indicators; 
(d) Build a database to collate core indicator data obtained from treatment
agencies.
EXAMPLE 2: DEVELOPING DATABASE AT LOCAL PSYCHIATRIC FACILITY
Step 1: Obtain information on data collection from psychiatric facility
Action: Visit psychiatric facility, examine data collection forms, obtain data cate-
gories used and definitions used for data collection categories where they exist.
Step 2: Assessment of data
Existing data is based on client records, and drug abuse is not routinely recorded.
Where drug abuse is recorded, it is unclear what type of drug was abused, or
whether diagnoses for substance abuse had been made. Records were recorded
manually, and data could only be retrieved by a manual count of all cases.
Resources available: Staff at the centre were able to make diagnoses relating to
substance abuse, according to diagnostic criteria set forth in the Diagnostic and
Statistical Manual of Mental Disorders (Washington, D.C., American Psychiatric
Association, 1994), but needed assistance with diagnosis of substance-related
comorbid conditions. There was no access to a computer or database software for
data entry. The existing administrative staff, who currently entered and retrieved
the manual data log books, would be able to assist with data entry. Staff did not
have extensive training in data entry and analysis.
Step 3: Strategic analysis 
Priority development need: To develop a local database on psychiatric admissions
relating to drug abuse.
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Step 5: writing the report of the information, needs and
resources analysis
(See annex I, working sheet — step 5)
Each step in the process of information, needs and resources analysis parallels a section
in the report of the information, needs and resources analysis, so having completed the
analysis, all of the necessary information to produce the report should be available. To
actually write the report, follow the content and formatting guidelines set out in annex II
of the present guide. To conclude the report of the information, needs and resources analy-
sis, overview the main findings in terms of information sources, resources, needs, and the
development strategy. 
Contact details of people who contributed information to the analysis should be contained
in annex I of the report (people resource file). Annex II should contain all other material
obtained during the process, including notes taken during meetings with individuals and
agencies about information sources.
Once the report of the information, needs and resources analysis is completed, dissemi-
nate it to the agencies/individuals who contributed information to the analysis. The next
step is to organize a joint meeting to discuss the report and make any necessary revisions
thereto. This meeting will effectively form the first network meeting for the integrated drug
information system. Using the report of the information, needs and resources analysis as
background resource material, proceed with the development of the integrated drug infor-
mation system using the guidelines provided for the development of an integrated drug
information system.
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EXAMPLE 2: DEVELOPING DATABASE AT LOCAL PSYCHIATRIC FACILITY
(continued)
Actions:
(a) Adapt client record to request specific information on drug related diagnoses
in patients (for example, include type of drug involved and diagnostic code);
(b) Train staff on identification of drug abuse among clients and diagnoses of
substance abuse;
(c) Obtain a computer by applying for funds to donor organizations; 
(d) Develop database with categories that match client log books;
(e) Train administrative staff in data entry;
(f) Train professional staff in data analysis and how to edit database.
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Working sheet—Step 1: identifying data sources 
  
Contact people and contact information for sources of data on drug abuse: 
 
 
National drug councils/authorities 
 
..................................................................................................................................................................... 
..................................................................................................................................................................... 
..................................................................................................................................................................... 
..................................................................................................................................................................... 
..................................................................................................................................................................... 
..................................................................................................................................................................... 
 
Survey data on the general populations (for example, government departments of health and welfare) 
 
..................................................................................................................................................................... 
..................................................................................................................................................................... 
..................................................................................................................................................................... 
..................................................................................................................................................................... 
..................................................................................................................................................................... 
..................................................................................................................................................................... 
 
Universities and research centres 
 
..................................................................................................................................................................... 
..................................................................................................................................................................... 
..................................................................................................................................................................... 
..................................................................................................................................................................... 
..................................................................................................................................................................... 
..................................................................................................................................................................... 
..................................................................................................................................................................... 
135
136
Relevant international agencies 
 
..................................................................................................................................................................... 
..................................................................................................................................................................... 
..................................................................................................................................................................... 
..................................................................................................................................................................... 
..................................................................................................................................................................... 
..................................................................................................................................................................... 
 
Drug treatment centres and/or psychiatric facilities that treat drug dependence 
 
..................................................................................................................................................................... 
..................................................................................................................................................................... 
..................................................................................................................................................................... 
..................................................................................................................................................................... 
..................................................................................................................................................................... 
..................................................................................................................................................................... 
 
Outreach services for at-risk groups (for example, street people, sex workers or youth) 
 
..................................................................................................................................................................... 
..................................................................................................................................................................... 
..................................................................................................................................................................... 
..................................................................................................................................................................... 
..................................................................................................................................................................... 
..................................................................................................................................................................... 
 
Non-governmental organizations that have contact with illicit drug abusers 
 
..................................................................................................................................................................... 
..................................................................................................................................................................... 
..................................................................................................................................................................... 
..................................................................................................................................................................... 
..................................................................................................................................................................... 
..................................................................................................................................................................... 
Hospitals and emergency rooms and/or ambulance service 
 
..................................................................................................................................................................... 
..................................................................................................................................................................... 
..................................................................................................................................................................... 
..................................................................................................................................................................... 
..................................................................................................................................................................... 
..................................................................................................................................................................... 
 
Police and forensics 
 
..................................................................................................................................................................... 
..................................................................................................................................................................... 
..................................................................................................................................................................... 
..................................................................................................................................................................... 
..................................................................................................................................................................... 
..................................................................................................................................................................... 
 
Forensic laboratories and coroner’s records 
 
..................................................................................................................................................................... 
..................................................................................................................................................................... 
..................................................................................................................................................................... 
..................................................................................................................................................................... 
..................................................................................................................................................................... 
..................................................................................................................................................................... 
 
Prisons and/or judicial system 
 
..................................................................................................................................................................... 
..................................................................................................................................................................... 
..................................................................................................................................................................... 
..................................................................................................................................................................... 
..................................................................................................................................................................... 
..................................................................................................................................................................... 
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Other 
 
..................................................................................................................................................................... 
..................................................................................................................................................................... 
..................................................................................................................................................................... 
..................................................................................................................................................................... 
..................................................................................................................................................................... 
..................................................................................................................................................................... 
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Check list for assessing data source 
Type of data (i.e., survey, 
existing indicator data, 
qualitative data) 
 
Procedure for data 
collection 
 
Categories used in data 
collection (i.e., 
demographics and drug 
categories) 
 
Procedure for data 
collated, analysis and 
reporting 
 
Resources available to 
assist with data collection 
(e.g., data analysis 
software, expertise) 
 
Barriers to data 
collection, collation and 
analysis 
 
What is needed to 
facilitate the data source 
being used in the network 
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Check list for assessing data source 
Type of data (i.e., survey, 
existing indicator data, 
qualitative data) 
 
Procedure for data 
collection 
 
Categories used in data 
collection (i.e., 
demographics and drug 
categories) 
 
Procedure for data 
collated, analysis and 
reporting 
 
Resources available to 
assist with data collection 
(e.g., data analysis 
software, expertise) 
 
Barriers to data 
collection, collation and 
analysis 
 
What is needed to 
facilitate the data source 
being used in the network 
 
 
 
 
 
 Check list for assessing data source 
Type of data (i.e., survey, 
existing indicator data, 
qualitative data) 
 
Procedure for data 
collection 
 
Categories used in data 
collection (i.e., 
demographics and drug 
categories) 
 
Procedure for data 
collated, analysis and 
reporting 
 
Resources available to 
assist with data collection 
(e.g., data analysis 
software, expertise) 
 
Barriers to data 
collection, collation and 
analysis 
 
What is needed to 
facilitate the data source 
being used in the network 
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Check list for assessing data source 
Type of data (i.e., survey, 
existing indicator data, 
qualitative data) 
 
Procedure for data 
collection 
 
Categories used in data 
collection (i.e., 
demographics and drug 
categories) 
 
Procedure for data 
collated, analysis and 
reporting 
 
Resources available to 
assist with data collection 
(e.g., data analysis 
software, expertise) 
 
Barriers to data 
collection, collation and 
analysis 
 
What is needed to 
facilitate the data source 
being used in the network 
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Working Sheet—Step 4: strategic analysis 
A. Data analysis 
Complete for each potential data source 
Data source  
Current development  
Coverage  
 
Compatible with annual 
reports questionnaire  
reporting categories  
 
 
Development potential 
 
Priority  
Sustainability  
 
Training and support 
needs 
 
Infrastructure needs  
Key institutions  
 
Proposed development 
strategy 
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B. Network analysis 
Organization of the network 
Objectives and focus of system  
 
 
Coverage of network  
Coordinating body  
Frequency of meetings and data 
collation 
 
Reporting mechanisms  
Other  
 
 
 
 
 B.     Network analysis (continued) 
Network members 
Name/organization 
Contribution to network  
(i.e., data source, expertise, data collation and reporting) 
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C. Strategic analysis 
 
Short-term goal 
Goal  
Resource 
requirements 
 
Proposed action  
Medium-term goal 
Goal  
Resource 
requirements 
 
Proposed action  
Long-term goal 
Goal  
Resource 
requirements 
 
Proposed action  
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Working Sheets—Step 5: INRA report template 
See attached report template and diskette 
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ANNEX II
Writing a report: content
and formatting guidelines

  
 
 
 
 
 Information, Needs and Resources 
Analysis  
 
  
 
 Country name, year 
  
 
 
 
 
Organization 
City, Country 
 
 
 
 
 
 
 
(Insert Logos here) 
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 The contents of this report represent the proceedings of the (insert meeting name), held in (insert 
meeting venue and date), which was supported by (insert funding and technical support agencies). 
 
 For further information, contact: (insert contact details) 
 
(Insert details of the authors and/or name of organization producing the report, the publisher and the place 
and year of printing.) 
 
 This report template was provided by the UNDCP Global Assessment Programme on Drug Abuse 
(GAP). For further information, visit the GAP website at www.undcp.org, email gap@undcp.org  
or contact the Demand Reduction Section, UNDCP, P.O. Box 500, A-1400 Vienna, Austria. 
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Executive Summary 
 
 
 A. Background 
 
 
 B. Information 
 
 
 C. Resources 
 
 
 D. Needs 
 
 
 E. Strategic plan 
 
 
 F. Conclusion 
 
 
157
I. Introduction 
 
 
A. Background  
 
 
 Describe the background of the information, needs and resources analysis and the purpose of the 
report of the information, needs and resources analysis. 
 
Example 
 
 Information, needs and resources analyses (INRAs) are being conducted under the UNDCP Global 
Assessment Programme on Drug Abuse. The purpose of INRA is to establish country capacity for collecting 
information on drug abuse. INRA involves auditing existing information on drug abuse, auditing 
infrastructure and resources available to support data collection activities, and identifying key needs for 
development of a drug information system. INRA is the first step in establishing ongoing drug abuse 
surveillance. The list of data sources and resources relating to drug abuse presented in this report is not 
exhaustive, and is intended to serve as a resource to stimulate discussion on drug abuse information, 
directing the reader toward potential data that can be used to monitor drug abuse.  
 
 
B. Country information 
 
 
 Include relevant information on the following:  
 
 (a) Geography, population, urbanization, ethnicity, religion and language; 
 
 (b) Economic development situation, political situation and priority issues in the country; 
 
 (c) Broad perceptions of drug abuse in the country. 
 
 
C. Information, needs and resources analysis for the (insert country name) 
 
 
 This section of the report should outline the focus and purpose of the information, needs and 
resources analysis in the country concerned, how the analysis was undertaken and who was involved in the 
process. 
 
 
II. Information on drug abuse 
 
 
A. Survey data 
 
 
 Include a description of any surveys undertaken, including: 
 
 (a) General population surveys; 
 
 (b) School or youth surveys; 
 
 (c) Specialized surveys, such as, workplace surveys and rapid situation assessments. 
 
 Specifically, include information on when the survey was conducted, the sample and methods used, 
and a brief summary of the main findings. Also include a reference to any reports arising from the survey.  
 
 In the resource library (annexes), include a copy of any reports obtained and questionnaires used, as 
well as the contact details of the people involved in undertaking the surveys. 
 
 
B. Existing data 
 
 
 Construct a separate section for each source of existing data that is investigated. In each section, the 
following should be described: 
 
 (a) The nature of the data collected (e.g., representing treatment admissions relating to drugs and 
alcohol); 
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 (b) How the data are collected (e.g., questionnaire on admission to hospital or patient records); 
 
 (c) What is the coverage of data collection (city, regional or national); 
 
 (d) How are the data recorded (e.g., computer database, written records or log book); 
 
 (e) How frequently are the data entered into a central database and collated; 
 
 (f) What data categories are kept in the records (e.g., age, gender or drug type); 
 
 (g) Whether cases are coded according to drug type;  
 
 (h) How data are reported and disseminated;  
 
 (i) Barriers to data collection, collation and dissemination; 
 
 (j) Resources needed to develop data collection activities. 
 
 Obtain a sample of recent data, and present this in the report along with an interpretation of the data. 
Use information from the person providing the data to assist with the interpretation of the data. Their 
expert opinion can also be used to supplement the data provided. For example, a treatment provider may 
explain patterns of polydrug use and common routes of administration, where the data may only indicate 
main drug used. 
 
 Obtain the contact details of people involved with the data collection activities, and include them in 
annex I. Also, obtain copies of any questionnaires or forms used for data collection and include them in the 
resource library (annex II) for future reference.  
 
 Examples of existing data sources that might be included in the report are as follows: 
 
 (a) Treatment data; 
 
 (b) General hospital data; 
 
 (c) Mortality data; 
 
 (d) Psychiatric hospital data; 
 
 (e) Law enforcement data 
 
 (f) Other indicator data sources. 
 
 
C. Qualitative data 
 
 
 Include in this section other sources of information that might be encountered, in particular 
qualitative information and expert opinion. Qualitative research, such as focus groups, key informant 
surveys or ethnographic studies should be included in this section. For example, user-group representatives 
may provide self-report information on patterns of drug use, while night-club security staff may provide 
information on new types of party drugs. Use qualitative information to gain more detailed information on 
patterns and trends in drug abuse, the context of drug abuse, and high-risk behaviours among drug abusers. 
Specific questions that it might be possible to answer using qualitative information include: 
 
 (a) Types of drug used; 
 
 (b) Demographic characteristics of drug users; 
 
 (c) Frequency of use; 
 
 (d) Patterns of polydrug use; 
 
 (e) Route of administration; 
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 (f) Context of use (e.g., where and with whom do they use); 
 
 (g) Problems associated with use; 
 
 (h) Risk-taking behaviour among drug users (e.g., needle sharing). 
 
 Describe each qualitative research study, including a description of the methods used, the sample and 
the findings from the study. Describe information obtained from experts in terms of who they were 
reporting on, the types of drugs used by this group, trends in drug use within the group, and problems and 
risk-taking behaviour among members of the group. 
 
 Include contact details of relevant people in annex I. Obtain any reports arising from qualitative 
research, together with questionnaires used, and include them in the resource library (annex II).  
 
 
III. Resources 
 
 
The purpose of this section is to determine what resources for establishing a drug information system exist 
in the country. Information on the following should be included: 
 
 (a) People and organizations that could potentially form part of a drug information system; 
 
 (b) Potential data sources that can contribute to the network; 
 
 (c) The nature and level of technical knowledge and expertise relating to data collection activities, 
survey research and other specific drug research; 
 
 (d) The availability of infrastructure to collect data and communicate between network members 
(e.g., computers, data entry software, email and Internet access and access to stationery); 
 
 (e) Capacity for financing data collection and networking activities and providing staff time to 
undertake activities. 
 
 
IV. Needs 
 
 
On the basis of the assessment of resources existing in the country, itemize areas where information, 
resources, training and infrastructure are needed to build a drug information system. Describe the specific 
needs for each of the following areas: 
 
 (a) Training (e.g., need for training in setting up a database); 
 
 (b) Infrastructure (e.g., need for software for data entry); 
 
 (c) Communication and networking (e.g., need for Internet connection to facilitate networking). 
 
 Any other needs related to setting up data collection activities and networking may also be included. 
 
 
V. Strategic analysis 
 
 
A. Analysis of data sources 
 
 
 Insert the tables from the “Analysis of data sources” section on each data source analysed together 
with the summary of priority data sources. This information should come from the strategic analysis 
undertaken during the information, needs and resources analysis and should describe the following: 
 
 (a) Data source; 
 
 (b) Current development; 
 
 (c) Coverage; 
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 (d) Compatibility of the annual reports questionnaire; 
 
 (e) Development potential; 
 
 (f) Priority; 
 
 (g) Sustainability; 
 
 (h) Training and support needs; 
 
 (i) Infrastructure needs; 
 
 (j) Key institutions; 
 
 (k) Proposed development strategy. 
 
 
B. Epidemiological network 
 
 
 Provide an outline of the proposed network, describing in detail the people and focal points involved, 
the data sources that will be used, and methods of communication and information dissemination that 
could be used by the network. This information should come from the strategic analysis undertaken during 
the information, needs and resources analysis. 
 
 
C. Proposal for strategic development 
 
 
 Provide a brief explanation of the planned integrated drug information system in terms of coverage, 
focus, objectives and output. Include specific goals and actions in the sections indicated below under the 
headings “Short-term goals”, “Medium-term goals” and “Long-term goals”. This information should come 
from the strategic analysis carried out during the information, needs and resources analysis. 
 
 
1. Short-term goals 
 
 
 
2. Medium-term goals 
 
 
 
3. Long-term goals 
 
 
 
 
 
IV. Conclusion 
 
 
 The conclusion of the report should include the following: 
 
 (a) A brief review of the purpose of the report; 
 
 (b) A summary of information obtained on drug abuse (for example, most common drugs and 
patterns of use) and potential data sources on drug abuse in the country; 
 
 (c) A summary of existing resources (including data sources) to establish a drug information 
system; 
 
 (d) A summary of the main development needs of the country;  
 
 (e) A statement of priority goals to achieve with respect to developing a drug information system. 
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Annex I 
 
 
Contact details of information providers 
 
 
 Include the contact details of relevant people contacted during the information, needs and resources 
analysis. 
 
Example of format 
 
Name: 
 
Position: 
 
Organization: 
 
Address: 
 
Telephone: 
 
Fax: 
 
Email: 
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Annex II 
 
 
Resource library 
 
 
 Include reports and questionnaires obtained while undertaking the information, needs and resources 
analysis. 
 
 Include notes from meetings undertaken during the information, needs and resources analysis. 
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